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Summary 
 
Epigenetic marks like DNA methylation, post-translational histone modifications and 
associated chromatin states modulate gene expression, chromatin structure and 
cellular differentiation. DNA methyltransferase 1 (Dnmt1) plays an essential role in 
the maintenance of DNA methylation patterns after DNA replication and is tightly 
regulated by a multitude of intra- and intermolecular interactions.  
In this study, I analyzed the cell cycle dependent localization, activity and dynamics 
of Dnmt1 and its interaction partners PCNA and Np95 in living cells. The goal was to 
achieve a better understanding of the complex regulation of Dnmt1 in vivo and how 
these interactions are involved in the stable inheritance of DNA methylation patterns.  
For this purpose, I developed tools and techniques to monitor Dnmt1, PCNA and 
Np95 in their natural, cellular environment. More specifically, I established advanced 
live cell microscopy and photobleaching techniques in somatic and embryonic stem 
(ES) cells and generated specific monoclonal antibodies to study Dnmt1, PCNA and 
red fluorescent fusion proteins in different cell biological and biochemical applications.  
The association of Dnmt1 with PCNA throughout S phase was proposed as an 
efficient mechanism, coupling the replication of genetic and epigenetic information. 
Whether the PCNA binding domain (PBD) mediated interaction with the replication 
machinery is strictly required for the faithful propagation of DNA methylation marks 
in vivo was still elusive. I have addressed this question by comparing the subcellular 
localization, binding kinetics and activity of GFP-tagged wt Dnmt1 and PCNA-binding 
deficient mutants via live cell photobleaching assays and in vivo Dnmt activity 
measurements (trapping assay). I could show that the interaction of Dnmt1 with 
PCNA is highly transient, increases the efficiency of postreplicative methylation by 
twofold, but is not strictly required for maintaining global CpG methylation. I propose 
that the dynamic binding of Dnmt1 to PCNA may increase local protein concentration 
at replication sites and may thereby serve as additional safety mechanism.  
As part of the large N-terminal region of Dnmt1, the zinc finger (ZnF) domain was 
suggested to play an essential role in Dnmt1 enzyme activation and DNA substrate 
recognition. In this study, I observed a nuclear binding of the isolated ZnF domain, 
whereas it seemed to be dispensable for the overall Dnmt1 localization, dynamics 
and activity in context of the full-length protein.  
Recently, Np95 emerged as key regulator of DNA methyltransferases. The 
recognition of hemimethylated DNA substrates via Np95 and subsequent targeting of 
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Dnmt1 to these DNA sites is considered a crucial step in the DNA methylation 
maintenance process. Hence, I investigated the influence of different methylation 
levels on Np95 localization, activity and dynamics in living wt and knockout ES cells. 
Surprisingly, Np95 localization and binding kinetics were not affected by either 
reduced (dnmt1-/-) or completely absent (TKO; dnmt1-/-3a-/-3b-/-) DNA methylation 
compared to wt (J1) ES cells. I found a strong binding of Np95 to pericentric 
heterochromatin that was dominated by the SRA domain and suggest that the stable 
interaction of Np95 with chromatin may serve as anchor point for the transient 
binding of Dnmt1. Furthermore, in vitro data showed that Np95 preferentially binds 
trimethylated but not acetylated H3 N-terminal histone tails (H3K9) via a tandem 
Tudor domain that accommodates the histone tail in an aromatic cage similar to that 
of HP1β. Finally, the interplay of Np95 with Dnmts and histone modifying enzymes, 
together with its binding to DNA and repressive histone marks, point to a central role 
in the integration of various epigenetic silencing mechanisms and the mediation of 
epigenetic crosstalk. 
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1. Introduction 
 
1.1. DNA methylation-mediated epigenetic control 
During embryonic development a single cell, the zygote, gives rise to a multitude of 
different cell types all carrying essentially the same genetic information. Biochemical 
processes determining transcriptionally active and silent states make it possible to 
establish, based on one and the same genome, the many alternate expression 
programs that specify all the functional and structural diversity among the cell types 
produced during the lifespan of an organism. Canonical transcription factor networks 
respond to developmental signals and environmental cues and crucially contribute to 
initiate specific transcriptional programs. However, due to the complexity of genomic 
functions in eukaryotes transcription factors are not sufficient for full establishment 
and long term stability of transcriptional states. A number of additional factors and 
processes contribute to the setup of specific chromatin structures that in turn control 
transcriptional activity. These processes include DNA methylation, post-translational 
histone modification, incorporation of specific histone variants and chromatin 
remodeling. At least for DNA methylation and some histone modifications the 
respective marks and associated chromatin states are inherited through successive 
cell generations constituting a memory system for gene expression programs. In 
special cases, specific epigenetic states are even inherited through the germ line 
from one generation of an organism to the next (Roemer et al., 1997; Lolle et al., 
2005; Cropley et al., 2006; Morgan and Whitelaw, 2008). As these processes affect 
chromatin structure leaving the underlying genomic sequence unaltered they are 
termed epigenetic and their comprehensive makeup across the genome is generally 
referred to as the epigenome (Bird, 2007). Although epigenetic marks function to 
stabilize transcriptional states, they and their associated chromatin states can be 
altered under specific conditions. Thus epigenetic systems allow proliferating cells to 
preserve their identity while retaining the necessary plasticity to adapt to 
environmental conditions or respond to developmental signals and differentiate.  
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1.1.1. DNA methylation in vertebrates 
DNA methylation is the longest known and perhaps most extensively characterized 
epigenetic mark. DNA methylation is a postreplicative modification that occurs 
exclusively at the C5 position of cytosine residues (5mC) and predominantly in the 
context of CpG dinucleotides in vertebrates. The covalent addition of a methyl group 
to cytosine is catalyzed by DNA (cytosine-C5) methyltransferases (Figure 1). 
Vertebrate DNA methyltransferases (Dnmts) contain a highly conserved catalytic 
domain which includes ten sequence motives also found in prokaryotic DNA 
(cytosine-C5) methyltransferases (Goll and Bestor, 2005). Therefore, it is thought 
that all these enzymes use the same catalytic mechanism involving substrate 
recognition, flipping of the target cytosine out of the DNA double helix, formation of a 
covalent complex with the C6 position of the cytosine, transfer of the methyl group 
from S-adenosylmethionine to the activated C5 position and release of the enzyme 
by ß-elimination (Santi et al., 1983; Chen et al., 1991; Klimasauskas et al., 1994). 
Apart from Dnmt2 all Dnmts comprise in addition to a C-terminal catalytic domain 
(CTD) also a regulatory N-terminal domain (NTD) with several distinct subdomains. 
 
 
Figure 1: Schematic representation of the mammalian DNA methyltransferase family.  
All Dnmts exhibit a similar catalytic domain that features highly conserved motifs (I-X) also found in 
prokaryotic DNA (cytosine-C5) methyltransferases. The Dnmts differ however in their regulatory region. 
Dnmt1 contains the PCNA binding domain (PBD), the pericentric heterochromatin targeting sequence 
(TS), a CXXC type zinc finger motif (ZnF), and two bromo adjacent homology domains (BAH). The 
start codon of the long (ATGL) and short (ATGS) isoforms, as well as the seven lysine-glycine repeat 
linker (KG7) are indicated. The regulatory domains of Dnmt3a and 3b comprise a PWWP domain 
named after a conserved Pro-Trp-Trp-Pro motif and a plant homeodomain (PHD). 
 
Bioinformatic analysis suggests that Dnmt1 evolved by fusion of at least three 
ancestral genes, one contributing to the CTD and two to the NTD (Margot et al., 
2000). Dnmt1 is ubiquitously expressed and by far the most abundant Dnmt in 
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proliferating somatic cells, interacts with the DNA replication clamp proliferating cell 
nuclear antigen (PCNA) throughout S phase, displays substrate preference for 
hemimethylated DNA and its genetic deletion results in drastic loss of DNA 
methylation (Leonhardt et al., 1992; Li et al., 1992; Chuang et al., 1997; Easwaran et 
al., 2004). These properties constitute the basis for a major role of Dnmt1 in 
maintaining genomic methylation patterns through successive DNA replication cycles.  
Dnmt2 comprises only a catalytic domain, shows very weak DNA methyltransferase 
activity and is involved in methylation of cytoplasmic tRNAAsp (Hermann et al., 
2004a; Goll et al., 2006). Dnmt2 may also be responsible for rare cytosine 
methylation at sequence contexts other than CpG (Kunert et al., 2003; Mund et al., 
2004). To date a clear phenotype after ablation or reduction of Dnmt2 levels including 
differentiation defects in retina, liver and brain has been shown only in zebrafish 
(Okano et al., 1998; Rai et al., 2007). 
Dnmt3a and 3b are largely responsible for de novo establishment of genomic 
methylation patterns during development (Okano et al., 1999; Kaneda et al., 2004). 
Dnmt3L lacks crucial catalytic motifs and is enzymatically inactive. However, Dnmt3L 
interacts with Dnmt3a and 3b, stimulates their catalytic activity and is essential for 
establishment of maternal imprints and methylation of retrotransposable elements in 
the male germ line (Bourc'his et al., 2001; Hata et al., 2002; Margot et al., 2003; 
Bourc'his and Bestor, 2004). 
A categorical distinction between maintenance Dnmt1 and de novo Dnmt3 enzymes, 
however, does not precisely reflect their respective functions. On one hand, Dnmt3 
enzymes seem to be required for proper maintenance of DNA methylation in both 
somatic and embryonic stem (ES) cells (Liang et al., 2002; Chen et al., 2003; Dodge 
et al., 2005). On the other hand, some de novo methylation was reported in ES cells 
lacking both Dnmt3a and 3b, although it is not clear whether this is due to the activity 
of Dnmt1 or Dnmt2 (Lorincz et al., 2002). Also, direct interaction of Dnmt1 with 
transcription factors and its recruitment to their target sequences suggests an 
involvement of Dnmt1 in de novo methylation of these sequences (Robertson et al., 
2000; Di Croce et al., 2002; Esteve et al., 2006). Importantly, while evidence for 
interaction and cooperation of Dnmt1 with Dnmt3 enzymes is available, the precise 
mechanisms, mode of targeting and protein complex composition are unknown 
(Fatemi et al., 2001; Kim et al., 2002; Datta et al., 2003).  
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Approximately 60-70% of CpG sites are methylated in mammalian genomes. This 
includes all types of sequences: single copy genes and intergenic sequences as well 
as all kinds of repetitive elements, the latter displaying higher methylation density. 
Conspicuous exceptions are relatively short regions characterized by high CpG 
density (CpG islands) and mainly located at promoters and first exons of 
housekeeping genes. Nearly ubiquitous genomic methylation has been proposed as 
a mechanism to reduce spurious transcriptional activity (transcriptional noise) (Bird, 
2002). Promoters and enhancers with relatively low CpG density are often 
differentially methylated in different tissues and there is now very substantial 
evidence for dynamic changes of methylation patterns at these sites during cell 
differentiation, especially at promoters of lineage-specific and pluripotency genes 
(Fouse et al., 2008; Meissner et al., 2008; Mohn et al., 2008). However, it is still 
debated whether absence of DNA methylation only from selected regulatory regions 
is a mere consequence of transcription factor occupancy or a mechanism to favor 
selective binding of transcription factors to target sequences (for detailed review see 
(Suzuki and Bird, 2008)). Nevertheless, it is generally accepted that DNA methylation 
marks these sequences for heritable transcriptional silencing. This forms the basis for 
the crucial role of DNA methylation in embryonic development, cell differentiation, 
neoplastic transformation, imprinting and X chromosome inactivation (Bird, 2002). 
However, as the net transcriptional state is the result of several interconnected 
epigenetic processes, cytosine methylation does not always translate in 
transcriptional repression (Fouse et al., 2008). Dense methylation at repetitive 
elements is also thought to play a crucial role in genome stability at the level of whole 
organisms, as exemplified by the high tumor incidence in hypomethylated mice due 
to mobilization of retrotransposons and human syndromes resulting from 
hypomethylation of satellite repeats (Xu et al., 1999; Gaudet et al., 2003). 
Surprisingly though, no major genomic alteration is apparent in cultured cells with 
drastically reduced or nearly no methylation (Tsumura et al., 2006; Lande-Diner et al., 
2007). 
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Genomic methylation patterns are known to be actively erased both at specific 
developmental stages (e.g. demethylation of sperm DNA upon fertilization) and 
during artificial reprogramming procedures such as somatic cell nuclear transfer and 
fusion of somatic and highly pluripotent stem cells. In vertebrates active 
demethylation mechanisms have long been elusive and controversial, but there is 
now increasing evidence for enzymatic deamination of 5mC to thymidine followed by 
base or nucleotide excision repair (BER / NER) of G:T mismatches (Barreto et al., 
2007; Metivier et al., 2008; Rai et al., 2008; Ma et al., 2009; Schmitz et al., 2009). 
Both Dnmt3 enzymes and cytidine deaminases of the AID / APOBEC family have 
been involved in 5mC deamination, while BER is likely mediated by thymidine 
deglycosylases TDG and MBD4 (Kim et al., 2009b). In order to avoid deleterious 
accumulation of C to T transitions, these two processes seem to be tightly coupled by 
members of the Gadd45 protein family. Nonetheless, several important aspects 
remain to be defined, including whether this is the only pathway for active DNA 
demethylation operating in vertebrates, how many alternative and/or additional 
factors are involved and how the demethylation machinery is targeted to specific 
sequences.  
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1.1.2. Connection between DNA replication and DNA methylation 
 
Within the eukaryotic cell, proliferating cell nuclear antigen (PCNA) plays an essential 
role in DNA replication, DNA repair, cell cycle regulation, and postreplicative 
transactions like DNA methylation and chromatin remodeling. PCNA orchestrates 
these cellular processes by recruiting key players to the replication fork and thus 
tethering them to their potential target sites (Maga and Hubscher, 2003).  
PCNA was originally characterized as processivity factor of the eukaryotic DNA 
polymerase δ and belongs to the family of evolutionary highly conserved DNA sliding 
β-clamps (Bravo et al., 1987; Kelman and O'Donnell, 1995; Wyman and Botchan, 
1995). PCNA is a homotrimeric ring-shaped protein that encircles the DNA. 
Crystallographic studies revealed that the PCNA clamp constitutes a highly 
symmetric assembly of three identical head to tail arranged monomers (Figure 2) 
(Krishna et al., 1994; Ivanov et al., 2006). Each PCNA monomer is composed of two 
subdomains (N-terminus and C-terminus) linked by a long chain termed the 
interdomain connecting loop (IDCL) that crosses back over the outer surface. The 
inner layer of the homotrimeric ring displays positively charged α-helices that mediate 
the association with DNA, whereas the outer surface of PCNA is organized in 
β-sheets.  
 
Figure 2: Crystal structure of the human PCNA ring. PDB: 1VYM 
Cartoon model of the PCNA ring (A). Monomers are displayed in different colors. Secondary structure 
coloring (B). α-helices (cyan), sheets (pink), loops (salmon). Surface model of the PCNA ring (C). 
Positively charged amino acids (blue), negatively charged amino acids (red), neutral amino acids 
(white). The figure was generated using the PyMol software (DeLano, 2002). 
 
The three dimensional structure connects the PCNA ring topologically to the DNA, 
besides maintaining the ability to slide along the DNA double helix. This property 
constitutes the basis for the role of PCNA in acting as stationary loading platform for 
multiple, transiently interacting partners participating in various DNA transactions 
(reviewed in (Moldovan et al., 2007)).  
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The association of Dnmt1 with the replication machinery was proposed as an efficient 
mechanism coupling the replication of genetic and epigenetic information (Leonhardt 
et al., 1992; Chuang et al., 1997). By traveling along with the replication machinery, 
Dnmt1 would be able to restore genomic methylation pattern as soon as 
hemimethylated CpG sites are generated. Later, direct interaction between Dnmt1 
and PCNA was shown and could be mapped to a highly conserved region termed the 
PCNA binding domain (PBD) (Figure 3 A) (Chuang et al., 1997; Easwaran et al., 
2004). Moreover, the PBD-PCNA interaction was shown to be crucial in targeting 
Dnmt1 not only to sites of DNA replication but also to sites of DNA repair, indicating a 
direct coupling of the restoration of epigenetic information after the repair of the 
genetic information (Mortusewicz et al., 2005).  
The PBD of Dnmt1 is located within the regulatory NTD and consists of ~20 amino 
acids. Remarkably, besides Dnmt1, most of the PCNA interacting partners 
participating directly or indirectly in DNA replication, -repair or cell cycle progression 
contain this PBD motif (Figure 3 B; Figure 3 C). The core element of the PBD is a 
peptide called PCNA-interacting-peptide (PIP)-box with the consensus sequence 
Q-xx-(L/I/M)-xx-(H/Y/F)-(F/Y) that is C-terminally flanked by several basic amino 
acids (Warbrick, 1998).  
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Figure 3: Schematic representation of the mouse Dnmt1 structure (A) and alignment of PCNA 
binding domains (PBD) from different species (B) or different PCNA binding proteins in Mus 
musculus (C).  
Highly conserved amino acids within the PIP-Box motif (boxed) are gray shaded. Accession numbers: 
(B) Mus musculus P13864; Homo sapiens P26358; Rattus norvegicus Q9Z330; Bos taurus Q6Y856; 
Sus scrofa Q4TTV6; Ovis aries Q865V5; Gallus gallus Q92072; Monodelphis domestica Q8MJ28; 
Xenopus laevis Q6GQH0; Paracentrotus lividus Q27746; Xiphophorus maculatus Q9I8X6; 
Brachydanio rerio Q8QGB8. (C) Accession numbers: Dnmt1 P13864; Fen1 P39749; p21 P39689; 
DNA Ligase1 P37913; Polymerase δ/ ∆p66 Q9EQ28; XPG P35689; UNG P97931; MSH6 P54276. 
 
Intriguingly, all PBD containing proteins bind to exactly the same interface present on 
each PCNA subunit (Figure 4), suggesting that binding to PCNA is highly competitive 
and likely mutual exclusive. Structural studies of the PCNA ring in complex with the 
PBD of human p21 revealed an extensive set of interactions spanning almost the 
entire length of the peptide (Figure 4). There, the PBD shows an anti-parallel binding 
alongside the IDCL of PCNA. The canonical PIP-Box is folded into a 310-helix 
conformation that perfectly fits into a hydrophobic pocket by forming a three-forked 
(M147; F150; Y151) hydrophobic plug (Warbrick et al., 1995; Gulbis et al., 1996; 
Bruning and Shamoo, 2004).  
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Figure 4: Crystal structure of the trimeric human PCNA ring in complex with human p21-PBD 
peptide. 
(A) Amino acid sequence of the human p21-PBD peptide. The PIP-Box motif is highlighted. Identical 
or highly conserved amino acids within the PIP-Box are depicted in red. Additional PBD amino acids 
are shown in green. (B; C) Crystal structure of the human p21 peptide in complex with PCNA, either 
shown as monomer (B) or as trimeric PCNA ring (C). The peptide runs alongside the PCNA monomer. 
Each PCNA monomer carries one PBD molecule. M147 is accommodated in a hydrophobic pocket 
and Q144 might anchor the peptide. PDB: 1AXC. The figure was generated using the PyMol software 
(DeLano, 2002).  
 
The highly conserved glutamine (Q144) is present in all PBD containing proteins and 
might anchor the whole peptide at the C-terminal part of the PCNA monomer. The 
PBD-PCNA binding interface is completed by ion-pairings and hydrogen bondings 
that are formed within the β-sheet alongside the IDCL.  
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Apart from the mentioned function as processivity factor or loading platform, PCNA 
was shown to stimulate protein activity of flap-endonuclease 1 (Fen1) and 
DNA ligase 1 (Lig1). Upon PCNA binding via the PBD domain, a conformational 
change of these enzymes is induced that enhances subsequent DNA binding activity 
and substrate preference (Chapados et al., 2004; Sakurai et al., 2005; Pascal et al., 
2006). Whether this mechanism is also necessary to induce or enhance catalytic 
activity of Dnmt1 in vivo remained to be defined and was investigated in this thesis. 
Even taking into account the trivalent nature of the PCNA ring, the sheer number of 
its potential PBD-containing binding partners exceeds this capacity, suggesting that 
binding to PCNA must be highly regulated and is likely competitive and mutually 
exclusive (Bruning and Shamoo, 2004; Ivanov et al., 2006).  
PCNA expression, localization and dynamics change during cell cycle progression 
(Sporbert et al., 2002; Essers et al., 2005; Sporbert et al., 2005). In the course of 
DNA replication distinct chromatin regions are duplicated at different time points. The 
patterns of appearing replication foci can be visualized by pulse labeling with the 
nucleotide analogue BrdU (Dimitrova and Berezney, 2002). Alternatively, PCNA or 
Lig1 fused to any fluorescent protein can be used as specific S phase marker to track 
cell cycle progression in living cells (Figure 5) (Easwaran et al., 2005; Sporbert et al., 
2005). In mammals three S phase patterns are distinguishable (Leonhardt et al., 
2000; Somanathan et al., 2001).  
 
 
Figure 5: Cell cycle dependent localization of mRFP-PCNA in mouse C2C12 myoblast cells.  
In early S phase, the replication of euchromatin takes place that is reflected by several small foci in the 
entire nucleus. In mid S phase facultative heterochromatin is replicated, which is located at the 
periphery of the nucleus and around the nucleoli. In late S phase typical horseshoe-like foci are 
appearing, which indicate the replication of constitutive heterochromatin. Bar, 5 µm. 
 
In addition, PCNA serves as a proliferation marker and is therefore an interesting 
antigen for diagnostic purposes, especially in the prognosis of tumor development 
(Jain et al., 1991). Changes in the expression level of PCNA are directly related to 
the malignancy of various tumors (Nolte et al., 1998; Paunesku et al., 2001).  
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1.1.3. Mechanisms of DNA methylation-mediated transcriptional repression 
and their interconnection with other epigenetic pathways  
 
DNA methylation mediated transcriptional repression is thought to occur through at 
least two types of mechanism. The methylation mark can directly prevent the binding 
of transcription factors when present at their target sites, as it is the case for CTCF 
binding at the H19/Igf2 imprinting control region (reviewed in (Bird, 2002)). 
Alternatively, methylated CpG sites (mCpGs) are specifically recognized by mCpG 
binding proteins (MBPs) that recruit repressive chromatin modifiers and remodeling 
complexes. At least three types of domains and corresponding MBP families have 
been shown to bind mCpGs: the methyl-CpG binding domain (MBD), the SRA 
domain containing protein and the Kaiso protein families (Figure 6).  
 
Figure 6: The three classes of mCpG binding proteins (MBPs). 
The ability to recognize methylated CpG sites is mediated by different modules, the methyl-CpG 
binding domain (MBD), the Set and Ring associated (SRA) domain or zinc finger (ZnF) motifs. MBD 
proteins are shaded in yellow. In addition to the MBD, MBD1, MBD2 and MeCP2 contain a trans-
repressor domain (TRD). The MBD1 α isoform is shown. Amino acid repeats (GR and E) are depicted 
in orange. The second class of MBPs (Kaiso, Kaiso-like and ZBTB38) is characterized by several zinc 
finger motifs. Binding to methylated DNA is mediated by a C2H2 zinc finger motif (yellow). The broad 
complex, tramtrack and bric à brac/Poxvirus and zinc finger (BTB/POZ) domain is depicted in gray. 
Np95 and the very similar Np97 (shaded in blue) recognize methylated DNA via the SRA domain and 
contain in addition an Ubiquitin-like (Ubl) motif, a Tudor domain, a plant and homeodomain (PHD) and 
a Ring finger.  
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The methyl-CpG binding domain (MBD) protein family 
 
Four out of five members of the mammalian MBD family specifically bind mCpGs, the 
exception being MBD3 due to sequence divergence in its MBD (Hendrich and 
Tweedie, 2003). Apart for the above mentioned MBD4, all other MBDs form 
complexes with histone deacetylase (HDAC) and nucleosome remodeling activities 
(such as MeCP1 and NuRD) associated with transcriptional silencing (reviewed in 
(Hendrich and Tweedie, 2003)). MBD1 also interacts with histone H3 lysine 9 
methyltransferase (H3K9MT) SetDB1 to enforce silencing (Figure 8 A) (Sarraf and 
Stancheva, 2004). Interestingly, both MBD1 and MeCP2 have been found to bind 
DNA and induce chromatin compaction independently of DNA methylation (Georgel 
et al., 2003; Jorgensen et al., 2004; Nikitina et al., 2007). Surprisingly, a large scale 
survey indicated that the majority of MeCP2 target genes in neurons are 
transcriptionally active (Yasui et al., 2002). The relatively mild phenotypes of mice 
lacking individual MBD members have been taken to suggest a high extent of 
functional redundancy. However, this is in contrast with the lack of sequence and 
structural similarity among MBD family members outside of the MBD. Taken together, 
these studies suggest that the function of MBD proteins is highly context dependent.  
 
Kaiso and Kaiso-like proteins 
 
Kaiso and Kaiso-like proteins ZBTB4 and ZBTB38 share a three zinc-finger motif and 
a broad complex, tramtrack and bric à brac (BTB) /poxvirus and zinc finger (POZ) 
domain at the C-terminus and are differentially expressed in mouse tissues (Yoon et 
al., 2003; Filion et al., 2006). In vitro and in vivo studies showed that Kaiso binds 
methylated DNA through the zinc finger motif, but in contrast to the MBD and Np95 
families, it requires two consecutive mCpGs for efficient binding. Biochemical 
analyses revealed a direct interaction of Kaiso with the repressive NCoR complex, 
which also contains HDAC and remodeling activities, again linking methylated DNA 
sequences with a deacetylated and a highly structured chromatin state (Figure 8 C). 
In another parallel with MBD proteins, Kaiso was reported to bind a consensus 
sequence devoid of DNA methylation, suggesting also in this case complex, context 
dependent functions. 
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Np95 as cofactor for the maintenance of DNA methylation 
 
Recently, the Set and Ring associated (SRA) domain protein Np95 (also known as 
Uhrf1 or ICBP90) emerged as an essential cofactor for the maintenance of DNA 
methylation (Bostick et al., 2007; Sharif et al., 2007; Achour et al., 2008). It has been 
shown that Np95 binds to hemimethylated DNA, interacts and colocalizes with Dnmt1 
at replication foci and that its genetic depletion leads to remarkably similar genomic 
hypomethylation and developmental arrest to those observed in Dnmt1 null mice 
(Uemura et al., 2000; Bostick et al., 2007; Papait et al., 2007; Sharif et al., 2007; 
Achour et al., 2008). Np95 and the very similar Np97 are highly conserved during 
evolution and appeared probably with the development of vertebrates (Bronner et al., 
2007). Np95 expression is highly cell cycle regulated and peaks during S phase 
(Muto et al., 1995; Miura et al., 2001). In addition expression levels are elevated in 
most proliferating cells including tumor tissues and all types of primary cancers 
(reviewed in (Bronner et al., 2007)). Np95 harbors several functional subdomains 
including an Ubiquitin-like domain (Ubl), followed by a tandem Tudor (Tudor) domain, 
a plant homeodomain (PHD), a Set and Ring associated domain (SRA) and finally a 
really interesting new gene (Ring) domain. The structure of each of these single 
modules either from Np95 or Np97 was solved (Figure 7).  
 
Figure 7: Solved structures within the multi-domain protein Np95 or its relative Np97.  
The Ubiquitin-like domain (Ubl; PDB 2FAZ), the tandem Tudor domain (PDB 3DB4), the plant and 
homeo (PHD) domain (PDB 2E6S), the Set and Ring associated (SRA) domain (PDB 2ZO1) and 
finally the Ring domain (PDB 1Z6U). The figure was generated using the PyMol software (DeLano, 
2002). 
 
Crystallographic studies revealed that the SRA domain flips the 5mC out of the DNA 
double helix, a mechanism first identified with DNA methyltransferases (Arita et al., 
2008; Avvakumov et al., 2008; Hashimoto et al., 2008; Qian et al., 2008). Thus, it has 
been proposed that Np95 mediates maintenance of genomic methylation by 
recruiting Dnmt1 to hemimethylated CpG sites generated during DNA replication. 
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Even plants express several SRA containing proteins (Vim proteins), including two 
with H3K9MT activity, but with a less complex structure (Johnson et al., 2007; Woo et 
al., 2007; Woo et al., 2008). Interestingly, Np95 was reported to interact with the 
H3K9MT G9a and HDAC1 and was involved in silencing of tumor suppressor genes 
(Unoki et al., 2004; Kim et al., 2009a). Several observations suggest additional roles 
of Np95 in linking CpG methylation with histone modification. Np95 contains a PHD 
domain that is involved in binding to histone H3 and heterochromatin decondensation 
(Citterio et al., 2004; Papait et al., 2008). Available crystallographic data show the 
tandem Tudor domain of Np95 (PBD 3DB3) in complex with histone H3 peptide. 
However, further experimental data was still missing. The Ring domain of Np95 has 
been shown to mediate ubiquitination of histone H3 in vitro (Citterio et al., 2004). 
However, the exact mechanisms and specificity of Np95 in connecting DNA 
methylation to repressive chromatin states are still to be resolved.  
It is important to realize that in addition to DNA methylation being translated into 
repressive chromatin structures, DNA methylation and chromatin modification and 
remodeling pathways reciprocally affect each other in multiple ways. An example is 
the demethylation of H3K4 by LSD1. This creates a binding site for the PHD of 
Dnmt3L, which in turn recruits the Dnmt3a, linking the H3K4 methylation state to 
DNA methylation (Figure 8 D) (Jia et al., 2007). However, LSD1 also controls 
maintenance of DNA methylation by demethylating Dnmt1, as Dnmt1 methylation 
drastically decreases its stability (Wang et al., 2009). Dnmt1 and/or Dnmt3 enzymes 
have been shown to interact directly with SNF2H, an ATPase subunit common to 
several chromatin remodeling complexes, the H3K9MTs Suv39h1, SetDB1 and G9a, 
components of the polycomb repressive complex 2 (PRC2), heterochromatin protein 
1 (HP1) and HDACs (Fuks et al., 2000; Robertson et al., 2000; Fuks et al., 2001; 
Fuks et al., 2003; Geiman et al., 2004; Li et al., 2006b; Vire et al., 2006; Epsztejn-
Litman et al., 2008) (reviewed in (Cedar and Bergman, 2009)). While G9a and the 
PRC2 complex have been proposed to recruit Dnmts at their target genes, no 
functional hierarchy has been established in other cases. Nevertheless, the 
interaction network formed by Dnmts, MBPs, H3K9MTs, HP1 and HDACs (and 
including HP1 binding to H3K9MTs, methylated H3K9 and MeCP2) suggests the 
existence of positive feedback loop mechanisms stabilizing and possibly spreading 
silent chromatin states (Figure 8 E) (Lachner et al., 2001; Nielsen et al., 2002; 
Agarwal et al., 2007).  
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In addition, direct interaction between Dnmt1 and G9a at replication foci was 
proposed as a mechanism coupling maintenance of DNA and H3K9 methylation 
(Figure 8 B) (Esteve et al., 2006).  
 
Figure 8: Molecular links between DNA methylation, histone modification and chromatin 
structure.  
(A) MBD1 binds methylated DNA via the MBD domain and recruits the lysine methyltransferase 
SetDB1 to enforce silencing. (B) Replication coupled maintenance of DNA methylation and histone 
modification. PCNA serves as a loading platform for Dnmt1 and Np95. Np95 recognizes 
hemimethylated CpG sites via the SRA domain, interacts with Dnmt1 and thus allows maintenance of 
genomic methylation. Interacting chromatin modifying enzymes such as HDAC1, HDAC2 
(deacetylation), G9a (dimethylation of H3K9) or Suv39h1 (trimethylation of H3K9) enforce gene 
silencing by removing permissive acetyl-groups and introducing repressive lysine methylation on 
histones. (C) Kaiso binds pairs of methylated CpG sites via the zinc finger motif. Interaction with the 
NCoR repressive complex and HDAC3 (deacetylation) promotes repression of transcription. (D) 
De novo methylation requires the DNA methyltransferases Dnmt3a and 3b. Dnmt3L serves as 
regulatory factor and via its plant homeodomain (PHD) mediates the interaction with unmethylated 
histone H3 lysine 4 (H3K4) generated by LSD1. (E) Binding of HP1 mediates long term silencing of 
chromatin regions. A positive feedback loop is created by HP1 recruiting Suv39H1 that trimethylates 
H3K9 generating additional binding sites for HP1.  
 
Finally, the remodeling factors of the SNF2H ATPase family Lsh and ATRX have 
been involved in control of DNA methylation. ATRX mutations affect DNA methylation 
at rDNA loci and other repeats and ATRX interacts with HP1, MeCP2 and the PRC2 
component Ezh2 (Gibbons et al., 2000; Nan et al., 2007). Genetic targeting of Lsh 
resulted in global genomic hypomethylation and Lsh was shown to be required for 
de novo DNA methylation (Dennis et al., 2001; Zhu et al., 2006). However, 
involvement of Lsh in chromatin remodeling has been questioned and Lsh was 
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shown to mediate silencing of Hox loci by associating with both Dnmt3b and PRC1 
(Xi et al., 2007; Myant and Stancheva, 2008).  
A major unresolved issue about the DNA methylation system (as well as other 
epigenetic pathways) concerns target specificity. Only few interactions between 
Dnmts and sequence specific factors have been described and it cannot be excluded 
that most have gone undetected due to their sheer numbers and transient nature. 
Another possibility is that structural chromatin features, i.e. other epigenetic marks, 
generate a spectrum of affinity sites for Dnmt complexes. An example is 
demethylation of H3K4 by LSD1, which creates an affinity site for the PHD of Dnmt3L 
and thus may recruit the Dnmt3a-Dnmt3L complex. However, this only shifts the 
question of specificity to other epigenetic pathways. An exciting alternative is 
provided by small non coding RNAs. While RNA directed DNA methylation is well 
established in plants, a similar mechanism has only been recently described in 
mammalian cells for Piwi protein family associated RNAs (piRNAs) involved in 
de novo methylation and silencing of transposable elements during differentiation of 
the male germ line (Kuramochi-Miyagawa et al., 2008). However, the precise 
mechanism by which piRNAs direct de novo DNA methylation is not currently known. 
Also, changes in promoter methylation have been associated with small RNA 
mediated transcriptional gene silencing in mammalian cells, but it is not clear whether 
these RNAs are actually guiding de novo methylation to the target sequence or 
methylation is a consequence of the silencing process (reviewed in (Guil and Esteller, 
2009)).  
Currently, complete epigenomes of a variety of different cell types are being 
established that include detailed information on genome wide DNA methylation 
(Lister et al., 2009), histone modifications and nucleosome positioning as well as 
binding of regulatory factors and non coding RNAs. In parallel, a rapidly growing 
number of factors, posttranslational modifications and interactions are being 
identified that establish, maintain and modify these epigenomes. The ultimate 
challenge for the next decades is to understand how these regulatory epigenetic 
networks change during development and disease and explain in quantitative terms 
their effect on gene expression patterns. Given the number of factors involved and 
the complexity of their interactions it is clear that any comprehensive understanding 
of these epigenetic networks will require sophisticated and powerful bioinformatics 
tools.   
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1.2. Tools and techniques to monitor Dnmt1 and interacting proteins in 
their natural environment 
The understanding of complex biological systems like the epigenetic protein network 
improved drastically with the ability to visualize participating factors in their cellular 
context. The oldest and one of the most successful strategies to detect proteins in 
their natural environment is based on antibody-antigen interactions. There, specific 
antibodies detect endogenous proteins and give information about protein 
abundance, localization and modifications. However, this method normally requires 
cell fixation, depicting only a snap shot of the current cellular status. Protein detection 
was revolutionized by the discovery of fluorescent proteins (FPs) that can be used as 
in vivo transcriptional and translational reporter molecules (Chalfie et al., 1994; Matz 
et al., 1999; Tsien, 2005). This new application of fusing the protein of interest to 
visible markers allows in vivo protein tracking by noninvasive fluorescence imaging 
and finally to gain insights in protein mobility, type of protein interaction and cell cycle 
dependent regulation. Nowadays, both, antibodies and FPs offer versatile and 
powerful tools to detect proteins in biochemical, cell biological and clinical 
applications. Both techniques to monitor Dnmt1 and interacting proteins in their 
natural environment were applied in this thesis.  
 
1.2.1. Antibody based protein detection 
Over the last decades, antibodies became the most versatile and ubiquitously used 
tool in a variety of scientific and medical disciplines (reviewed in (Conroy et al., 
2009)). Antibodies are compactly folded glycoproteins that are synthesized and 
secreted into plasma or extracellular fluids as part of the humoral host defense 
reaction and serve as principle effectors of the adaptive immune system. This 
adaptive system is based on the clonal selection of lymphocytes bearing a single 
type of receptor with a unique antigen specificity (Janeway et al., 2005). Antigen 
binding with a high affinity is followed by the activation of the B-lymphocyte and 
results in proliferation and differentiation to effector cells (plasma cells and memory 
cells). Antibodies are then produced by these specific plasma cells and secreted as 
soluble receptor form that recognizes the antigenic epitope with the same specificity 
as the corresponding B-cell receptor before. A subset of these proliferating 
lymphocytes differentiates into long-living memory cells, which enable a rapid 
immune response and enhanced protection after reinfection (McCullough and 
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Summerfield, 2005). Antibodies contribute to ultimate pathogen destruction by either 
neutralization, opsonization or complement activation (humoral immunity) (Janeway 
et al., 2005). 
The typical Y-shaped structure of a conventional antibody / Immunoglobulin (Ig) 
results from two antigen binding fragments (Fragment antigen binding; Fabs) that are 
connected via a flexible hinge region with the constant effector-determining region 
(Fc) (Figure 9) (Padlan, 1994). Hence, each antibody is at least bivalent in antigen 
binding.  
 
 
Figure 9: The modular structure of the immunoglobulin IgG2a.  
Conventional antibodies are Y-shaped and made up of two antigen binding fragments (Fab) and one 
constant effector determining region (Fc) that are connected by a flexible hinge region. Light chains 
consist of one constant (CL) and one variable (VL) domain, whereas the heavy chain is composed of 
three constant regions (CH1, CH2, CH3) and one variable domain (VH). Antigen binding is mediated by 
two variable domains (Fv) each harboring three complement determining regions (CDR loops) that 
define the antibody specificity. Mid panel shows the crystal structure of a mouse IgG2a molecule 
(PDB: 1IGT) generated using PyMol (DeLano, 2002). The Fab fragment including CDR1 (yellow), 
CDR2 (cyano) and the CDR3 (red) is enlarged on the right.  
 
The antibody molecule is assembled out of four polypeptide chains. Two heavy and 
two light chains are joined together by disulphide bridges and non-covalent bonds, 
building a globular unit with around 150 kDa (Lipman et al., 2005). Antigen binding is 
mediated by both variable chains (heavy VH and light VL), forming a binding interface 
with three hypervariable regions at the tip of each FAB fragment (Figure 9). These 
complementarity determining regions (CDRs) are looped out of the antibody structure 
and are able to bind the corresponding antigen with an induced fit conformation 
without any covalent contact.  
Vertebrates are able to generate an antibody repertoire of sufficient diversity to 
recognize the antigenic component of virtually any potential pathogen or toxin 
(Pancer and Cooper, 2006). This enormous repertoire (~1011) is a result of various 
mechanisms, including combinatorial diversity of heavy and light (kappa and lambda) 
chains, by virtue of rearrangeable Ig gene segments (VDJ recombination), imprecise 
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joining during recombination and somatic hypermutation in the CDR regions (Lipman 
et al., 2005; Casali et al., 2006; Jungnickel, 2006). In mammals, five main Ig classes 
(IgG and isotypes, IgM, IgA, IgE and IgD) protect the host organism against foreign 
pathogens. Each Ig class comprises a special antibody shape and each is linked with 
different biological functions. Figure 9 shows the typical structure of an IgG2a 
antibody that is the most abundant form in blood sera and mediates antigen 
neutralization or complement activation. The unique feature of antibodies to bind an 
antigen with high specificity and affinity makes them potent effectors in the 
mammalian host defense reaction and highly attractive as diagnostic and versatile 
research reagent.  
Nowadays, we are provided with an enormous toolbox of different types of antibodies 
that are generated and produced via several strategies. Besides polyclonal 
antibodies (PAbs) (Kurpisz et al., 1988; Overkamp et al., 1988) that recognize 
multiple epitopes within the same antigen, also a broad spectrum of monoclonal 
antibodies (MAbs) (Kohler and Milstein, 1975) that are monospecific for an antigen is 
available. Moreover, recombinant antibodies or antibody fragments such as Fab, Fv 
(heterodimers of VH and VL domains) and single chain scFv have been successfully 
engineered and expressed in bacteria, yeast or fungi (Better et al., 1988; Huston et 
al., 1988; Skerra and Pluckthun, 1988), (reviewed in (Joosten et al., 2003)). Since 
these new antibody fragments are easily designed and recombinantly fused to any 
possible effector molecule, they are widely used as human immuno-therapeutics. 
Especially in cancer therapy, antibodies carrying Fc-regions linked with 
antibody-dependent cellular cytotoxicity (ADCC) or complement initiating activity are 
used to destroy the targeted tumor cells (Presta, 2008; Deckert, 2009). Very recently, 
the discovery of small camelidae antibodies, only consisting of the heavy chain unit 
(VHH) (Hamers-Casterman et al., 1993; Muyldermans et al., 1994), led to a boost in 
antibody technology since these nanobodies are able to target and trace antigens 
even in living cells (Muyldermans, 2001; Rothbauer, 2006).  
Each of the mentioned strategies has its advantages and limitations, but the decision, 
which antibody type or production technology to chose depends on the intended 
application. The following part of the introduction will focus on the generation of 
MAbs via the hybridoma technology, since this method was applied in this study to 
generate MAbs against Dnmt1, PCNA and red fluorescent proteins.   
INTRODUCTION
 
- 24 - 
Monoclonal antibodies and hybridoma technology 
 
In the mid-1970s, Georges Köhler, César Milstein and Niels Jerne devised a 
technique to generate MAbs that are monospecific for a desired antigen and 
producible in large amounts (Kohler and Milstein, 1975). Based on lymphocyte-cell 
fusions they generated hybrid cells (hybridomas) and thereby combined the 
immortality of myeloma cells with the ability to produce specific antibodies via a 
single B lymphocyte clone. For the invention of this hybridoma technology the three 
scientists earned the Nobel Prize in 1984 (reviewed in (Alkan, 2004)).  
The multiple steps of generating MAbs via the hybridoma technology are illustrated in 
Figure 10 and outline the procedure applied in this study (See results 2.1, 2.2 and 
2.4). Normally, mice or rats are used for immunization. In distinction to mice, rats 
have several advantages. First, rats have a bigger spleen that can be subdivided into 
two to three parts after immunization. While the fusion is performed with lymphocytes 
from just one part of the spleen, the other parts can be stored as backup. Second, rat 
MAbs are less frequent, thus enabling multiplexing with e.g. mouse, rabbit and sheep 
antibodies. Third, rats are cheaper in purchasing and as Elisabeth Kremmer says 
"rats are better mice".  
Before fusion, the myeloma cells were rendered drug sensitive by a mutation in the 
growth essential salvage gene hypoxanthine-guanine-phosphoribosyltransferase 
(HGPRT) (Stout and Caskey, 1985). The cell mixture is then cultured in 
hypoxanthine-aminopterine-thymidine (HAT) medium (reviewed in (Nelson et al., 
2000)). The medium component aminopterin acts as a folate metabolism inhibitor 
and thereby blocks DNA de novo synthesis that is crucial for each cell division cycle. 
Hence, unfused myeloma cells die, as they cannot produce nucleotides by de novo 
synthesis or evade via the salvage pathway (HGPRT─). Although B cells (HGPRT+) 
could survive the aminopterin block, unfused B cells will die due to their limited 
lifespan. Only hybridoma cells comprising both characteristic functions survive this 
procedure. 10 days after fusion and subsequent culturing, stable antibody producing 
cells are prescreened regarding antibody-antigen specificity and Ig subclass. To this 
aim, hybridoma supernatants containing the secreted MAbs are collected and tested 
via e.g. enzyme-linked immunosorbent assay (ELISA) (Hornbeck, 2001). Once 
established in culture, the selected hybridoma cells are stably subcloned, expanded 
and tested further in different applications like western blot or immunofluorescence 
assay.  
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Figure 10: The generation of monoclonal antibodies using the hybridoma technology. 
Typical workflow from the immunization step to stable production of specific and affine monoclonal 
antibodies suitable for different applications as enzyme linked immunosorbent assay (ELISA), western 
blot (WB) or immunofluorescence (IF) assays. Purified proteins or peptides are injected both 
intraperitoneally and subcutaneously into Lou/C rats using CpG2006 adjuvant. After removing the rat 
spleen, immune cells including B-cells are isolated and chemically fused with immortal myeloma tumor 
cells (P3X63-Ag 8.653) using polyethylene glycol (PEG) (Lentz, 2007).  
 
Finally, the selected hybridoma clones are permanently stored in liquid nitrogen and 
are utilized for the stable production of desired MAbs with selective antigen specificity 
in high quality and quantity.  
The unique ability of MAbs to recognize and bivalently bind antigens in a highly 
specific manner makes them attractive agents for targeted disease elimination 
(Adams and Weiner, 2005; Deckert, 2009), clinical diagnostics and biomedical 
research (Reichert et al., 2005; Conroy et al., 2009).  
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Since small changes in the specific epitope can affect antigen binding, MAbs are 
often used as sensor-molecules to detect changes in protein conformation, 
interactions and posttranslational modifications (Lipman et al., 2005). Nowadays, 
even humanized or human antibodies are produced by advanced hybridoma 
technologies (reviewed in (Chiarella and Fazio, 2008)). For this purpose, spleen cells 
are taken from transgenic mice where the murine immunoglobulin locus was 
replaced by human genes (Lonberg et al., 1994; Lonberg, 2005; Zhu et al., 2005).  
Since the production of MAbs via the hybridoma technology is still not a 
high-throughput method, requires time, expertise and money, alternatives and 
improvements have been searched to minimize these shortcomings. To this aim, 
multiplex immunizations from two to 80 antigens in parallel were performed 
(E. Kremmer) (De Masi et al., 2005; Larsson et al., 2006; Ning et al., 2006) and 
protocols for semi-automated hybridoma fusion and culturing were improved. 
Moreover, large-scale detection and screening methods like antigen microarrays 
(Michaud et al., 2003; Nielsen and Geierstanger, 2004; De Masi et al., 2005) or 
automated ELISA via robotic technology (Rohner et al., 2005) were developed. In the 
era of epigenomics and proteomics there are now trials to generate proteome binders 
(Taussig et al., 2007) that are suitable for systematic first-line phenotyping of mouse 
models (Gailus-Durner et al., 2009). Despite great efforts to improve the hybridoma 
technology, the characterization of MAbs still remains a bottleneck in large scale 
antibody production.  
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1.2.2. Fluorescent protein tags and photobleaching techniques 
 
Fluorescent proteins 
 
Fluorescent proteins (FPs) are widely used as in vivo reporter molecules and are 
available in multiple colors spanning almost the entire visible light spectrum (Tsien, 
2009). Genetically fused to any target protein, FPs offer a powerful tool to study 
protein localization, interactions and dynamics in vivo using photobleaching 
techniques such as fluorescence recovery after photobleaching (FRAP), 
fluorescence loss in photobleaching (FLIP) or fluorescence resonance energy 
transfer (FRET) (Belmont, 2001; Misteli, 2001; Lippincott-Schwartz et al., 2003; van 
Royen et al., 2009b). The diversity of FPs has dramatically expanded from the 
prototypical green fluorescent protein (GFP) (Shimomura et al., 1962; Prasher et al., 
1992; Chalfie et al., 1994) isolated from the jellyfish Aequorea Victoria, to engineered 
mutants (enhanced eGFP) and additional spectral variants (cyan CFP, yellow YFP, 
etc.) thereof (reviewed in (Tsien, 2005)). The discovery of a red fluorescent protein 
(DsRed) in the coral Discosoma sp. provided a new red-shifted reporter tool with 
better spectral separation from cellular autofluorescence and allowed multicolor 
tracking of fusion proteins in one cell (Matz et al., 1999; Wall et al., 2000). However, 
the obligate tetramerization of DsRed caused serious problems for its use in live-cell 
imaging. Subsequent mutagenesis of the red progenitor has resulted in several 
monomeric red FPs (mRFP1, mCherry, mOrange, mPlum, etc) (Campbell et al., 
2002; Shaner et al., 2004; Wang et al., 2004; Tsien, 2005; Shu et al., 2006). These 
improved red FPs are characterized by higher brightness and photostability, 
complete chromophore maturation and promise a wide variety of features for 
biological imaging and multicolor labeling (Mizuno et al., 2001; Zhang et al., 2002; 
Shaner et al., 2005). Very recently, an infrared-fluorescent protein (IFP) with 
excitation and emission maxima of 684 and 708 nm, respectively, has been 
engineered, that allows penetration of excitation light in tissues and thus is suitable 
for whole-body imaging (Shu et al., 2009).  
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Fluorescence recovery after photobleaching (FRAP)-technique to measure 
protein kinetics in vivo 
 
Photobleaching techniques, such as fluorescence recovery after photobleaching 
(FRAP), fluorescence loss in photobleaching (FLIP) or fluorescence resonance 
energy transfer (FRET), are powerful methods to explore protein localization, 
interactions and dynamics in vivo (Periasamy, 2001; Lippincott-Schwartz et al., 2003; 
van Royen et al., 2009b). Two decades ago photobleaching methods were 
developed to detect diffusion characteristics in living cells (Axelrod et al., 1976). Later 
on, the experimental approach was extended to study binding of lipid proteins in the 
plasma membrane, cytoskeleton dynamics and nucleocytoplasmic protein shuttling 
(Edidin et al., 1976; Amato and Taylor, 1986; Koster et al., 2005). Today, 
fluorescence imaging is commonly used and is expanding rapidly because of 
synergistic advancements in fluorescent protein tags, instrumentation and data 
analysis, enabling single-molecule detection, multi-protein and live-cell imaging 
(Giepmans et al., 2006). Especially, advanced confocal laser scanning systems 
enable to measure protein dynamics via FRAP or FLIP in vivo (Stephens and Allan, 
2003; van Royen et al., 2009a).  
A FRAP experiment is based on the irreversible photobleaching of fluorescent fusion 
proteins in a selected compartment within the cell nucleus by a high-powered 
focused laser beam (Figure 11). Subsequent diffusion of surrounding non-bleached 
fluorescent molecules into the bleached area leads to recovery of fluorescence over 
time by displacing the bleached molecules until an equilibrium is reached 
(steady-state) (Figure 11 A). Complete recovery of fluorescence will only occur, if the 
underlying entire protein population is dynamically exchanged and no immobile 
population is present (Phair et al., 2004a; Beaudouin et al., 2006). Comparable 
kinetic parameters can be extracted from the normalized recovery curve by the 
relative measures of the half time of recovery (t1/2) and the mobile fraction (MF) 
(Figure 11 C) (Lippincott-Schwartz et al., 2001; Reits and Neefjes, 2001). 
Furthermore, FRAP analyses and subsequent kinetic modeling yield qualitative and 
quantitative information about the number of binding states and the binding strength 
of molecular interactions (Carrero et al., 2003; Sprague and McNally, 2005; McNally, 
2008; Dobay et al., in preparation). Hence, protein mobility reflects the current 
function in the cell.  
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Figure 11: Representative FRAP experiment from image acquisition to data evaluation.  
(A) Half nucleus FRAP series of a C2C12 cell, transiently expressing a GFP-fusion protein (Dnmt1). 
Selected pre-and postbleach frames show time-dependent fluorescence recovery of the fusion protein 
until a steady state equilibrium is reached after 80 seconds (s). Rectangle indicates the bleached 
region of interest (ROI). Bar: 5 µm. (B) ROI and set of compartments necessary for subsequent 
normalization and data extraction as shown in C. Quantitative evaluation of the FRAP experiment (C). 
Fluorescence intensities in the bleached and unbleached region were measured over time and 
normalized to correct for bleaching during image acquisition, nuclear import, bleaching depth and 
background. Triple normalized (*) data take into account the loss of fluorescence recovery occurring 
during the last bleach and the first postbleach time point (Dobay et al., in preparation). F∞ indicates 
the plateau level of fluorescence reached after complete equilibration and indicates the immobile / 
mobile fraction; t1/2 marks the halftime of fluorescence recovery. Notably, as the half of the nucleus 
was bleached, convergence of the bleached and unbleached curves occurs at 0.5 of relative intensity 
and indicates only a little immobile, stably bound fraction (<6%).  
 
Within the eukaryotic cell, protein mobility and dynamic exchange is of key 
importance for many cellular functions and essential to provide cellular plasticity and 
efficient responses to external signals (Gorski et al., 2006). Indeed, several nuclear 
factors display a high degree of mobility (Phair and Misteli, 2000; Phair et al., 2004b; 
Misteli, 2005). Transient binding to rather immobile structures such as chromatin, or 
stationary enzyme complexes like the replication machinery, decreases protein 
mobility (Dundr and Misteli, 2001; Misteli, 2001). Notably, the mobility of one and the 
same protein can differ drastically dependent on its current function or binding 
partners. One example is PCNA that forms a trimeric ring and stably slides along the 
DNA double strand, acting as central loading platform for interacting factors in DNA 
replication and repair (Mortusewicz et al., 2005; Sporbert et al., 2005; Moldovan et al., 
2007). While one fraction of nucleoplasmic PCNA molecules reveals high mobility in 
its unengaged state, a second fraction becomes temporarily immobilized at DNA 
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replication or repair sites, the sites of action (Sporbert et al., 2002; Essers et al., 
2005). Hence, the dynamic properties of a protein are crucial for determining the 
function within the cell. However, photobleaching techniques have still some 
drawbacks since bleaching and imaging of the fluorescent fusion proteins by 
intensive laser radiation might induce DNA damage and could affect cell viability 
(Dobrucki et al., 2007). In addition, the significant size of the fused fluorescent protein 
tag might interfere with protein function, localization or interactions.  
 
Direct visualization of Dnmt1 enzyme activity in living cells 
 
The catalytic activity of Dnmt1 can be monitored directly in vivo via a trapping assay 
(Schermelleh et al., 2005; Schermelleh et al., 2008). This method is based on the 
application of the nucleoside analog 5-aza-2′-deoxycytidine (5-aza-dC), which gets 
incorporated into the newly synthesized DNA during replication and serves as 
mechanism-based inhibitor. When Dnmt1 undertakes the methyl group transfer 
reaction at the 5-aza-dC residue, an irreversible covalent complex is formed and 
Dnmt1 gets immobilized (trapped) at replication foci (RF), the site of action. This 
time-dependent immobilization of GFP-Dnmt1 (trapping rate) can be measured by 
FRAP analyses and reflects the enzymatic activity of the fusion protein. Applying this 
method, one can study Dnmt1 activity and binding preference to its natural substrate 
in the physiological environment, a living cell. Furthermore, this assay allows the 
comparison of wt GFP-Dnmt1 and mutants thereof concerning subnuclear targeting 
and postreplicative methylation efficiency.  
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1.2.3. Mouse embryonic stem cells as model system to analyze protein 
dynamics, interactions and complex protein networks in vivo 
 
Embryonic stem (ES) cells are derived from the inner cell mass of blastocysts and 
possess a high level of cellular plasticity, allowing indefinite self-renewal and 
differentiation into every potential cell type of the three primary germ layers; 
endoderm, mesoderm and ectoderm (Evans and Kaufman, 1981; Bradley et al., 
1984; Lake et al., 2000). During differentiation, ES cells lose their pluripotency and 
undergo dramatic morphological and functional changes without any change in DNA 
sequence. The underlying changes of gene expression patterns are established and 
maintained by epigenetic processes like DNA methylation, histone modifications and 
chromatin architecture (Jaenisch and Young, 2008). In recent years, mouse ES cells 
became indispensable tools in research. Gene knockout or transgenic technologies 
provide the possibility to create genetically modified cell lines or mice, enabling to 
explore gene function, complex regulatory pathways and cellular development in vitro 
and in vivo. This feature is indeed very helpful in studying Dnmt proteins, since 
genetic knockout or even knockdown of the Dnmt proteins in somatic cells results in 
genome instability and lethality (Gaudet et al., 2003; Dodge et al., 2005; Karpf and 
Matsui, 2005; Egger et al., 2006; Chen et al., 2007; Spada et al., 2007). In contrast, 
ES cells deficient for either Dnmt1 (dnmt1-/-), Dnmt3a and Dnmt3b (DKO) or all three 
simultaneously (TKO; dnmt1-/-3a-/-3b-/-) are viable and genetically stable, with 
reduction of global DNA methylation levels (Li et al., 1992; Lei et al., 1996; Jackson 
et al., 2004; Tsumura et al., 2006). Hence, ES cells are a perfect model system to 
characterize selectively Dnmt proteins, identify their interaction partners and 
elucidate the complex regulation in the epigenetic network in vivo. Using advanced 
live cell microscopy and FRAP analyses, it is possible to monitor the subcellular 
distribution and binding kinetics of Dnmts in several knockout ES cells with normally 
methylated (wt J1), reduced methylated (dnmt1-/-, np95-/-), and unmethylated (TKO) 
genomes. By performing rescue experiments, one can test specific Dnmt mutant 
proteins regarding localization, complex formation and the functional consequences 
of these mutations in the regulation of DNA methylation.  
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1.3. Aims of the work 
 
The main objective of this study was the analysis of the cell cycle dependent 
localization, activity and dynamics of Dnmt1 and its interaction partners PCNA and 
Np95 in living cells. The goal was, to achieve a better understanding of the complex 
regulation of Dnmt1 in vivo and how these interactions are involved in the stable 
inheritance of DNA methylation patterns.  
For this purpose, tools and techniques to monitor Dnmt1, PCNA and Np95 in their 
natural, cellular environment had to be developed. More specifically, advanced live 
cell microscopy and photobleaching techniques had to be established in somatic and 
embryonic stem (ES) cells. In addition, specific monoclonal antibodies had to be 
generated as tools to study Dnmt1, PCNA and red fluorescent fusion proteins in a 
different set of cell biological and biochemical applications including western blot, 
immunofluorescence- and immunoprecipitation assays.  
Using these tools and techniques, the cell cycle dependent regulation of Dnmt1/Np95 
and mutants thereof had to be explored. By comparing the subcellular localization 
and binding kinetics of GFP-tagged wt-Dnmt1 and specific mutants, the function of 
the PBD and ZnF domain, their interactions and their contribution to the maintenance 
of epigenetic information after DNA replication had to be analyzed. Furthermore, the 
catalytic activity and binding preference of Dnmt1 and mutant proteins had to be 
investigated using a live cell trapping assay. To elucidate the mechanistic basis of 
the Np95 function, deletion mutants and isolated Np95 domains had to be generated 
to solve the individual domain properties using different in vitro and in vivo 
approaches. Finally the influence of methylation levels and patterns on Dnmt1/Np95 
protein localization, activity and mobility had to be tested by measuring in vivo 
binding kinetics via FRAP analyses in ES cells with normal (wt J1; wt E14), reduced 
(dnmt1 -/- ; np95 -/-) or absent (TKO) genomic DNA methylation.  
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2. Results 
 
 
 
 
 
 
 
 
 
 
 
 
2.1. Generation and Characterization of a Rat Monoclonal Antibody 
against multiple red fluorescent proteins. 
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Abstract
Fluorescent proteins (FP) are widely used as in vivo reporter molecules and are available in multiple colors
spanning almost the entire visible light spectrum. Genetically fused to any protein target, FPs offer a powerful
tool to study protein localization and dynamics. After the isolation of the prototypical green fluorescent pro-
tein (GFP) from the jellyfish Aequorea victoria, a red fluorescent protein (DsRed) was discovered in the coral Dis-
cosoma sp. that provided a better spectral separation from cellular autofluorescence and allowed multicolor
tracking of fusion proteins. However, the obligate tetramerization of DsRed caused serious problems for its use
in live-cell imaging. Subsequent mutageneses of the red progenitor have resulted in several monomeric red FPs
(mRFP1, mCherry, mOrange, mPlum, etc). These improved red FPs are characterized by higher brightness and
photostability, complete chromophore maturation, and promise a wide variety of features for biological imag-
ing and multicolor labeling. Here we report the generation and characterization of the first rat monoclonal an-
tibody (MAb) against multiple red FPs, designated as multi-red 5F8. We demonstrate that multi-red 5F8 is a
MAb with high affinity and specificity against the DsRed derivatives and corresponding fusion proteins, and
that it is suitable for ELISA, immunoblotting, immunoprecipitation, and immunofluorescence assays. Apply-
ing our versatile antibody, one and the same red fluorescent protein tag can be used to perform not only mi-
croscopic studies, but also multiple biochemical assays.
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Introduction
THE UNDERSTANDING OF COMPLEX biological systems ishighly dependent on the ability to visualize participat-
ing factors in their cellular context. Fluorescent proteins (FP)
are transcriptional and translational reporters commonly
used in real-time imaging approaches where they help mon-
itor the cellular distribution, interactions, and dynamics of
targeted proteins in vivo. In the past few years the diversity
of FPs has dramatically expanded from the prototypical
green fluorescent protein (GFP)(1) isolated from the jellyfish
Aequorea victoria, to its engineered mutants (enhanced eGFP)
and additional spectral variants (cyan CFP, yellow YFP, etc.)
thereof.(2)
The discovery of a red fluorescent protein (DsRed) in the
coral Discosoma sp.(3) provided a new red-shifted reporter
tool with better spectral separation from the cellular auto-
fluorescence and allowed the simultaneous visualization of
multiple fusion proteins in one cell. However, live-cell imag-
ing and analysis of protein dynamics were limited due to the
obligate tetrameric properties of the DsRed protein, leading
to crosslinking, aggregation, and precipitation of the fusion
protein. To circumvent the oligomerization of the fusion pro-
teins, the tetrameric progenitor DsRed was re-engineered by
targeted as well as random mutagenesis. The improved
monomeric first-generation (mRFP1) and second-generation
(mCherry, mPlum, mOrange, etc.) fluorescent proteins ex-
hibit increased brightness, photostability, solubility, and
complete chromophore maturation properties.(2,4,5) These re-
engineered red FPs are therefore extremely useful in single-
or multicolor fluorescence assays like fluorescence recovery
after photobleaching (FRAP) or fluorescence resonance en-
ergy transfer (FRET).(6,7)
On the one hand, the development of new red fluorescent
proteins has increased drastically and is still ongoing, and
on the other hand, there is a lack of corresponding antibod-
ies detecting these FPs in biochemical approaches. Currently
there is a limited number of polyclonal and monoclonal an-
1Center for Integrated Protein Science Munich, Department of Biology, Ludwig Maximilians University Munich, Planegg-Martinsried,
Germany.
2Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Institute of Molecular Immunology, Munich,
Germany.
3Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
tibodies raised against DsRed available. To extend the ap-
plication range of FPs, especially to enable the detection of
red fluorescent fusion proteins in biochemical approaches,
we generated the first rat monoclonal antibody detecting
multiple red FPs. We show here the suitability of this 
high-affinity and highly specific antibody for ELISA, im-
munoblotting, immunoprecipitation, and immunofluores-
cence assays. This first anti-multi-red FP antibody allows the
simultaneous analysis of one and the same red fluorescent
fusion protein via bioimaging as well as biochemical ap-
proaches.
Materials and Methods
Cell lines
Mouse C2C12 myoblasts and human HEK 293T embry-
onic kidney cells were cultured in DMEM containing 50
g/mL gentamicin supplemented with 20% and 10% FCS,
respectively.
Expression constructs and purification of red fluorescent
proteins (antigen preparation)
The full-length red FPs mRFP1, mCherry and mOrange,
cloned into pRSETB bacterial expression vectors, adding an
N-terminal histidine (His6) tag were kindly provided by R.Y.
Tsien (Dept. of Chemistry and Biochemistry, UCSD, La Jolla,
CA).(4,8) The cDNA of mPlum was cut out of the pBAD bac-
terial expression vector (also provided by R.Y. Tsien(5)) and
cloned into pRSETB similar to the other FPs. His-tagged red
FPs were expressed in E. coli BL21(DE3) cells (Novagen, Darm-
stadt, Germany) and purified with the TALON Superflow
Metal Affinity Resin system (Clontech, Saint Germain, France)
under native conditions. The cell pellets of each 200 mL bac-
terial culture were resuspended in 20 mL TALON extraction
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole
[pH 8.0]) and homogenized for 10 min. The lysate was cleared
by centrifugation (12,000 g, 30 min, 4°C), and the supernatant
was mixed with 2 mL of TALON Superflow Metal Affinity
resin, pre-equilibrated in TALON extraction buffer. After in-
cubation at 4°C for 2 h, the beads were washed with 50 mL
TALON extraction buffer, and the red proteins were eluted
by adding 150 mM imidazole to the TALON extraction buffer.
Elution fractions were dialyzed against 1 PBS and the pu-
rity of the eluted fractions were analyzed by SDS-PAGE fol-
lowed by Coomassie Blue staining. The protein concentrations
were determined by absorption at 280 nm.
The mammalian expression constructs eGFP-PCNA and
mRFP1-PCNA were described earlier.(9,10) The mCherry-
PCNA, mPlum-PCNA, and mOrange-PCNA expression 
constructs were derived from the mRFP1-PCNA construct.
The mRFP1 was removed by restriction enzyme digestion
and was exchanged with the corresponding red FP variant.
Inserts were verified by DNA sequencing. 
Immunization, generation of hybridomas, and 
ELISA screening
The His-tagged red FPs were pooled and approximately
100 g were injected both intraperitoneally (i.p.) and subcu-
taneously (s.c.) into Lou/C rats using CpG2006 (TIB MOL-
BIOL, Berlin, Germany) as adjuvant. After 8 weeks, a boost
was given i.p. and s.c. 3 days before fusion. Fusion of the
myeloma cell line P3X63-Ag8.653 with the rat immune
spleen cells was performed using polyethylene glycol 1500
(PEG 1500, Roche, Mannheim, Germany). After fusion, the
cells were plated in 96-well plates using RPMI 1640 with 20%
fetal calf serum, penicillin/streptomycin, glutamine, pyru-
vate, and non-essential amino acids (PAA, Cölbe, Germany)
supplemented by aminopterin (Sigma, St. Louis, MO). Hy-
bridoma supernatants were tested in a solid-phase im-
munoassay. Microtiter plates were coated overnight with
His-tagged multi-red proteins at a concentration of 3–5
g/mL in 0.1 M sodium carbonate buffer (pH 9.6). After
blocking with non-fat milk (Frema, Neuform, Zarrentin, Ger-
many), hybridoma supernatants were added. Bound rat
MAbs were detected with a cocktail of biotinylated mouse
MAbs against the rat IgG heavy chains, thus avoiding IgM
MAbs (-IgG1, -IgG2a, -IgG2b [ATCC, Manassas, VA], -
IgG2c [Ascenion, Munich, Germany]). The biotinylated
MAbs were visualized with peroxidase-labeled avidin
(Alexis, San Diego, CA) and o-phenylenediamine as chro-
mogen in the peroxidase reaction. Multi-red 5F8 (rat IgG2a)
was stably subcloned and further characterized.
Immunoblot analysis
For immunoblot analysis, serial dilutions (1.25–20 ng) of
purified FPs (mRFP1, mCherry, mOrange, mPlum, and
eGFP) were homogenized in SDS-containing loading buffer,
separated on a 12% SDS-PAGE, and electrophoretically
transferred to a nitrocellulose membrane (Bio-Rad Labora-
tories, Hercules, CA). In addition, 1  107 HEK 293T cells,
either mock treated or transiently transfected with expres-
sion vectors coding for fluorescent fusion proteins mRFP1-
PCNA, mCherry-PCNA, mOrange-PCNA, mPlum-PCNA,
and eGFP-PCNA, were harvested in ice cold PBS, washed
twice, and incubated in 60 L buffer (PBS, DNaseI [1.2
mg/mL], 2 mM PMSF, 5 mM MgCl) for 15 min on ice. Fi-
nally, the cells were homogenized in SDS-containing load-
ing buffer. 5  104 cells/lane were separated on a 10% SDS-
PAGE and electrophoretically transferred to nitrocellulose
membrane (Bio-Rad Laboratories). After protein staining
with Ponceau S solution (Sigma), the membrane was blocked
for 10 min with 3% milk in PBS containing 0.075% Tween-
20. 0.2 g of the multi-red antibody 5F8 was added and in-
cubation continued for 1 h at room temperature. In addition
a mouse monoclonal anti-GFP antibody (Roche) and a rat
monoclonal anti-PCNA antibody (clone 16D10(11)) were used
as primary antibodies. After washing with PBS containing
0.1% Tween-20, the blots were incubated with a secondary
anti-rat IgG-HRP or anti-mouse Ig-HRP antibody (Jackson
ImmunoResearch Europe). Immunoreactive bands were vi-
sualized with ECL Western Blot Detection reagents (GE
Healthcare, Freiburg, Germany).
Immunoprecipitation
For immunoprecipitation, 1  107 HEK 293T cells, either
mock treated or transiently transfected with expression vec-
tors coding for fluorescent fusion proteins mRFP1-PCNA,
mCherry-PCNA, mOrange-PCNA, mPlum-PCNA, and
eGFP-PCNA, were harvested in ice cold PBS, washed twice,
and subsequently homogenized in 200 L lysis buffer (20
mM Tris/HCl [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 1 mM
PMSF, 0.5% NP40). After a centrifugation step (10 min, 14,000
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g, 4°C), the supernatant was adjusted with dilution buffer
(20 mM Tris/HCl [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 1
mM PMSF) to 500 L. 50 L were mixed with SDS-contain-
ing sample buffer (referred to as input [I]). For immunopre-
cipitation, 4 g of the multi-red antibody 5F8 were added
and incubated 1 h at 4°C. For pull down of immunocom-
plexes, 30 L of dilution buffer equilibrated protein G
agarose beads (GE Healthcare) were added and incubation
continued for 1 h. After centrifugation (2 min, 5000 g, 4°C)
50 L of the supernatant was collected (referred to as non-
bound/or flowthrough [F]) while the remaining supernatant
was removed. The beads were washed twice with 1 mL di-
lution buffer containing 300 mM NaCl. After the last wash-
ing step, the beads were resuspended in 100 L SDS-con-
taining sample buffer and boiled for 10 min at 95°C. For im-
munoblot analysis, 1% of the input and the flowthrough as
well as 10% of the bound (B) fraction were separated on a
10% SDS–PAGE, electrophoretically transferred to a nitro-
cellulose membrane, and subjected to immunoblot analysis
as described above.
Immunofluorescence
For immunostainings, C2C12 cells were grown on cover-
slips and transfected transiently with mRFP-PCNA,
mCherry-PCNA, mOrange-PCNA, and mPlum-PCNA using
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FIG. 1. Multiple red fluorescent proteins (FPs). (A) Sequence alignment of the red FPs mRFP1, mPlum, mCherry, and
mOrange. Identical residues are indicated by asterisks; highly conserved residues are marked with two vertical dots and
lesser-conserved residues with a single dot below the sequence. The chromophore core is boxed. (B) Crystal structure of
the mCherry monomer (PDB 2H5Q).(12) The beta-barrel shaped structure (gray) encircles the central alpha-helix containing
the embedded chromophore core (dark gray, sticks). The image was generated using PyMOL.(13) (C) Purified FPs mRFP1,
mCherry, mOrange, and mPlum were subjected to a 15% SDS-PAGE and stained with Coomassie. The molecular weight
markers are indicated on the left.
polyethylenimine (PEI Sigma, St. Louis, MO). Cells were
fixed with 3.7% formaldehyde in PBS. As primary antibody,
multi-red 5F8 (diluted 1:20 [6–10 g/mL]) in PBS containing
2% BSA) was used. The primary antibody was detected with
a secondary anti-rat IgG antibody (diluted 1:400 in PBS 
containing 2% BSA) conjugated to Alexa Fluor 488 (Molecu-
lar Probes, Eugene, OR). Cells were counterstained with 
DAPI and mounted in Vectashield (Vector Laboratories,
Burlingame, CA). Images of the cells were obtained using a
widefield epifluorescence microscope (Axiophot 2, Zeiss,
Oberkochen, Germany) using a 63x/1.4 NA Plan-Apochro-
mat oil immersion objective.
Results and Discussion
Generation of a rat MAb against multiple red 
fluorescent proteins
In vivo imaging has benefited greatly from the possibility
of visualizing and tracking proteins by creating genetically
encoded fusions with a red or green fluorescent protein tag
(fusion tagging).
mOrange, mRFP1, mCherry, and mPlum are the most fre-
quently used red fluorescent reporters, exhibiting an excita-
tion and emission maxima ranging from 548 to 590 nm and
562-649 nm, respectively.(4) The widespread chromophore
spectra of the red FPs result from simple rearrangements of
the chromophore cavity or autonomous multi-step post-
translational modifications that include one or more cova-
lent modifications to the polypeptide backbone.(12) The
amino acid sequences as well as the three-dimensional struc-
tures of the four red DsRed descendants are highly con-
served (Fig. 1A and B). As described previously,(4) the GFP-
type termini of the DsRed variants result in a higher
tolerance to N- and C-terminal fusions. The red chromophore
is directly encoded in the amino acid sequence (Fig. 1A, box).
Figure 1B shows the crystal structure of mCherry (PDB
2H5Q) with the typical -barrel shape (gray), which stably
encircles the central alpha-helix containing the embedded
chromophore core (F70, M71, Y72 to G73, black). 
The complementation of live cell imaging data with bio-
chemical studies of one and the same red-labeled fusion pro-
tein is limited due to sparely available and applicable anti-
bodies against red FPs. Here, we present the first rat
monoclonal antibody against a set of red FPs useful in mi-
croscopic as well as in biochemical approaches.
To generate a multi-red antibody, the cDNAs of the full-
length red FPs mRFP1, mCherry, mOrange, and mPlum with
an N-terminal His6 tag were expressed separately in Esche-
richia coli and purified under native conditions for antigen
production. To test the purity of the eluted fractions, the pu-
rified proteins were subjected to SDS-PAGE followed by
Coomassie Blue staining (Fig. 1C). The recombinant proteins
were highly soluble and the yield of purified protein was
15 mg/mL.
In order to generate monoclonal antibodies against a mul-
tiple set of red FPs and due to their high sequence similari-
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FIG. 2. Immunoblot analyses to test the specificity and affinity of the rat monoclonal multi-red antibody 5F8. (A) Multi-
red immunoblot. 20 ng of purified red FP, eGFP, and E. coli protein extract (control) were loaded and subjected to SDS-
PAGE. Immunostaining was performed with either the anti-multi-red 5F8 (A, upper panel) or with an anti-GFP antibody
(A, lower panel). The molecular weight markers are indicated on the right. (B) A serial dilution of purified mRFP1 protein
and E. coli protein extract (control) were loaded to test the affinity of the multi-red antibody. The mRFP1 protein migrates
at 32 kDa. The detection limit of the multi-red MAb ranges between 1.25 and 2.5 ng of purified mRFP1. (C) Immunoblot
of red fluorescent fusion proteins mRFP-PCNA, mCherry-PCNA, mOrange-PCNA, and mPlum-PCNA. Soluble protein ex-
tracts of HEK 293T cells expressing the red-PCNA fusions, GFP-PCNA or mock treated (293T control) were loaded on SDS-
PAGE. Immunostaining was performed with the multi-red 5F8 antibody (C, upper panel). Detection of PCNA was used to
control for expression and loading (C, lower panel). The molecular weight markers are indicated on the right.
ties, all purified red FPs were pooled in equal amounts and
were used to immunize Lou/C rats. A panel of hybridomas
was generated by fusing spleen cells from immunized ani-
mals with the myeloma cell line P3X63-Ag8.653. The anti-
bodies produced by the hybridomas were initially screened
in a solid-phase immunoassay (indirect ELISA). Plates
coated with His6-tagged pooled red FPs were incubated with
the hybridoma supernatants containing monoclonal anti-
bodies. Specific antigen binding was detected with a mixture
of biotinylated mouse MAbs against the rat IgG heavy
chains. In a next step, 17 positive hybridoma supernatants
were screened by an immunoblot assay using whole cell ex-
tracts from human HEK 293T transiently transfected with
multiple red fusion proteins (data not shown). One antibody
designated as multi-red 5F8 was selected, established, and
expanded. The isotype of the specific antibody was found to
be rat IgG2a. 
Immunoblotting and immunoprecipitation with the 
multi-red 5F8 antibody 
For a first functional analysis, we tested the ability of 
the multi-red antibody 5F8 to detect a set of red FPs in 
immunoblotting. 20 ng of the purified red FPs mRFP1,
mCherry, mPlum, and mOrange were subjected to SDS-
PAGE and blotted onto a nitrocellulose membrane (Fig. 2A).
To investigate the specificity of the multi-red antibody for
only red FPs, we included in our Western blot analysis the
green fluorescent protein eGFP as well as E. coli cell extract
as negative control. The 5F8 antibody recognized all DsRed
derivatives but not the unrelated eGFP, and confirmed that
the generated antibody is a real multi-red FP-specific anti-
body. To determine the affinity of the multi-red antibody 5F8
in immunoblotting, a serial dilution of purified mRFP1 rang-
ing from 1.25 to 20 ng was separated in SDS-PAGE, blotted
onto nitrocellulose membrane, and incubated with 0.2 g
multi-red 5F8 antibody (Fig. 2B). The monoclonal antibody
was able to detect 1.25 ng of mRFP1 protein. As expected,
this signal was not present in the E. coli extract, which was
used as a negative control.
Figure 2A and 2B demonstrates that the multi-red anti-
body 5F8 recognized multiple purified red FPs in Western
blot. Nevertheless, the main application area of the multi-
red antibody 5F8 is the detection of red-labeled fusion pro-
teins in cell extracts. Soluble protein extracts from equal
numbers of human HEK 293T cells, either transiently trans-
fected with the red- or green-labeled PCNA fusion proteins
or mock treated, were separated by SDS-PAGE and trans-
ferred onto an nitrocellulose membrane. As shown in Figure
2C, multi-red 5F8 was able to detect red-labeled fusion pro-
teins with a molecular weight of 70 kDa. Moreover, the ab-
sence of any cross-reacting bands underlined the highly spe-
cific antigen binding of this antibody. As loading control and
to verify the high specificity of the multi-red 5F8 antibody
in immunoblot, we took advantage of our recently published
anti-PCNA rat MAb 16D10(11) and detected the PCNA in the
fusion proteins as well as the endogenous PCNA (lower
panel). Besides the endogenous PCNA at 31 kDa, two ad-
ditional bands were detectable. The upper band at 70 kDa
co-localized with the anti-multi-red MAb signal, whereas the
lower band at 55 kDa represents an additional degrada-
tion product of the corresponding fusion protein. The weaker
signal of mOrange-PCNA could be explained by differences
in expression levels apparent in the anti-PCNA control blot.
These data illustrated the high specificity and affinity of the
multi-red 5F8 antibody for immunoblot applications.
To further test the specificity of multi-red 5F8 to recognize
the native, folded red fusion proteins, we performed im-
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FIG. 3. Immunoprecipitation of red fluorescent fusion proteins. Human HEK 293T cells were transiently transfected with
either red PCNA fusions, GFP-PCNA fusion or mock treated (293T control). Soluble cell extracts were subjected to im-
munoprecipitation analysis using the multi-red antibody 5F8. One percent of input (I) and flowthrough (F) fractions and
10% of the bound (B) fractions were subjected to SDS-PAGE followed by immunoblot analysis. (A) Successful immuno-
precipitation and blotting were confirmed via Ponceau staining. The molecular weight markers are indicated on the left.
(B) Precipitated red PCNA fusions were subsequently detected by immunostaining with multi-red 5F8. Fusion proteins as
well as denatured heavy (HC) and light chains (LC) of the IgGs are marked by arrowheads. 
munoprecipitation assays. To this end, we used the same set
of different fluorescently labeled PCNA fusions from whole
cell lysates of transiently transfected human HEK 293T cells.
After incubation of the soluble cell extract with the antibody
followed by extensive washing, the bound protein was
eluted and subjected to SDS-PAGE electrophoresis and im-
munoblotting (Fig. 3). The Ponceau S staining of the nitro-
cellulose membrane (Fig. 3A) demonstrated the efficient and
clean immunoprecipitation with the multi-red 5F8 antibody,
shown by distinct bands in the bound fractions. The protein
band of 70 kDa subsequently reacted with the multi-red
5F8 antibody (Fig. 3B). The two lower bands (25 kDa, 50
kDa) correspond to the heavy and light chains of the dena-
tured IgGs. No unspecifically precipitated proteins could be
observed in the bound fraction of the negative controls GFP-
PCNA and mock-treated 293T cells. A quantitative analysis
of the non-bound (F) fraction revealed a nearly complete de-
pletion of red PCNA fusion from human cell extracts after
immunoprecipitation with multi-red 5F8. This result showed
that the multi-red 5F8 antibody recognized its epitope un-
der native conditions, when it is part of larger nuclear com-
plexes.
We verified the immunoprecipitation data with the anti-
PCNA antibody 16D10(11) and detected the PCNA in the red-
labeled fusion proteins after immunoprecipitation and im-
munoblot (data not shown). The high pulldown efficiency of
multi-red 5F8 provides a significant improvement for the
analysis of all kinds of multiple red fluorescent fusion pro-
teins.
Immunofluorescence stainings of red-labeled PCNA
fusions with the monoclonal antibody
To investigate whether the multi-red antibody 5F8 is also
suitable to detect red-labeled PCNA fusions in situ, we per-
formed immunofluorescence stainings of transiently trans-
fected C2C12 cells. PCNA, as a key component of the nu-
clear replication machinery, accumulates at sites of DNA
replication, the so-called replication foci.(9) Fluorescently la-
beled PCNA fusion proteins are widely used in microscopy
to identify replication foci and to distinguish S-phase stages
(cell cycle marker). The results of the immunofluorescence
analyses with the multi-red antibody 5F8 are summarized in
Figure 4. C2C12 cells, transiently transfected with either
mRFP1-PCNA, mCherry-PCNA, mPlum-PCNA, or mOrange-
PCNA expression constructs, were fixed with formaldehyde
and stained with the multi-red antibody 5F8. Subcellular lo-
calization of the red-PCNA fusions are shown in the left
panel, antibody specific signals are shown in the middle
panel, and the distribution of AT-rich heterochromatic re-
gions are highlighted by DAPI staining (right panel). Typi-
cal late S-phase cells, containing few horse shoe-like foci rep-
resenting late replicating heterochromatin, are shown in
Figure 4A. The antibody staining showed a complete co-lo-
calization with all the red PCNA fusion proteins. No cross-
reaction was observed in untransfected C2C12 cells (Fig. 4B).
Methanol fixation yielded similar results (data not shown).
The immunofluorescence stainings demonstrated that multi-
red 5F8 specifically recognized its epitope also in the com-
plex cellular environment.
In summary, we have generated the first rat MAb with a
high specificity and affinity for multiple red fluorescent pro-
teins (mRFP1, mCherry, mPlum, mOrange) and associated
fusions. We could demonstrate that multi-red 5F8 is highly
suitable for ELISA, immunoblotting, immunoprecipitation,
and immunofluorescence assays. With this versatile anti-
body, we provide a valuable tool for the simultaneous anal-
ysis of one and the same red fluorescent fusion protein via
bioimaging and biochemical approaches.
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ABSTRACT
Proliferating cell nuclear antigen (PCNA) is a homotrimeric ring-shaped protein that encircles the DNA and
acts as a stationary loading platform for multiple, transiently interacting partners participating in various
DNA transactions. This essential cellular component, originally characterized as a nuclear antigen of divid-
ing cells, is evolutionary highly conserved from yeast to human. Within the eukaryotic cell, PCNA serves as
a processivity factor for DNA polymerase  and plays a key role in DNA replication, repair, cell cycle regu-
lation, and post-replicative transactions like DNA methylation and chromatin remodelling. All these cellular
processes are regulated by a complex network comprising cell cycle dependent changes in expression levels,
dynamics, interactions, and localization of PCNA. Here we report the generation and characterization of the
first rat monoclonal antibody (MAb) against human PCNA, designated as PCNA 16D10. We demonstrated
that PCNA 16D10 is a highly affine and specific MAb suited for ELISA, immunoblotting, immunoprecipita-
tion, and immunofluorescence. The characteristic punctate staining of S phase cells allows the identification
of proliferating cells and the monitoring of cell cycle progression.
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INTRODUCTION
PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) was origi-nally characterized as a processivity factor for the eukary-
otic DNA polymerase  and belongs to the family of evolu-
tionary highly conserved DNA sliding  clamps.(1–3)
Crystallographic studies revealed that the PCNA clamp con-
stitutes a highly symmetric assembly of three identical head-
to-tail arranged monomers, each comprising two similar do-
mains.(4–6) The inner layer of the homotrimeric ring is com-
posed of positively charged -helices mediating the association
with the DNA, whereas the surface is organized in -sheets.
This three-dimensional structure connects the PCNA ring topo-
logically to the DNA, besides maintaining the ability to slide
along the double helix.
The PCNA clamp serves as a stationary loading platform 
for numerous interacting partners that rapidly and transiently
exchange in a mutually exclusive manner.(7–10) These PCNA
interacting proteins can be classified in three major cate-
gories––namely, DNA replication/repair, cell cycle control, and
chromatin regulation/transcription.(11)
The DNA replication machinery is one example for the dy-
namic complexity in the spatio-temporal interplay of PCNA
with multiple interacting proteins. During the replication pro-
cess, a large number of DNA replication factors like Pol , Lig1,
FEN1, CAF-1, and Cyclin A interact with PCNA at overlap-
ping binding sites but in highly ordered chronology.(12–17) In
addition, PCNA acts as loading platform recruiting repair fac-
tors to sites of DNA damage.(18,19) Beside presenting a sliding
platform for multiple partners and thus facilitating the interac-
tion with DNA, PCNA is capable of stimulating the catalytic
efficiency of several enzymes like Flap endonuclease-1 (FEN1)
through structural rearrangements caused by direct interac-
tion.(20,21)
In addition, PCNA serves as a proliferation marker and is
therefore an interesting antigen for diagnostic purposes, espe-
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2Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Molecular Immunology, Munich, Germany.
3Delbrueck Center for Molecular Medicine, Berlin, Germany.
4Institute of Medical Immunology, Charité-Berlin, Berlin, Germany.
cially in the prognosis of tumor development.(22) Changes in
the expression level of PCNA are directly related to the ma-
lignancy of various tumors.(23,24)
So far several poly- and monoclonal antibodies were raised
against PCNA.(25) To extend the range of applications, espe-
cially to enable double staining with monoclonal antibodies, we
generated the first rat monoclonal antibody against human
PCNA. We could demonstrate the suitability of this highly
affine and specific antibody for ELISA, immunoblotting, im-
munoprecipitation, and immunofluorescence in mouse and hu-
man cells.
MATERIALS AND METHODS
Cell lines
Mouse C2C12 myoblasts, human EBNA cells, human HeLa
cells, human SHEP neoblastoma cells, rat L6E9 cells, and ham-
ster BHK cells were cultured in DMEM containing 50 g/mL
gentamicin supplemented with 20% and 10% FCS, respectively.
Expression and purification of human PCNA 
(antigen preparation)
The human full-length PCNA with an N-terminal His6-tag
was cloned into the pRSET bacterial expression vector and ex-
pressed in BL21(DE3) cells (Novagen, Darmstadt, Germany).
His-tagged human PCNA was purified with the Talon Super-
flow Metal Affinity Resin system (Clontec, Saint Germain,
France) under native conditions. After freezing for 1 h at –20°C
the cell pellet of a 500 mL bacterial culture was resuspended
in 20 mL Talon extraction buffer (50 mM NaH2PO4, 300 mM
NaCl, 10 mM imidazole [pH 8.0]) and homogenized for 10 min.
The lysate was cleared by centrifugation (12,000 g, 30 min,
4°C), and the supernatant was mixed with 3 mL of Talon Su-
perflow Metal Affinity resin, pre-equilibrated in Talon extrac-
tion buffer. After incubation at 4°C for 2 h, the beads were
washed with 50 mL Talon extraction buffer, and the PCNA pro-
tein was eluted by adding 150 mM imidazole to Talon extrac-
tion buffer. Elution fractions were dialyzed against 1x PBS, and
the purity of the eluted fractions were analyzed by SDS-PAGE
followed by Coomassie staining. The protein concentration was
determined by photometrical measurement at 280 nm.
Immunizations, generation of hybridomas, 
and ELISA screening
Approximately 50 g of PCNA-His-tagged protein were in-
jected both intraperitoneally (i.p.) and subcutaneously (s.c.) into
Lou/C rats using CPG2006 (TIB MOLBIOL) as adjuvant. Af-
ter 8 weeks, a boost was given i.p. and s.c. 3 days before fu-
sion. Fusion of the myeloma cell line P3X63-Ag8.653 with the
rat immune spleen cells was performed using polyethylene gly-
col 1500 (PEG 1500, Roche Mannheim, Germany). After fu-
sion, the cells were plated in 96-well plates using RPMI1640
with 20% fetal calf serum, penicillin/streptomycin, and pyru-
vate, non-essential amino acids (PAA) supplemented by
aminopterin (Sigma, St. Louis, MO). Hybridoma supernatants
were tested in a solid-phase immunoassay. PCNA-His-tagged
proteins were coated overnight at a concentration of 3 g/mL
in 0.1 M sodium carbonate buffer (pH 9.6). After blocking with
non-fat milk (Frema, Neuform Zarrentin, Germany), hybridoma
supernatants were added. Bound rat MAbs were detected with
a cocktail of biotinylated mouse MAbs against the rat IgG heavy
chains, thus avoiding IgM MAbs (-IgG1, -IgG2a, -IgG2b
[ATCC, Manassas, VA] and -IgG2c [Ascenion, Munich, Ger-
many]). The biotinylated MAbs were visualized with peroxi-
dase-labeled Avidin (Alexis, San Diego, CA) and o-phenylene-
diamine as chromogen in the peroxidase reaction. PCNA 16D10
(rat IgG2b) was stably subcloned and is characterized in this
study.
Peptide array synthesis and binding analyses 
(epitope mapping)
Cellulose membrane-bound peptides were automatically pre-
pared according to standard Spot synthesis protocols(26) using
a Spot synthesizer (Intavis, Cologne, Germany). Sequence files
for the peptide array were generated with LISA 1.71 software.
Peptides were synthesized on an N-modified cellulose-amino-
hydroxypropyl ether membrane (N-CAPE).(27)
The cellulose-bound peptides were pre-washed once with
EtOH for 10 min, with Tris-buffered saline (TBS, [pH 8.0])
three times for 10 min each, and then blocked overnight with
blocking buffer (blocking reagent [Sigma-Aldrich] in TBS [pH
8.0], containing 5% sucrose). The membranes were incubated
with the anti-PCNA MAb (1:100 in blocking buffer) for 2.5 h
at room temperature. The interactions of the MAb with the pep-
tides were detected by anti-rat-HRP (Jackson ImmunoResearch
Europe, Suffolk, United Kingdom) (1:10,000 in blocking
buffer) for 1.5 h at room temperature. To remove excess of an-
tibody the membrane was washed with TBS (pH 8.0) (3  10
min) after each antibody incubation step. An Uptilight HRP blot
chemiluminescent substrate (Uptima-Interchim, Montlucon,
France) was applied for detection using a LumiImager (Roche,
Mannheim, Germany).
Western blot analysis
For immunoblot analysis EBNA, HeLa, C2C12, L6E,9 and
BHK cells were harvested in ice cold 1x PBS, washed twice,
and subsequently lysed in 60 L lysis buffer (1x PBS, DNaseI
[1.2 mg/mL], 2 mM PMSF, 5 mM MgCl) for 15 min. Finally
the cell extracts were homogenized in SDS-containing loading
buffer. A serial dilution (2.5–50 103 cells/lane) was separated
on a 12% SDS-PAGE and electrophoretically transferred to ni-
trocellulose membrane (Bio-Rad Laboratories, Hercules, CA).
After blocking the membrane for 30 min with 3% milk in PBS
containing 0.075% Tween-20, 0.1 g of PCNA 16D10 was
added and incubation continued for 1 h at room temperature.
After washing with PBS containing 0.1% Tween-20, the blots
were incubated with a secondary anti-rat-HRP (Jackson Im-
munoResearch Europe). Immunoreactive bands were visualized
with ECL Western Blot Detection Kit (GE Healthcare, Freiburg,
Germany).
Immunoprecipitation
For immunoprecipitation, 1 107 cells were harvested in
ice cold 1x PBS, washed twice, and subsequently homogenized
in 200 L lysis buffer (20 mM Tris/HCl [pH 7.5], 150 mM
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NaCl, 0.5 mM EDTA, 2 mM PMSF, 0.5% NP40). After a cen-
trifugation step (10 min, 20,000 g, 4°C), the supernatant was
adjusted with dilution buffer (20 mM Tris/HCl [pH 7.5], 150
mM NaCl, 0.5 mM EDTA, 2 mM PMSF) to 500 L. Fifty L
were mixed with SDS-containing sample buffer, referred to as
input (I). For immunoprecipitation, 2 g of the PCNA antibody
was added and incubated 1 h at room temperature. For pull
down of immunocomplexes, 25 L of equilibrated protein G
agarose beads (GE Healthcare) were added and incubation con-
tinued for 1 h. After centrifugation (2 min, 5000 g, 4°C), the
supernatant was removed and 50 L were collected, referred
to as non-bound/or flowthrough (F). The beads were washed
twice with 1 mL dilution buffer containing 300 mM NaCl. Af-
ter the last washing step, the beads were resuspended in 2x SDS-
containing sample buffer and boiled for 10 min at 95°C.
For immunoblot analysis, 1% of the input and the
flowthrough, as well as 10% of the soluble supernatants, were
separated on 12% SDS–PAGE, electrophoretically transferred
to a nitrocellulose membrane, and subjected to immunoblot
analysis as described.
Immunofluorescence
For immunostaining, C2C12 cells were grown on cover slips.
Cells were fixed with 3.7% formaldehyde in PBS and subse-
quently permeabilized with ice-cold methanol for 5 min. As a pri-
mary antibody PCNA 16D10 (diluted 1:20 in PBS containing 2%
BSA) was used. The primary antibody was detected with a sec-
ondary anti-rat antibody (diluted 1:400 in PBS containing 2%
BSA) conjugated to Alexa Fluor 488 (Molecular Probes, Eugene,
OR). Cells were counterstained with DAPI and mounted in Vec-
tashield (Vector Laboratories, Burlingame, CA). Images of the
cells were obtained using a TCS SP2 AOBS confocal laser scan-
ning microscope (Leica, Wetzlar, Germany) using a 63x/1.4 NA
Plan-Apochromat oil immersion objective. Fluorophores were ex-
cited with the 488 nm line of an argon laser.
RESULTS AND DISCUSSION
Generation of rat monoclonal antibodies against
human PCNA
The full-length human PCNA with an N-terminal His6-tag
was expressed and purified from Escherichia coli for antigen
production. The recombinant protein was highly soluble and the
yield of purified protein was 4 mg/L of bacterial culture. By
performing gelfiltration analysis of the recombinant protein, we
observed the formation of a homotrimeric complex, which is in
accordance to our previous observations of an endogenous
trimeric PCNA complex in human and mouse cells (data not
shown).
The native recombinant PCNA protein was used to immu-
nize Lou/C rats, and a panel of clonal hybridomas was gener-
ated by fusing lymphocytes from immunized animals with the
myeloma cell line P3X63-Ag8.653.
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FIG. 1. Epitope mapping of the rat MAb PCNA 16D10. (A) Binding analysis of PCNA 16D10 to a peptide array representing
the human PCNA. Binding of PCNA 16D10 to four peptides (35, 36, 37, 38) is detected identifying a continuous epitope. (B)
Amino acid sequence of the human PCNA monomer. The recognized core epitope comprises the amino acids E109 to D120
marked in bold letters. (C–E) Three-dimensional structure of the PCNA monomer and the trimeric PCNA ring. The recognized
epitope is part of a -sheet at the outer surface of the PCNA monomer (highlighted in red). The PCNA monomers forming the
trimeric ring are shown in blue, green and yellow. The figure was generated using PyMOL.(28)
The antibodies produced by the hybridomas were initially
screened in a solid-phase immunoassay (indirect ELISA). Plates
coated with His6-tagged PCNA protein were incubated with the
hybridoma supernatants containing monoclonal antibodies.
Specific antigen binding was detected with a mixture of bio-
tinylated mouse MAbs against the rat IgG heavy chains. In the
next step, 17 positive hybridoma supernatants were tested by
an immunoblot assay using human recombinant PCNA, as well
as whole cell extracts derived from human HeLa cells and
mouse C2C12 myoblast cells. After comparative analysis, one
single clone designated as PCNA 16D10 was selected, estab-
lished, and expanded. The isotype of this specific antibody was
found to be rat IgG2b.
Epitope mapping
To determine the binding site of PCNA 16D10 within the
PCNA protein, we performed a pepscan analysis. To this end,
the amino acid sequence of the human PCNA was subdivided
into 83 synthetic 15-mer peptides so that each peptide sequence
overlaps with the preceding, as well as the following, peptide
by the length of 12 amino acids. The peptides were spotted on
an N-modified cellulose-amino-hydroxypropyl ether (N-CAPE)
membrane and incubated with PCNA 16D10 (Fig. 1A). A spe-
cific binding of the MAb antibody could be observed at four
consecutive spots corresponding to the positions 35, 36, 37, and
38. Analyses of these peptides indicate the binding of PCNA
16D10 to a linear epitope ranging from amino acid E109 to
D120 of PCNA (Fig. 1B).
To define the minimal epitope of the antibody, we performed
a substitution and length analysis of the initially mapped bind-
ing site EKVSDYEMKLMD. For substitution analysis, syn-
thetic peptides were generated, where each amino acid position
within the epitope (ordinate) was exchanged with every possi-
ble other amino acid (abscissae). As positive controls, peptides
with the wild-type sequence (wt) were used. The substituted
peptides were spotted on a cellulose membrane and incubated
with the PCNA 16D10 antibody (Suppl. Fig. 1A). The analysis
showed that exchange of the central amino acids SDYEMKL
severely affected antibody binding, which indicates that these
amino acids constitute the minimal core epitope recognized by
the antibody.
In a second approach, we performed an epitope length ana-
lysis to determine the minimal antibody recognition site. Sin-
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FIG. 2. Immunoblot analyses with the rat MAb PCNA 16D10. Various amounts of purified PCNA and protein extracts from
HeLa cells and E. coli (control) were loaded to test affinity and specificity. (A) The detection limit of the PCNA 16D10 anti-
body ranges between 1.25 and 2.5 ng of recombinant purified PCNA. (B) Endogenous PCNA can be detected in extracts from
as few as 2500 and 5000 human HeLa cells. The PCNA protein migrates at 31 kDa. (C) Sequence alignment of the recognized
PCNA epitope from different species. The epitope is indicated in parentheses and highly conserved residues are shaded in gray.
(D) Multi-species immunoblot. Cell extracts of mouse (C2C12), rat (L6E9), hamster (BHK), and human (EBNA) were loaded
in equal amounts. The molecular weight of the PCNA protein is indicated on the right.
gle amino acid residues were removed from the initial epitope
peptide EKVSDYEMKLMD, either from the N- or the C-ter-
minus alone or in combination, until a number of four amino
acids was reached. Those resulting 45 peptides were spotted on
the same membrane as the peptides for substitution analysis,
and binding of the MAb was detected as described before
(Suppl. Fig. 1B). The length analysis of the epitope shows that
further shortening of the core domain SDYEMKL impeded the
recognition by the PCNA 16D10 (spot 20–45), which is con-
sistent with the substitutional analysis and confirms that these
seven amino acids are sufficient for the specific binding of the
PCNA 16D10 antibody.
The visualization of the minimal epitope within the crystal
structure of the human PCNA showed that the recognized amino
acids are part of a -sheet structure on the outer surface of the
PCNA monomer (Fig. 1C). Interestingly, this linear epitope is
located at the head-to-tail interface of the trimeric PCNA ring
and therefore important to ensure the correct assembly of the
complex trimeric structure of PCNA(4) (Fig. 1D and E).
Immunoblotting and immunoprecipitation with the
PCNA 16D10 antibody
To determine the sensitivity and specificity of the PCNA
16D10 antibody for immunoblotting, a serial dilution of puri-
fied PCNA ranging from 1.25–20 ng was blotted onto nitro-
cellulose membrane and incubated with 0.05 g PCNA 16D10.
The detection limit of the monoclonal antibody lies between
1.25 and 5 ng, shown by a distinct signal of around 31 kDa. As
expected, this signal was not present in the E. coli extract, which
was used as a negative control (Fig. 2A). Next we tested the
ability of the PCNA 16D10 to recognize its endogenous anti-
gen. Soluble protein extracts from different numbers of human
HeLa cells were separated by SDS-PAGE and transferred onto
a nitrocellulose membrane. As shown in Figure 2B, PCNA
16D10 was able to detect endogenous PCNA in extracts from
as few as 5 103 HeLa cells. Moreover, the absence of any
cross-reacting bands underlines the highly specific antigen
binding of this antibody. The sequence alignment showed that
the recognized epitope EKVSDYEMKLMD is evolutionarily
highly conserved from plants to humans (Fig. 2C). This re-
markable sequence similarity in the epitope opens a wide ap-
plication area for PCNA 16D10. To test the ability of PCNA
16D10 to recognize endogenous PCNA from different species,
we performed a multi-species immunoblot. Cell extracts from
mouse C2C12 cells, rat L6E9 cells, hamster BHK cells, and hu-
man EBNA cells were subjected to SDS-PAGE, blotted on a
nitrocellulose membrane, and incubated with PCNA 16D10
(Fig. 2D). PCNA 16D10 was able to detect specifically en-
dogenous PCNA from different species. Those results demon-
strate the high specificity and affinity of the PCNA 16D10 an-
tibody for classical immunoblot applications in different
species.
To test whether PCNA 16D10 antibody recognizes the na-
tive, folded PCNA, we performed immunoprecipitations of en-
dogenous PCNA from whole cell lysates of human HeLa, hu-
man neuroblastoma (SHEP), and mouse myoblast C2C12 cells.
For immobilization, the PCNA 16D10 was coupled to protein
G agarose beads. After short-time incubation (30 min to 1 h)
of the soluble cell extract with the bead-coupled antibody fol-
lowed by extensive washing of the beads, the bound protein
was eluted and subjected to SDS-PAGE electrophoresis and im-
munoblotting. By Ponceau staining of the nitrocellulose mem-
brane, a protein band of 31 kDa was visible in the bound frac-
tion, which subsequently reacted with the PCNA 16D10
antibody (Fig. 3). A quantitative analysis of the non-bound (F)
fraction revealed a nearly complete depletion of PCNA from
human cell extracts after immunoprecipitation with PCNA
16D10. This result shows that the PCNA 16D10 recognizes its
epitope not only under denaturing conditions, but also when it
is part of larger nuclear complexes. The high pulldown effi-
ciency of PCNA represents a significant improvement for the
analysis of factors interacting with PCNA.
Immunofluorescence staining and detection of the cell
cycle dependent distribution of PCNA with the PCNA
16D10 monoclonal antibody
We tested whether the PCNA 16D10 antibody is also suitable
to detect PCNA specific pattern occurring throughout the cell cy-
cle. PCNA, as a key component of the nuclear replication ma-
chinery accumulates at sites of DNA replication, the so-called
replication foci (RF).(16) During S phase progression, the distri-
bution of replication machineries changes from countless RF lo-
calized throughout the entire nucleus corresponding to early-
replicating genes, up to a few larger foci of late-replicating hetero-
chromatin. These specific patterns allow a detailed analysis of S
phase progression and cell proliferation of eukaryotic cells.
We examined the immunoreactivity of PCNA 16D10 in
mouse C2C12 myoblast cells and developed a two-step fixa-
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FIG. 3. Immunoprecipitation of endogenous PCNA. Soluble cell extracts of mouse C2C12 myoblasts, human HeLa, and SHEP
cells were subjected to immunoprecipitation analysis using the PCNA 16D10 antibody. One percent of input (I) and flowthrough
(F) fractions and 10% of the bound (B) fractions were subjected to SDS-PAGE followed by immunoblot analysis. Precipitated
PCNA was detected by immunostaining with the PCNA 16D10. The molecular weight of the PCNA protein is indicated on the
right.
tion protocol. In the first step, we fixed the cells with formalde-
hyde to maintain the three-dimensional structure of the nucleus.
In the second step, we performed a fixation and permeabiliza-
tion with methanol (see section on Material and Methods).
The results of the immunofluorescence analyses with
PCNA 16D10 are summarized in Figure 4. Antibody spe-
cific signals in C2C12 cells are shown in the left panel and
the distribution of AT-rich heterochromatic regions is high-
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FIG. 4. Cell cycle dependent distribution of PCNA detected with PCNA 16D10 antibody. Shown are confocal mid-sections of mouse
C2C12 myoblasts fixed by a two-step fixation with formaldehyde and methanol (A–E). The immunostaining of endogenous PCNA
occurs in the cell nucleus and is associated with replication foci (RF) during different stages of S phase (left panel). The DNA was
counterstained with DAPI (mid panel). The right panel shows an overlay of both signals in the cell nuclei. Scale bar, 5 m.
A
B
C
D
E
lighted by DAPI staining (mid panel). An overlay of im-
munostaining and DAPI staining could be seen in the right
panel. The image on the first panel shows the detection of
initial replication foci in early S phase by immunofluores-
cence staining of PCNA (Fig. 4A). In mid S phase the fac-
ultative heterochromatin mainly gets replicated. At this stage
we could detect a PCNA pattern at the nuclear periphery and
around the nucleoli (Fig. 4B). A specific localization of
PCNA at mouse C2C12 chromocenters could be detected in
late S phase when replication of the constitutive hete-
rochromatin takes place (Fig. 4C). In non S phase we could
observe a dispersed distribution of PCNA throughout the en-
tire nucleus (Fig 4D), while the immunofluorescence stain-
ing shows an exclusion of PCNA from chromatin during mi-
tosis (Fig. 4E).
The detection of the characteristic PCNA localization
during different cell cycle stages demonstrates that the
PCNA 16D10 antibody is suited to analyse S phase pro-
gression and cell cycle dynamic changes of the replication
machinery.
In summary, the sliding clamp PCNA plays a central role in
DNA replication, repair, cell cycle regulation, and post-replica-
tive modifications by orchestrating the involved proteins and
mediating the interaction with DNA. This prominent role in the
inheritance of genetic and epigenetic information makes PCNA
a highly interesting antigen for antibody production.
We have now generated the first rat monoclonal antibody
with a high affinity and specificity for human PCNA. The
PCNA 16D10 antibody recognizes PCNA from multiple species
and is highly suitable for ELISA, immunoblotting, immuno-
precipitation, and immunofluorescence stainings, making it a
valuable tool for cell cycle analysis, proliferation assays, and
tumor diagnosis.
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ABSTRACT
Postreplicative maintenance of genomicmethylation
patterns was proposed to depend largely on the
binding of DNA methyltransferase 1 (Dnmt1) to
PCNA, a core component of the replication machin-
ery. We investigated how the slow and discontinu-
ous DNA methylation could be mechanistically
linked with fast and processive DNA replication.
Using photobleaching and quantitative live cell
imaging we show that Dnmt1 binding to PCNA is
highly dynamic. Activity measurements of a PCNA-
binding-deficient mutant with an enzyme-trapping
assay in living cells showed that this interaction
accounts for a 2-fold increase in methylation effi-
ciency. Expression of this mutant inmouse dnmt1/
embryonic stem (ES) cells restored CpG island
methylation. Thus association of Dnmt1 with the
replication machinery enhances methylation effi-
ciency, but is not strictly required for maintaining
global methylation. The transient nature of this
interaction accommodates the different kinetics of
DNA replication and methylation while contributing
to faithful propagation of epigenetic information.
INTRODUCTION
Genomic DNA in mammalian cells is commonly methyl-
ated at position 5 of cytosine residues in CpG sequences.
This epigenetic modiﬁcation plays an important role in the
regulation of gene expression and chromatin structure and
is essential for normal development, cell diﬀerentiation,
X chromosome inactivation and genomic imprinting (1,2).
Cell-type-speciﬁc methylation patterns are established
de novo in early developmental stages by the action of
Dnmt3a and 3b and are then maintained through
subsequent cell generations primarily by the action of
Dnmt1 (3,4). In somatic cells, Dnmt1 is the predominant
DNA methyltransferase in terms of abundance, contribu-
tion to global methyltransferase activity and to genomic
methylation levels (2,5). Reduction of Dnmt1 levels leads
to hypomethylation, genomic instability and cancer (6).
Aberrant genomic methylation is often associated with
human disease and tumorigenesis (7).
Due to its strong preference for hemimethylated
substrate DNA in vitro (8–10) and its accumulation at
replication sites during S-phase (11,12) Dnmt1 is thought
to act on hemimethylated CpG sites generated during
DNA replication. The association of Dnmt1 with
replication factories was proposed as an eﬃcient
mechanism for coupling maintenance of genomic methyl-
ation patterns to DNA replication (11). Later, direct
interaction with the replication processivity factor PCNA
was shown and a small PCNA-binding domain (PBD)
was mapped to the N-terminal region of Dnmt1 (12,13).
This domain was also shown to be necessary for
recruitment of Dnmt1 to DNA damage sites, suggesting
that it is responsible for coupling DNA repair and
restoration of methylation patterns (14). Thus, direct
interaction with PCNA would ensure that methylation
patterns are faithfully preserved in diﬀerent situations
involving DNA synthesis. However, DNA replication is
highly processive taking about 0.035 s per nucleotide
(15), while in vitro steady-state kinetic analysis of puriﬁed
recombinant Dnmt1 revealed rather low turn-over rates
of about 70–450 s per methyl group transfer (16).
Although DNA methylation by Dnmt1 may be faster
in vivo, it is not likely to come close to the 3–4 orders of
magnitude faster DNA replication. In fact, cytosine
methylation is a highly complex reaction involving
recognition of hemimethylated CpG sites, binding of
S-adenosylmethionine, ﬂipping of the cytidine base out
of the double helix, formation of a covalent bond
between the enzyme and the cytidine, transfer of the
methyl group and release of the covalent bond by
b-elimination (17–19). These considerations leave open
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the question of how DNA replication and methylation
are kinetically and mechanistically coordinated.
In addition to Dnmt1 several other factors directly and
indirectly involved in DNA replication, such as DNA
Ligase I, Fen1, CAF-1 and Cyclin A have been shown to
redistribute to replication foci during S-phase (20–24).
Many of these factors have been found to interact directly
with PCNA, which forms a homotrimeric ring around the
DNA helix and serves as a platform for tethering them to
the replication machinery (25). Even taking into account
the trivalent nature of the PCNA ring, the sheer number
of its potential binding partners during replication makes
it clear that they cannot all possibly bind at the same time
in a constitutive manner.
The functional relevance of the interaction between
Dnmt1 and PCNA and its contribution to the main-
tenance of epigenetic information after DNA replication,
however, remains unclear. We have addressed this
question by comparing the kinetics and activity of GFP-
tagged wild-type Dnmt1 and PCNA-binding-deﬁcient
mutants in live cell assays and Dnmt1 deﬁcient embryonic
stem (ES) cells. Our data show that the interaction of
Dnmt1 with PCNA is highly transient, increases the
eﬃciency of postreplicative methylation by 2-fold, but is
not required for restoring CpG methylation in Dnmt1
deﬁcient ES cells.
MATERIALS AND METHODS
Expression constructs
The expression constructs RFP-PCNA, GFP-Ligase,
GFP-Dnmt1wt, GFP-Dnmt11-171, GFP-Dnmt1C1229W as
well as the PBD-GFP construct were described earlier
(13,21,26,27). The GFP-Dnmt1Q162E and GFP-
Dnmt1F169S expression constructs were derived from the
GFP-Dnmt1wt construct by overlap extension PCR
mutagenesis (28,29) using the outer forward primer
50-CAG ATC TCG AGC TCA AGC TTC-30, the inner
reverse primer 50-GTG TCA AAG CTC TGA TAG ACC
AGC-30, the inner forward primers 50-GAACCACCAG
GGAGACCACCATC-30 for Q162E and 50-CACGGCTC
ACTCCACGAAGG-30 for F169S and the outer reverse
primer 50-CTGGAATGACCGAGACGCAGTCG-30.
The ﬁnal PCR fragments containing the mutations were
digested with BglII and HindIII and exchanged with the
corresponding fragment in the GFP-DNMT1wt construct.
Mutations were conﬁrmed by DNA sequencing and
molecular size of fusion proteins was tested by expression
in HEK 293T cells and western blot analysis. For stable
transfections we inserted the cassette containing the wt
Dnmt1 cDNA fused to GFP from the GFP-Dnmt1wt
construct into the pCAG-IRESblast vector (30).
Cell culture, transfection and FACS-sorting
Human embryonic kidney (HEK) 293T cells and mouse
C2C12 myoblasts were cultured in DMEM supplemented
with 10% and 20% fetal calf serum, respectively, and
50 mg/ml gentamycine. HEK 293T cells were transfected
with polyethylenimine (Sigma) (31). For live cell observa-
tions C2C12 myoblasts were grown to 30-40% conﬂuence
on Lab-Tek chamber slides (Nunc) or m-slides (Ibidi)
and transfected with TransFectin transfection reagent
(Bio-Rad) according to the manufacturer’s instructions.
Cells were then incubated overnight before performing
live cell analysis. Nuclear localization of GFP-Dnmt1wt
was identical to endogenous Dnmt1 as determined by
immunostaining with an aﬃnity puriﬁed polyclonal
antiserum against the N-terminal domain of mouse
Dnmt1. GFP-Dnmt1 localization was not aﬀected by
additional co-expression of RFP-PCNA (controls not
shown). Dnmt1 immunostaining showed that typical
expression levels of transfected GFP-Dnmt1 constructs
in cells selected for live cell imaging were comparable to
those of endogenous Dnmt1 protein (Supplementary
Figure 1). For stable expression of GFP-Dnmt1wt,
C2C12 cells were grown in a p100 tissue culture dish
and transfected as described earlier. Cells were then
cultured with 10 mg/ml blasticidin for at least 20 days
before homogeneity and levels of expression were deter-
mined by ﬂuorescence microscopy and western blotting
(Supplementary Figure 2). Mouse wild type and dnmt1/
J1 ES cells (s allele) (5) were cultured without feeder cells
in gelatinized ﬂasks as described (27). J1 cells were
transfected with Transfectin (BioRad) 3–4 h after seeding
and GFP-positive cells were sorted with a FACS Vantage
SE cell sorter (Becton–Dickinson).
Co-immunoprecipitation
HEK 293T cells were transiently transfected with
expression plasmids as described above. After 48 h about
70–90% of the cells expressed the GFP constructs as
determined by ﬂuorescence microscopy. Extracts from
1 107 cells were prepared in 200 ml of lysis buﬀer
(20mM Tris/HCl pH 7.5, 150mM NaCl, 0.5mM EDTA,
2mM PMSF, 0.5% NP40). After centrifugation super-
natants were diluted to 500 ml with lysis buﬀer without
NP40. Extracts were incubated with 1 mg of a GFP-
binding protein coupled to sepharose (manuscript in
preparation) for 1 h at 48C with constant mixing.
Immunocomplexes were pulled down by centrifugation.
The supernatant was removed and 50 ml were collected
(referred to as non-bound). The beads were washed twice
with 1ml of dilution buﬀer containing 300mM NaCl and
resuspended in SDS-PAGE sample buﬀer. Proteins were
eluted by boiling at 958C and subjected to SDS-PAGE
followed by immunoblotting. Antigens were detected with
a mouse monoclonal anti-GFP antibody (Roche) and a
rat monoclonal anti-PCNA antibody (32).
In vitromethyltransferase assay
Extracts from HEK 293T cells expressing the indicated
GFP constructs were prepared and immunoprecipitations
were performed as described above. After washing with
dilution buﬀer containing 300mM NaCl the beads were
washed twice with assay buﬀer (100mM KCl, 10mM
Tris pH 7.6, 1mM EDTA, 1mM DTT) and resuspended
in 500 ml of assay buﬀer. After adding 30 ml of methyl-
ation mix {[3H]-SAM (S-adenosyl-methionine); 0.1mCi
(Amersham Biosciences), 1.67 pmol/ml hemimethylated ds
35 bp DNA (50 pmol/ml), 160 ng/ml BSA} incubation was
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carried out for 2.5 h at 378C. The reactions were spotted
onto DE81 cellulose paper ﬁlters (Whatman) and the
ﬁlters were washed 3 times with 0.2M (NH4)HCO3, once
with ddH2O and once with 100% ethanol. After drying,
radioactivity was measured by liquid scintillation. Samples
without enzyme and with 2mg of puriﬁed human
recombinant DNMT1 were used as negative and positive
controls, respectively.
Combined bisulfite restriction analysis (COBRA)
Genomic DNA was isolated by the phenol–chloroform
method (33) and bisulﬁte treatment was as described (34)
except that deamination was carried out for 4 h at 558C.
Primer sets and PCR conditions for CpG islands of
skeletal -actin, H19 (region A) and dnmt1o promoters,
Xist exon 1 and intracisternal type A particle long terminal
repeats (IAP LTRs) were as described (35–39). PCR
products were digested with the following enzymes:
skeletal -actin and dnmt1o promoters and IAP LTRs
with HpyCH4IV (New England BioLabs); H19 with
Bsh136I and Xist with TaqI (both from Fermentas).
Digests were separated by agarose electrophoresis except
for IAP LTR fragments, which were separated in 10%
acrylamide gels. Digestion fragments were quantiﬁed from
digital images using ImageJ software (http://rsb.info.nih.
gov/ij/). The results were corrected for PCR bias, which
was calculated as described (40). Brieﬂy, COBRA assays
were performed on genomic DNA from untransfected
Dnmt1/ J1 cells methylated in vitro with recombinant
SssI methyltransferase (New England BioLabs) and mixed
in diﬀerent proportions with unmethylated DNA from the
same cells (Supplementary Figure 6). Bias curves and
corrections were calculated using WinCurveFit (Kevin
Raner Software). For each ampliﬁed sequence digestion
with restriction enzymes whose recognition sequence
includes cytosine residues in a non-CpG context was
used to control for complete bisulﬁte conversion except
for the skeletal -actin promoter, where bisulﬁte sequen-
cing revealed about 99% conversion eﬃciency in all
samples (Supplementary Figure 5).
Live cell microscopy, FRAP analysis and trapping assay
Live cell imaging and FRAP experiments were performed
on a TCS SP2 AOBS confocal laser scanning microscope
(Leica) using a 63 /1.4NA Plan-Apochromat oil immer-
sion objective. The microscope was equipped with a
heated environmental chamber set to 378C. Fluorophores
were excited with the 488 nm line of an argon laser and a
561 nm solid state diode laser. Confocal image series were
typically recorded with a frame size of 256 256 pixels, a
pixel size of 100 nm, and with 150ms time intervals. The
laser power was typically set to 2–4% transmission with
the pinhole opened to 3 Airy units. For FRAP analysis,
half of the nucleus was photobleached for 300ms with all
laser lines of the argon laser set to maximum power at
100% transmission. Typically 20 prebleach and 400
postbleach frames were recorded for each series.
Quantitative evaluation was performed using ImageJ.
The mean ﬂuorescence intensities of the bleached
and unbleached region for each time point were back-
ground subtracted and normalized to the mean of the last
10 prebleach values (single normalized). These values were
divided by the respective total nuclear ﬂuorescence in
order to correct for total loss of nuclear ﬂuorescence as
well as for the gain of nuclear ﬂuorescence due to import
from the cytoplasm over the time course (double normal-
ized). Since the ﬂuorescence in the bleached region diﬀered
from cell to cell and typically did not reach background
level the values were also normalized to zero. Here, only
the distal two-thirds of the unbleached part in the ﬁrst
postbleach frame were considered as reference to take into
account fast diﬀusing molecules invading into the
bleached half (triple normalized). For each construct
and cell cycle stage 6–10 nuclei were averaged and the
mean curve as well as the standard error of the mean
(SEM) was calculated. Half times of recovery were
calculated from the mean curves.
The trapping assay to measure postreplicative methyla-
tion eﬃciency in living cells was previously described (27).
5-Aza-20-deoxycytidine (Sigma) was added at a ﬁnal
concentrations of 30 mM and cells were incubated for the
indicated periods before performing FRAP experiments.
Microscope settings were as described above except that a
smaller ROI (3mm 3 mm) was selected and the time
interval was set to 208ms. FRAP data were double
normalized as described above.
For presentation, we used linear contrast enhancement
on entire images. For color ﬁgures we chose magenta as
false color for red ﬂuorescence to accommodate for
colorblindness.
RESULTS
Point mutations within the PBD abolish the interaction of
Dnmt1 with PCNA
We recently demonstrated a loss of association with
replication foci in early and mid S-phase of a GFP-Dnmt1
fusion construct with a deletion of the ﬁrst 171 amino
acids which includes most of the PBD (GFP-Dnmt11-171)
(13). To address the function of the PBD in early and mid
S-phase more speciﬁcally and to exclude potential
misfolding of the protein due to the large deletion we
have generated GFP-Dnmt1 constructs bearing single
point mutations of highly conserved residues within the
PIP (PCNA-interacting peptide)-Box (41) of the PBD
(GFP-Dnmt1Q162E and GFP-Dnmt1F169S) (Figure 1).
Either of these mutant constructs were expressed in
C2C12 mouse myoblasts together with RFP-PCNA,
which served as S-phase marker (42). Both Dnmt1
constructs showed a diﬀuse nuclear distribution in early
and mid S-phase cells (Figure 2B and Supplementary
Figure 3), in contrast to the wild-type Dnmt1 construct
(GFP-Dnmt1wt) which was concentrated at replication
foci during early and mid S-phase (Figure 2A). In late
S-phase and G2, however, the wild type as well as all the
PBD mutant constructs, including GFP-Dnmt11–171,
were similarly concentrated at chromocenters (Figure 2A
and B and Supplementary Figure 1), conﬁrming the
additional binding to heterochromatin in late S-phase
mediated by the TS domain (13). Co-immunoprecipitation
experiments conﬁrmed that the Q162E point mutation
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abolishes the interaction between Dnmt1 and PCNA
(Figure 2C). Similar results were obtained with GFP-
Dnmt1F169S and GFP-Dnmt11–171 (Supplementary
Figure 3). Thus, both Q162E and F169S point mutations
prevent accumulation of Dnmt1 at replication foci during
early to mid S-phase, while localization at constitutive
heterochromatin in late S-phase and G2 is not aﬀected.
These results clearly conﬁrm the role of the PBD in
mediating the interaction between Dnmt1 and PCNA
in vivo.
The PBD-mediated interaction of Dnmt1 at replication sites
is highly transient
To investigate the dynamics of the PBD-mediated inter-
action at replication sites we measured ﬂuorescence
recovery after photobleaching (FRAP) of GFP-Dnmt1wt
throughout S-phase. GFP-Dnmt1wt and RFP-PCNA were
co-expressed in C2C12 cells and a small square region of
interest (ROI) was bleached (Figure 3). Consistent with
earlier observations (26,43) RFP-PCNA showed hardly
any recovery within the observation period of 100 s,
whereas in the same period GFP-Dnmt1 recovered fully,
with very similar kinetics in early and mid S-phase, but
notably slower in late S-phase. This result shows that the
binding of Dnmt1 at replication sites is more dynamic
during early and mid S-phase than in late S-phase, when
Dnmt 1 is likely slowed down by the additional interaction
with chromatin mediated by the TS domain (13).
To address the kinetic properties of the PBD-mediated
binding to replication sites more speciﬁcally, we per-
formed quantitative FRAP analysis of GFP-Dnmt1wt and
GFP-Dnmt1Q162E in G1 and early/mid S-phase. As
replication sites are not homogeneously distributed in
the nucleus, we chose to bleach half nuclei (half-FRAP) to
ensure that the bleached region contains a representative
number of potential binding sites (Figure 4A). In early/
mid S-phase nuclei GFP-Dnmt1wt recovered with a
halftime (t1/2) of 4.7 0.2 s and reached complete equili-
bration (t1) in about 56 s. These values place Dnmt1
among the more dynamic factors involved in chromatin
transactions previously determined with half-FRAP
analyses (44). In comparison to GFP-Dnmt1wt, GFP-
Dnmt1Q162E showed a slightly increased mobility
(t1/2=4.4 0.2 s; t1 45 s), which is likely due to
the lack of binding to PCNA rings at replication sites.
In the absence of active replication sites in G1, GFP-
Dnmt1wt and Dnmt1Q162E showed nearly identical
kinetics, which were remarkably similar to the kinetics
of Dnmt1Q162E in early/mid S-phase. These data indicate
that PCNA binding has only a minor contribution to
Dnmt1 kinetics in S phase.
The recovery rates measured for the full-length con-
structs were considerably slower than the rate of GFP
alone (t1/2=0.8 0.1 s; t1 10 s), which was used to
control for unspeciﬁc binding events. As t1/2 is roughly
proportional to the cubic root of the molecular mass
(45,46), the 8-fold size diﬀerence of GFP alone to the
full-length construct (27 and 210 kDa, respectively) would
only account for about a 2-fold slower recovery. Instead,
GFP-Dnmt1 full-length constructs recover more slowly,
pointing to one (or more) additional and yet uncharacter-
ized cell cycle independent interaction(s).
In order to dissect the PBD-mediated interaction from
superimposing eﬀects caused by other potential interac-
tions we assayed the FRAP kinetics of a GFP fusion with
the isolated PBD of Dnmt1, i.e. amino acids 159–178
(PBD-GFP). We found that in S–phase the recovery
was only about 2 times slower than GFP alone
(t1/2=1.5 0.1 s; t1 16 s), thus conﬁrming the highly
transient nature of the PBD interaction with PCNA. In
non-S-phase cells, PBD-GFP showed an increase in
mobility (t1/2=1.1 0.1 s; t1 11 s) similar to that
observed with the full-length wild-type construct.
For direct comparison we further analyzed another
PCNA-interacting enzyme, DNA Ligase I fused to GFP
(GFP-Ligase), and found a similar mobility shift in S
phase (t1/2=2.4 0.3 s; t1 27 s) compared to non-S-
phase cells (t1/2=2.1 0.3 s; t1 17 s). Thus, with all
three PCNA-interacting GFP fusion proteins (GFP-
Dnmt1wt, PBD-GFP and GFP-Ligase), but not with the
PCNA-binding mutant, the transient association with the
replication machinery (PCNA) caused a slower recovery
as compared to G1/non-S-phase (Figure 4B, inset).
Together the limited but signiﬁcant contribution of the
PBD-mediated interaction to the kinetic properties of
GFP-Dnmt1 and the high mobility of PBD-GFP in
Figure 1. Structure of Dnmt1 and alignment of PCNA-binding
domains (PBD). (A) Schematic representation of the mouse Dnmt1
consisting of an N-terminal regulatory and a C-terminal catalytic
domain. The PBD, the TS domain, the Zn-binding domain (Zn), the
two bromo-adjacent homology domains (BAH) and the catalytic center
(PC motif) are highlighted. (B) Alignment of Dnmt1 PBDs from
diﬀerent species. Highly conserved residues are gray shaded. Accession
numbers: Mus musculus P13864; Homo sapiens P26358; Rattus
norvegicus Q9Z330; Bos taurus Q6Y856; Sus scrofa Q4TTV6; Ovis
aries Q865V5; Gallus gallus Q92072; Monodelphis domestica Q8MJ28;
Xenopus laevis Q6GQH0; Paracentrotus lividus Q27746; Xiphophorus
maculatus Q9I8X6; Brachydanio rerio Q8QGB8. (C) Alignment of
PBDs in diﬀerent proteins from Mus musculus. Gray shaded amino
acids are highly conserved within the PIP-Box. Accession numbers:
Dnmt1 P13864; Fen1 P39749; p21 P39689; DNA Ligase1 P37913;
Polymerase d/subunit p66 Q9EQ28; XPG P39749; UNG:P97931
MSH6 P54276.
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S–phase clearly indicate that binding of Dnmt1 to PCNA
at replication foci is highly transient.
Interaction with PCNA enhances methylation efficiency
in vivo only moderately
Next we investigated the contribution of the highly
transient interaction with PCNA to the postreplicative
methylation activity of Dnmt1. Earlier it was shown that
N-terminal deletions of mouse Dnmt1 comprising the
PBD did not alter catalytic activity in vitro (47,48). To test
the catalytic activity of the GFP-Dnmt1 constructs used in
this study they were expressed in HEK 293T cells,
immunopuriﬁed and directly assayed for methyltransfer-
ase activity in vitro. While the catalytically inactive GFP-
Dnmt1C1229W mutant (27) displayed only background
activity, GFP-Dnmt1Q162E and GFP-Dnmt11-171 exhib-
ited enzymatic activity comparable to GFP-Dnmt1wt
(Figure 5D), indicating that neither the Q162E point
mutation nor deletion of the ﬁrst 171 amino acids aﬀect
the enzymatic activity of Dnmt1.
Figure 2. Mutation of the PBD abolishes Dnmt1 interaction with PCNA and prevents accumulation at replication sites in early and mid S-phase.
(A, B) Confocal mid sections of living mouse C2C12 myoblasts expressing either GFP-Dnmt1wt (A) or GFP-Dnmt1Q162E (B). Cells were
co-transfected with RFP-PCNA to identify replication foci and to distinguish S-phase stages. Scale bars: 5 mm. GFP-Dnmt1wt accumulates at
replication sites throughout S phase where it co-localizes with RFP-PCNA. In G2 cells a fraction of Dnmt1 remains associated with the late
replicating pericentric heterochromatin. In contrast, GFP-Dnmt1Q162E shows a fully dispersed nuclear distribution in early and mid S-phase stages,
whereas in late S-phase and G2 association with centromeric heterochromatin is still observed. (C) Endogenous PCNA eﬃciently
co-immunoprecipitates with GFP-Dnmt1wt but not with GFP-Dnmt1Q162E. Cell extracts were prepared from HEK 293T cells expressing either
GFP-Dnmt1wt or GFP-Dnmt1Q162E. Precipitated proteins were detected by immunostaining with antibodies against GFP and PCNA, respectively.
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To establish whether the binding to PCNA is required
for postreplicative methylation in vivo, we tested the
activity of GFP-Dnmt1wt and GFP-Dnmt1Q162E in living
cells using a recently developed trapping assay (27). This
assay takes advantage of the catalytic mechanism of
DNA (cytosine-5) methyltransferases which involves
transient formation of a covalent complex with the C6
position of the cytosine residue. When the cytosine
analogue 5-aza-20-deoxycytidine (5-aza-dC) is incorpo-
rated into the DNA during replication the covalent
complex of Dnmt1 and 5-aza-dC cannot be resolved and
Dnmt1 is trapped at the site of action. Time-dependent
immobilization, i.e. trapping of GFP-tagged Dnmt1 at
replication foci can be visualized and measured by FRAP
and reﬂects enzymatic activity of the fusion protein.
C2C12 cells co-transfected with RFP-PCNA and either
GFP-Dnmt1wt or GFP-Dnmt1Q162E as well as C2C12 cells
stably expressing GFP-Dnmt1wt were incubated in the
presence of 30 mM 5-aza-dC. In early S-phase the focal
enrichment of GFP-Dnmt1wt at replication sites increased
over time reﬂecting the accumulation of immobilized
enzyme and after 40min GFP-Dnmt1wt was completely
immobilized (Figure 5A). Similar kinetics were observed
in mid S-phase (data not shown). As shown above GFP-
Dnmt1Q162E displayed a diﬀuse nuclear distribution in
early S-phase cells (Figure 5B). However, with prolonged
incubation in the presence of 5-aza-dC an increasing focal
accumulation at replication sites was observed.
Quantitative FRAP analysis revealed that the immobiliza-
tion rate of GFP-Dnmt1Q162E, which is a direct measure of
its enzymatic activity, was only about 2-fold slower than
GFP-Dnmt1wt, resulting in complete trapping after
90min. These results indicate that the PCNA-binding-
deﬁcient mutant binds to DNA and is catalytically
engaged at hemimethylated sites generated during
replication.
Immobilization of GFP-Dnmt1wt at replication sites does not
prevent progression of the replication machinery
We then probed the stability of the interaction between
Dnmt1 and the replication machinery by trapping Dnmt1
with 5-aza-dC and long-term live imaging. In the case of
stable interaction, covalent immobilization of Dnmt1
would be expected to stall the progression of the
replication machinery. C2C12 cells co-transfected with
the GFP-Dnmt1wt and RFP-PCNA constructs were
incubated in the presence of 10 mM 5-aza-dC and
individual S-phase cells were imaged at consecutive time
points for an extended period of time (Figure 6).
Progressive separation of GFP-Dnmt1wt and RFP-
PCNA foci could be clearly observed over a time period
of 2 h, indicating that trapping of Dnmt1 did not prevent
the progression of replication factories. This result is
consistent with the FRAP kinetics of GFP-Dnmt1wt
demonstrating the transient nature of the interaction
between Dnmt1 and PCNA.
GFP-Dnmt1Q162E rescues CpGmethylation in Dnmt1/
ES cells
To investigate the contribution to maintenance of
methylation patterns by the PBD-mediated interaction
with PCNA in vivo we transiently expressed either GFP-
Dnmt1wt or GFP-Dnmt1Q162E in Dnmt1 deﬁcient mouse
ES cells, which are severely hypomethylated in all genomic
compartments (5,49). GFP-positive cells were isolated by
FACS sorting 24h and 48 h after transfection and
methylation of single-copy sequences and intracisternal
type A particle (IAP) interspersed repetitive elements was
analyzed by COBRA. An increase in methylation at all
tested sites was observed in cells expressing either the wild
type or the mutant Dnmt1 constructs already 24 h after
transfection (Figure 7 and Supplementary Figure 4A).
Figure 3. Transient binding of Dnmt1 at replication sites in diﬀerent S-phase stages. (A) GFP-Dnmt1wt (green) and RFP-PCNA (magenta)
co-expressed in mouse C2C12 cells co-localize at replication sites in early, mid and late S-phase. Fluorescence bleaching of a small region of interest
reveals fast recovery of GFP-Dnmt1wt, whereas RFP-PCNA shows almost no recovery within the observation period. (B) Quantitative evaluation of
the FRAP experiments shown in (A) reveal a signiﬁcantly faster recovery of GFP-Dnmt1wt in early and mid S-phase compared to late S-phase. Scale
bars: 5 mm.
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Figure 4. Eﬀect of the PBD on protein mobility in S-phase cells. (A) Half nucleus FRAP series of C2C12 cells expressing GFP-Dnmt1wt and GFP-
Dnmt1Q162E, PBD-GFP and GFP alone as indicated in the second column. Cell-cycle stages were identiﬁed by the subnuclear pattern of co-expressed
RFP-PCNA (ﬁrst column). Selected pre- and postbleach frames are shown in false color. Lower signal-to-noise ratio of FRAP series images is due to
the higher imaging frame rate. Rectangles indicate the bleached ROI. The column marked with t1/2 displays frames corresponding to the half time
of ﬂuorescence recovery. The column marked with t1 displays the frames corresponding to approximately the time points when ﬂuorescence
recovery reached the plateau. Bar: 5 mm. (B) Quantitative evaluation of FRAP experiments. Wild-type Dnmt1 shows a small but signiﬁcant decrease
in mobility in early/mid S-phase (dark blue curve) as compared to G1 phase (light-blue curve). A similar mobility shift between early/mid S and non-
S-phase cells is also seen for PBD-GFP (dark green and green curve, respectively) and for GFP-Ligase (dark gray and gray curve, respectively). No
such shift is observed for the PCNA-binding-deﬁcient Dnmt1 mutant (red and orange curve, respectively). GFP alone (light-green curve) is shown as
reference. For clarity only every fourth time point is displayed; data are represented as meanSEM. Kinetic shifts are indicated by shadings in the
enlarged inset.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4307
Further substantial increase of methylation 48 h after
transfection was observed only for the skeletal -actin
promoter where the methylation level approached that
observed in wild-type cells. The result for the skeletal
-actin promoter were conﬁrmed and extended by bisulﬁte
sequencing (Supplementary Figure 5). It was previously
reported that re-expression of wild-type Dnmt1 in
dnmt1/ ES cells does not lead to restoration of
methylation at imprinted genes since passage through
the germ line is needed for re-establishment of methylation
patterns in these sequences (49). We analyzed the
promoter of the imprinted H19 gene to control for the
Figure 5. PCNA-binding-deﬁcient mutant Dnmt1 is catalytically active and shows moderately reduced postreplicative methylation activity in vivo.
(A–C) Trapping assay for the analysis of postreplicative methylation activity in vivo. (A, B) Confocal mid sections (upper panel) and corresponding
FRAP series (lower panel) of a C2C12 mouse myoblast cell co-transfected with RFP-PCNA and either GFP-Dnmt1wt (A) or GFP-Dnmt1Q162E
(B) before and at selected time points after incubation with 5-aza-dC. Before drug treatment the observed cells were in early S-phase as indicated by
the RFP-PCNA pattern (left). Boxes indicate bleached ROI’s, which are shown magniﬁed in the lower panels at indicated time points of the FRAP
series. Quantitative FRAP analysis is shown on the right. Scale bars: 5mm. (C) Time-dependent increase of immobile fractions of GFP-Dnmt1wt and
GFP-Dnmt1Q162E. Individual cells assayed at consecutive time points are indicated by closed (GFP-Dnmt1wt) and open (GFP-Dnmt1Q162E) symbols.
Character symbols represent diﬀerent cells each assayed at a single time point. + symbol indicates data points obtained with C2C12 cells stably
expressing GFP-Dnmt1wt (C2C12-GMT1) without co-expression of RFP-PCNA. (D) In vitro methyltransferase assay for GFP-Dnmt1wt, GFP-
Dnmt11-171, GFP-Dnmt1Q162E and the catalytically inactive mutant GFP-Dnmt1C1229W. GFP fusions were expressed in HEK 293T cells,
immunopuriﬁed and the amount of [3H]CH3 transferred to a hemimethylated oligonucleotide substrate was measured. To normalize for the amount
of precipitated protein aliquots were analyzed by SDS-PAGE and Coomassie staining (lower panel).
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speciﬁcity of our assay and found that indeed expression
of neither GFP-Dnmt1wt nor GFP-Dnmt1Q162E resulted
in increased methylation of this sequence (Figure 7). To
further evaluate methylation of repetitive sequences we
stained transiently transfected dnmt1/ cells with an
antibody against 5-methylcytidine that detects highly
methylated satellite repeats present at mouse chromocen-
ters (pericentromeric heterochromatin). Restoration of
high DNA methylation levels at chromocenters was
observed in both cells expressing GFP-Dnmt1wt and
GFP-Dnmt1Q162E (Supplementary Figure 4B).
The experimental procedures employed did not allow
detection of signiﬁcant diﬀerences in remethylation
kinetics between the two constructs. Nevertheless, these
results show that the PCNA-binding-deﬁcient mutant is,
like wild-type Dnmt1, able to rescue methylation of both
single copy and repetitive sequences in vivo.
DISCUSSION
Faithful replication of genetic and epigenetic information
is crucial to ensure the integrity and identity of proliferat-
ing cells. Earlier work has demonstrated that the main-
tenance methyltransferase Dnmt1 binds to the replication
processivity factor PCNA and is thus recruited to
replication sites (12). The interaction between Dnmt1
and the replication machinery was proposed as a
mechanism for coupling maintenance of genomic methyl-
ation to DNA replication (11). By traveling along with the
replication machinery Dnmt1 would be able to restore
symmetrical methylation as soon as hemimethylated CpG
sites are generated. The estimated kinetics of DNA
replication in vivo and DNA methylation by Dnmt1
Figure 6. Immobilization of Dnmt1 does not prevent progression of
DNA replication. S-phase C2C12 myoblasts expressing GFP-Dnmt1wt
(green) and RFP-PCNA (magenta) were imaged without drug
treatment (upper row) and at the indicated time points after addition
of 10 mM 5-aza-dC to the medium (lower row). In the control cell the
two constructs largely co-localize during transition from mid to late
S-phase, whereas in the presence of 5-aza-dC progressive separation of
green and red foci indicate immobilization of GFP-Dnmt1wt at
postreplicative hemimethylated sites and progression of replication
foci containing RFP-PCNA. Projections of confocal mid sections are
shown. Scale bar: 5 mm.
Figure 7. PCNA-binding-deﬁcient mutant Dnmt1 restores methylation of single-copy sequences in dnmt1/ ES cells. Mouse dnmt1/ ES cells were
transiently transfected with either the GFP-Dnmt1wt or GFP-Dnmt1Q162E constructs and FACS-sorted 24h and 48 h after transfection. Methylation
of single-copy sequences was assayed by COBRA. Shown are methylation percentages at assayed CpG sites with respect to genomic DNA from
dnmt1/ ES cells methylated in vitro with the recombinant methyltransferase SssI (100% methylation; see also Supplementary Figure 6).
Mean values and standard errors of duplicate ampliﬁcations from each of two independent experiments are indicated.
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in vitro, however, diﬀer by 3–4 orders of magnitude
arguing against a stable coupling. Although DNA
methylation may be faster in vivo it is not likely to come
much closer to the DNA replication rate. In other words,
it is reasonable to assume that methylating a cytosine
takes far longer than to incorporate it. Also, DNA
replication is essentially a continuous process, while
methylated CpG sites are encountered discontinuously in
vertebrate genomes. Stable binding of Dnmt1 to the
replication machinery would stall replication at each
hemimethylated CpG site. Here we show that the
interaction of Dnmt1 with the replication machinery
in vivo is highly dynamic and that immobilization of
Dnmt1 at postreplicative hemimethylated sites does not
prevent the progression of DNA replication. The transient
nature of the interaction between Dnmt1 and the
replication machinery allows rapid release and transfer
of Dnmt1 to hemimethylated substrate sites, reconciling
the paradox of the relative rates of DNA replication and
methylation. According to basic principles of enzyme
kinetics the local enrichment of Dnmt1 at replication foci
would increase the postreplicative methylation rate. At the
same time, transient binding of Dnmt1 enables also other
replication factors to interact with PCNA. Similar binding
dynamics have been shown for the interaction of PCNA
with DNA Ligase I and Fen1 (26) and may thus represent
a common feature of PBD-containing factors.
Interestingly, the interaction between Dnmt1 and
PCNA is believed to be a major mechanism for the
methylation maintenance activity of Dnmt1, but its
functional relevance had never been tested experimentally.
Here we show two lines of evidence that this interaction is
not crucial for the maintenance of methylation patterns in
mammalian cells. First, postreplicative methylation rate of
wild-type Dnmt1 measured in vivo is only 2-fold faster
than that of a PCNA-binding-deﬁcient mutant. Second,
methylation of both single copy and repetitive sequences
in Dnmt1 deﬁcient ES cells was restored by this PCNA-
binding-deﬁcient Dnmt1 mutant with eﬃciency compar-
able to wild-type Dnmt1. The maintenance of DNA
methylation without direct coupling to the replication
machinery could in part be explained by the preference of
Dnmt1 for hemimethylated sites (8–10). Also, genetic
manipulation in the mouse indicate that Dnmt1 is at least
5-fold more abundant than necessary for maintaining
normal methylation levels (6,50). Thus, the combined
eﬀect of the aﬃnity for hemimethylated sites, relative
abundance and simple diﬀusion could explain the
relatively fast immobilization of PCNA-binding-deﬁcient
mutants in the presence of 5-aza-dC. In addition, the
ability of Dnmt1 to methylate nucleosomal DNA in vitro
(51–53), suggests that maintenance of DNA methylation is
not necessarily restricted to the short time window before
nucleosome assembly.
Recent structural data on Ligase I:PCNA and FEN-
1:PCNA complexes indicate that for these enzymes PCNA
does not simply serves as a loading platform for the
replication machinery, but also causes allosteric activation
(56,57). The data presented here cannot rule out a similar
mechanism for Dnmt1, but clearly show that interaction
with PCNA is not a prerequisite for enzyme activity
in vivo. The transient nature of this interaction also argues
against PCNA as a classic processivity factor for
postreplicative DNA methylation. The major role of the
PCNA interaction most likely is to increase the local
Dnmt1 concentration and thereby enhance methylation
eﬃciency at replication sites.
Notably, it is still unclear whether the role and
regulation of Dnmt1 is similar in diﬀerent cell types and
species. While Dnmt1 is clearly essential for maintenance
of DNA methylation in mouse cells (5,54), it seemed
dispensable in human tumor HCT116 cells (32). However,
two reports recently showed that DNMT1 is essential for
maintenance of DNA methylation also in these human
tumor cells (32,55). It turned out that genomic methyla-
tion was maintained by a residual, truncated DNMT1
form lacking the PBD, arguing that PCNA binding is not
strictly required in these cells (32).
Also, the requirement of Dnmt1 for cell viability remains
unsettled. In mouse ﬁbroblasts inactivation of the dnmt1
gene caused a continuous loss of genomic methylation
leading to apoptotic cell death after several cell division
cycles (54). Similar results were obtained after depletion of
DNMT1 activity by RNA interference in human cells (32).
Surprisingly, conditional deletion of the DNMT1 locus in
the same cells caused immediate apoptotic cell death long
before substantial passive loss of genomic methylation
could occur (58) arguing for additional roles of DNMT1.
In this regard, the association of Dnmt1 with hetero-
chromatin in G2 phase and occasionally in mitosis in
mouse cells (13) would ﬁt well with the mitotic catastrophe
observed upon deletion of the DNMT1 gene in HCT116
cells. In addition, the PBD-mediated association of Dnmt1
with repair sites (14) may indicate a direct role in the
maintenance of genome integrity (59). Clearly, more
experiments are required to resolve the species and cell-
type-speciﬁc role and regulation of Dnmt1.
In summary, we demonstrate that the association of
Dnmt1 with the replication machinery is not strictly
required for maintaining global methylation but still
enhances in vivo methylation eﬃciency by 2-fold.
Whereas the beneﬁt of Dnmt1 to be directly recruited to
replication foci seems subtle in short-term cell culture
experiments, it may be more relevant in long-lived
organisms and in situations where the nuclear concentra-
tion of Dnmt1 is limiting. Indeed, Dnmt1 levels vary
considerably in diﬀerent tissues and developmental stages
(60,61). Based on sequence features of the dnmt1 gene a
modular structure was proposed to originate from an
ancestral DNA methyltransferase that evolved by stepwise
acquisition of new domains (47). Thus, the improved
eﬃciency of postreplicative methylation achieved by the
PBD-mediated transient binding to PCNA likely repre-
sents an additional safety mechanism, which was acquired
in the course of evolution and contributes to the faithful
maintenance of epigenetic information over the entire
lifespan of complex organisms.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Supplementary Figure 1. Comparison of endogenous and GFP-tagged Dnmt1 levels in 
transiently transfected C2C12 myoblasts. Cells were fixed with 3.7% formaldehyde 24 h after 
transfection with the GFP-Dnmt1wt expression construct. Endogenous and GFP-tagged Dnmt1 
were detected with polyclonal rabbit antibodies against the N-terminal domain of Dnmt1 and 
Alexa555 coupled secondary antibodies. DNA was counterstained with 4’,6-diamidino-2-
phenylindole (DAPI). Widefield epifluorescence images were acquired with an Axiophot 2 
microscope (Zeiss) equipped with a 63x/1.4 NA oil objective and a 12-bit CCD camera. (A) 
The upper row shows exemplary images with a late S phase cell moderately expressing GFP-
Dnmt1 typically chosen for live cell microscopy (arrowhead). Dnmt1 immunostaining shows 
slightly higher fluorescence compared to untransfected cells (arrows) due to the ectopically 
expressed GFP-Dnmt1 in addition to endogenous Dnmt1. Overexpressing cells with much 
brighter nuclear fluorescence (lower row, asterisks) were not considered for live cell analyses. 
Scale bars: 10 µm. (B) Quantification of total Dnmt1 levels in transfected and untransfected 
cells. Average nuclear antibody signal (endogenous Dnmt1 and GFP-Dnmt1) from transfected 
and untransfected cells was determined for each image. Signal ratios of moderately and 
overexpressing transfected cells to untransfected cells were calculated for each image and 
then averaged. Error bars indicate SD. 
 
  
 
 
Supplementary Figure 2. Comparison of endogenous and GFP-tagged Dnmt1 levels in 
stably transfected C2C12 myoblasts (C2C12-GMT1) after 20 days of selection with 10 µg/ml 
blasticidin. (A) Cells were fixed with 3.7% formaldehyde and DNA was counterstained with 
4’,6-diamidino-2-phenylindole (DAPI). Widefield epifluorescence images were acquired with 
an Axiophot 2 microscope (Zeiss) equipped with a 63x/1.4 NA oil objective and a 16-bit CCD 
camera. About 75% of the cells show stable expression of GFP-Dnmt1. Scale bar: 10 μm.   
(B) Western blot analysis to compare the levels of GFP-Dnmt1wt and endogenous Dnmt1 in 
stably transfected C2C12 cells. The detection was performed with an antibody against the 
N-terminal domain of Dnmt1 (Grohmann et al., 2005, BMC Dev Biol 5, 18) and a monoclonal 
anti-GFP antibody (Roche). Untransfected C2C12 cells were used as a control. After 
correction for the fraction of expressing cells, the expression level of GFP-Dnmt1wt amounts 
to about 90% of the endogenous Dnmt1.  
 
  
Supplementary Figure 3. Mutations of the PBD abolish Dnmt1 interaction with PCNA and 
prevent accumulation at replication sites in early and mid S phase. (A, B) Confocal mid 
sections of living mouse C2C12 myoblasts expressing either GFP-Dnmt1F169S (A) or GFP- 
Dnmt1Δ1-171 (B). Both constructs show a dispersed nuclear distribution in early and mid S 
phase stages, whereas in late S phase association with pericentric heterochromatin is 
observed. Cells were co-transfected with RFP-PCNA to identify replication foci and to 
distinguish S phase stages. Scale bars: 5 µm. (C) Endogenous PCNA efficiently co-
immunoprecipitates with GFP-Dnmt1wt but not with GFP-Dnmt1F169S and GFP- Dnmt1Δ1-171. 
GFP fusion constructs were expressed in HEK 293T cells. Precipitated proteins were detected 
by immunostaining with antibodies against GFP and PCNA, respectively. 
 
 
 
Supplementary Figure 4. PCNA binding-deficient Dnmt1 mutants restore methylation of 
repetitive DNA sequences in Dnmt1 null ES cells. (A) Mouse dnmt1-/- J1 ES cells were 
transiently transfected with either the GFP-Dnmt1wt or GFP-Dnmt1Q162E constructs and 
FACS-sorted 24 and 48 h after transfection as in Figure 7. Methylation of IAP LTRs was assayed 
by COBRA. Shown are cumulative methylation percentages at 2 HpyCH4IV sites (ACGT) with 
respect to genomic DNA from dnmt1-/- ES cells methylated in vitro with the recombinant 
methyltransferase SssI (100% methylation). Mean values and standard errors of duplicate 
amplifications from each of two independent experiments are indicated. (B) 48 h after 
transfection with either GFP-Dnmt1wt or GFP-Dnmt1Q162E Dnmt1 null ES cells were stained with 
an antibody against 5-methylcytidine (5mC) and their DNA counterstained with TO-PRO-3 as 
described (Schermelleh et al., 2005, Nat Methods 2, 751). Staining of wild type ES cells is shown 
as a control in the first row. Individual channels are indicated at the top and in the merge channel 
GFP, 5mC and TO-PRO-3 stainings are shown in green, red and blue, respectively. Cells 
expressing either GFP-Dnmt1wt or GFP-Dnmt1Q162E showed remethylation of repetitive DNA at 
chromocenters. Similar results were obtained with the GFP-Dnmt1F169S and GFP-Dnmt1Δ1-171 
mutant constructs (data not shown). Scale bar: 5 µm. 
 
 
 
Supplementary Figure 5. Bisulfite sequencing of the skeletal α-actin promoter in wt, Dnmt1 
null and Dnmt1 null J1 ES cells transiently transfected with either the GFP-Dnmt1wt or 
GFP-Dnmt1Q162E constructs as in Figure 7. Transfected cells were FACS-sorted and genomic 
DNA isolated 24 and 48 h after transfection as indicated. Genomic DNA from dnmt1-/- ES cells 
methylated in vitro with recombinant SssI methyltransferase was used as a control. PCR products 
were cloned with the StrataClone PCR Cloning Kit (Stratagene) and individual clones sequenced 
by automated sequencing at MWG Biotech. Black lines represent sequences from individual 
clones. Open and closed circles represent unmethylated and methylated cytosines, respectively. 
Global percentages of converted cytosines and methylation at CpG sites within the analyzed 
sequence are indicated on the right.  
Supplementary Figure 6. Determination of PCR bias in COBRA assays. Genomic DNA 
from untransfected Dnmt1-/- J1 cells was methylated in vitro with recombinant SssI 
methyltransferase (New England BioLabs) and mixed with unmethylated DNA from the 
same cells in the proportions reported at the top of each lane. COBRA assays for the 
indicated sequences were performed on each sample as described in Materials and 
Methods. At the top of each panel the digests of bisulfite PCR fragments from these 
genomic DNA mixtures are shown. Uncut fragments, corresponding to unmethylated 
molecules, and restriction fragments (cut; only one out of two for skeletal -actin,
Dnmt1o and H19A promoters and two out of three for Xist exon 1), corresponding to 
methylated molecules, are shown. Measured methylation percentages were plotted 
against expected ones. Closed and open circles represent measured values and values 
expected in the absence of bias. Best fit curves and bias coefficients (b) were generated 
and calculated, respectively, using WinCurveFit (Kevin Raner Software) and according 
to the equation: 
y
yb
x
x


 100100
where x is the expected value and y the measured one. 
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2.4. DNMT1 but not its interaction with the replication machinery is 
required for maintenance of DNA methylation  
in human cells. 
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Introduction
In mammals, DNA methylation is crucially involved in control-
ling gene expression, cell differentiation, silencing of trans-
posable elements, X inactivation, imprinting, and neoplastic 
transformation (Bird, 2002; Baylin and Ohm, 2006). DNA 
methylation patterns are established and maintained by three 
major DNA methyltransferases (DNMTs): DNMT1, DNMT3A, 
and DNMT3B. DNMT1 is the only mammalian DNMT that has 
a preference for hemimethylated CpG sites (Bestor and Ingram, 
1983; Pradhan et al., 1999) and localizes at both replication foci 
and repair sites because of its interaction with the proliferat-
ing cell nuclear antigen (PCNA; Leonhardt et al., 1992; Chuang 
et al., 1997; Margot et al., 2001; Easwaran et al., 2004; 
 Mortusewicz et al., 2005).
As a result of these observations and data from genetic 
manipulations in the mouse, DNMT1 is thought to be the major 
enzyme responsible for postreplicative maintenance of DNA 
methylation. Homozygous null deletions of mouse dnmt1 are 
lethal early in development and result in an 80% reduction 
of global genomic methylation in embryonic stem cells and 
embryos (Lei et al., 1996). These and other studies also 
showed that despite growing normally, dnmt1−/− embryonic 
stem cells have reduced differentiation potential both in vivo 
and in vitro (Gaudet et al., 1998; Jackson et al., 2004). Later 
work using conditional deletion demonstrated that Dnmt1 is 
 indispensable for the survival of differentiated cells (Jackson-
Grusby et al., 2001).
An equivalent role of DNMT1 in human cells was ques-
tioned by the homozygous deletion of exons 3–5 of the DNMT1 
gene in HCT116 colorectal carcinoma cells (Rhee et al., 2000). 
This deletion encompasses the sequence encoding the PCNA-
binding domain (PBD) of DNMT1 and leaves the next exon out 
of frame. Thus, it was expected that this deletion would elimi-
nate DNMT1 maintenance activity and cause a dramatic drop in 
genomic methylation levels. Surprisingly, HCT116 cells bear-
ing this deletion (referred to here as MT1 knockout [KO] cells) 
showed only a 20% reduction of global genomic methylation 
levels and nearly no loss of methylation at CpG islands. The 
 issue was further complicated by studies in which DNMT1 
levels were knocked down by RNAi in human tumor cell lines 
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 DNA methylation plays a central role in the epigen-etic regulation of gene expression in vertebrates. Genetic and biochemical data indicated that DNA 
methyltransferase 1 (Dnmt1) is indispensable for the main-
tenance of DNA methylation patterns in mice, but target-
ing of the DNMT1 locus in human HCT116 tumor cells 
had only minor effects on genomic methylation and cell 
viability. In this study, we identiﬁ ed an alternative splicing 
in these cells that bypasses the disrupting selective marker 
and results in a catalytically active DNMT1 protein lack-
ing the proliferating cell nuclear antigen–binding domain 
required for association with the replication machinery. 
Using a mechanism-based trapping assay, we show 
that this truncated DNMT1 protein displays only twofold 
reduced postreplicative DNA  methylation maintenance 
activity in vivo. RNA interference–mediated knockdown of 
this truncated DNMT1  results in global genomic hypo-
methylation and cell death. These results indicate that 
DNMT1 is essential in mouse and human cells, but direct 
coupling of the  replication of genetic and epigenetic 
 information is not strictly required.
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(Leu et al., 2003; Robert et al., 2003; Suzuki et al., 2004). In 
these studies, a drastic decrease of methylation at CpG islands 
was observed, including a study using HCT116 cells (Leu et al., 
2003; Robert et al., 2003; Suzuki et al., 2004). At the same time, 
both the transient and stable knockdown of DNMT1 in HCT116 
cells seemed to have only a minor effect on methylation levels 
similar to those observed in MT1KO cells (Ting et al., 2004). 
Simultaneous KO of DNMT1 and DNMT3B in HCT116 cells 
(double KO [DKO] cells) resulted in a dramatic reduction of 
genomic methylation levels, suggesting a cooperative effect of 
DNMT1 and DNMT3B on the maintenance of DNA methyl-
ation (Rhee et al., 2002).
Interestingly, the combination of hypomorphic and null 
alleles in the mouse showed that animals expressing 20% of 
Dnmt1 wild-type (wt) levels are phenotypically inconspicuous 
and have normal levels of DNA methylation, whereas mice 
expressing 10% of Dnmt1 wt levels show severe hypomethy-
lation, are runted, and develop aggressive T cell lymphomas 
(Gaudet et al., 2003). Thus, there seems to be a threshold to the 
amount of Dnmt1 necessary for the maintenance of genomic 
methylation levels. This threshold amount of 10–20% roughly 
corresponds to the knockdown levels routinely achieved by 
RNAi and is hard to detect. Moreover, KO strategies may par-
tially be frustrated by alternative splicing yielding biologically 
active proteins, albeit at low levels. Indeed, the fi rst attempt to 
knock out Dnmt1 in mice eliminated only part of exon 4 and 
lead to a partial loss of function as a result of alternative splicing 
and weak expression of a truncated form of Dnmt1 (Li et al., 
1992, 1993; Lei et al., 1996).
We carefully revisited DNMT1 expression in MT1KO and 
DKO cell lines at the RNA and protein levels. Using RT-PCR 
and a newly developed antibody, we found that alternative splic-
ing occurs in MT1KO and DKO cell lines that bypasses the KO 
cassette and allows the expression of a DNMT1 variant lacking 
the PBD. We show that this truncated variant is enzymatically 
active in vitro and in vivo and that its levels are crucial for the 
maintenance of global genomic methylation and cell survival.
Results and discussion
MT1KO and DKO cells express 
an internally deleted DNMT1 variant
We fi rst checked for the presence of DNMT1 transcripts in 
MT1KO and DKO cells. Northern blot analysis showed that 
MT1KO cells expressed low levels of an mRNA species with 
a slightly lower molecular weight than full-length DNMT1 
mRNA (Fig. 1 A). Consistently, reverse transcription followed 
by PCR amplifi cation revealed the presence of DNMT1 mRNA 
species in parental HCT116 cells and DNMT KO derivatives 
(Fig. 1 B). A primer pair spanning exons 32–35 (corresponding 
to sequence coding for the catalytic domain) yielded different 
amounts of a specifi c PCR fragment in parental, MT1KO, and 
DKO cells. A second primer pair spanning exons 1–15 and in-
cluding the region targeted for deletion (exons 3–5; Fig. 1 C) 
produced fragments with different sizes in parental and MT1KO 
cells, whereas no product was detectable in DKO cells. How-
ever, reamplifi cation of these PCR reactions with a nested set of 
primers located in exons 2 and 10 produced the same two frag-
ments for MT1KO and DKO cells. Direct sequencing revealed 
that these fragments represent alternative splicing events, spec-
ifi cally from the precise joining of exon 2 with either exon 7 
(smaller fragment) or exon 6 (larger fragment; Fig. 1 C). Splic-
ing from exons 2–7 does not alter the reading frame and would 
result in a DNMT1 protein with an internal deletion spanning 
part of the DMAP1 interaction domain (Rountree et al., 2000) 
and PBD. In contrast, exons 2 and 6 are not in frame, and their 
joining results in a reading frame terminating after 30 nt in exon 6 
(Fig. 1 C).
The same nested PCR approach with RNA from parental 
HCT116 cells produced three fragments. Direct sequencing 
showed that the smallest of these fragments corresponds to the 
transcript encoding the major DNMT1 somatic isoform, that the 
medium-sized fragment corresponds to the DNMT1b transcript 
isoform, which includes an additional 48-bp exon between 
 exons 4 and 5 (exon 4a; Fig. 1 C; Hsu et al., 1999; Bonfi ls et al., 
2000), and that the largest fragment represents heteroduplex 
molecules of these two isoforms generated during the PCR 
 reaction. These results indicate that the alternative splicing is 
caused by genomic alterations of the DNMT1 KO allele.
To verify whether the detected alternatively spliced 
mRNAs are actually translated in vivo, we subjected whole cell 
extracts from parental, MT1KO, and DKO cell lines to Western 
blotting with a new monoclonal antibody against DNMT1 
(Fig. 1 D). A major band of 180 kD was detected in parental 
HCT116 cells, corresponding to the expected size of full-length 
DNMT1. In contrast, a single band with an approximate mole-
cular mass of 160 kD was detected in MT1KO and DKO cells. 
This size fi ts the predicted molecular weight of the exons 2–7 
splicing isoform. Quantifi cation after normalization with an 
antibody to lamin B showed that the relative abundance of the 
variant DNMT1 protein expressed in MT1KO and DKO cells 
with respect to the wt DNMT1 in parental HCT116 cells is at 
most 17 and 11%, respectively (Fig. 1 D). We conclude that 
MT1KO and DKO cell lines express decreased amounts of a 
mutant DNMT1 protein that originates from an alternative 
splicing event bypassing the deletion of exons 3–5. This mutant, 
which we hereafter refer to as DNMT1∆E3–6, lacks part of the 
DMAP1 interaction domain and PBD.
DNMT1𝚫𝚬3–6 is catalytically active both 
in vitro and in vivo and does not interact 
with PCNA
Next, we tested whether DNMT1∆E3–6 is a functional methyl-
transferase. To this aim, we fi rst transfected HEK293T cells 
with expression constructs for either human wt DNMT1, hu-
man DNMT1∆Ε3–6, mouse Dnmt1 lacking the PBD, or mouse 
Dnmt1C1229W all fused to GFP. In the latter construct, the cyste-
ine responsible for the transient formation of a covalent bond 
with the C5 position of the cytosine ring during the methyl-
ation reaction is replaced by tryptophan, resulting in a catalyti-
cally inactive enzyme (Schermelleh et al., 2005). Extracts were 
made from the transfected cells, and the respective GFP fusion 
proteins were immunopurifi ed and tested for their methyltrans-
ferase activity in vitro. Except for GFP-Dnmt1C1229W, which, 
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as expected, had no substantial catalytic activity, all GFP-
fused enzymes showed very similar levels of methyltransferase 
activity (Fig. 2 A). This result shows that DNMT1∆E3–6 is 
catalytically active in vitro. Importantly, GFP-DNMT1∆E3–6 
that was transiently expressed in human cells localized to the 
nucleus (Fig. 2 C), which is consistent with the identifi cation 
of multiple functional NLSs in mouse Dnmt1 (Cardoso and 
Leonhardt, 1999). This opened the possibility that the resid-
ual DNMT1∆E3–6 could contribute to maintenance of the rela-
tively high genomic methylation levels in MT1KO cells. As 
the deletion in DNMT1∆E3–6 eliminates the PBD, we checked 
whether GFP-DNMT1∆E3–6 is still capable of interacting with 
PCNA. Endogenous PCNA coimmunoprecipitated with GFP-
DNMT1wt expressed in HEK293T cells but not with GFP-
DNMT1∆E3–6 (Fig. 2 B).
To test whether DNMT1∆E3–6 is catalytically functional 
in vivo, we used a recently developed trapping assay (Scher-
melleh et al., 2005). HeLa cells were cotransfected with expression 
constructs for RFP-PCNA and either GFP-DNMT1wt or GFP-
DNMT1∆E3–6. 24 h after transfection, cells were incubated in the 
presence of 5-aza-deoxycytidine (5-aza-dC). During replica-
tion, this cytosine analogue is incorporated into newly synthe-
sized DNA. When DNMT1 engages in the methylation of 
5-aza-dC, a covalent complex is formed that cannot be resolved. 
As a consequence, DNMT1 is immobilized (trapped) at these 
sites. The trapping rate can be measured by FRAP as a time-
 dependent decrease of the mobile fraction of GFP-DNMT1 fu-
sions and refl ects their enzymatic activity in vivo. In contrast to 
GFP-DNMT1wt, GFP-DNMT1∆E3–6 did not accumulate at repli-
cation foci during early to mid S phase (Fig. 2 C). This is con-
sistent with our coimmunoprecipitation results and data obtained 
with a mouse Dnmt1 mutant lacking the PBD (Easwaran et al., 
2004). However, upon the addition of 5-aza-dC, a time-dependent 
focal accumulation of GFP- DNMT1∆E3–6 was observed. FRAP 
analysis revealed that GFP-DNMT1∆E3–6 is trapped with only an 
approximately twofold lower effi ciency than GFP-DNMT1wt 
Figure 1. DNMT1−/− (MT1KO) and DNMT1−/−;
DNMT3B−/− (DKO) HCT116 cell lines express 
an internally deleted DNMT1 variant. 
(A) Northern blot analysis of HCT116 cell lines, 
including parental cells (+/+), two independent 
DNMT1+/− clones, and one DNMT1−/− clone 
(MT1KO). The blot was hybridized with a 
DNMT1 cDNA probe and a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe as 
a loading control. The positions of the two tran-
scripts and molecular weight markers are indi-
cated. (B) RT-PCR analysis of parental (WT), 
DNMT1−/− (MT1KO), and DNMT1−/−;
DNMT3B−/− (DKO) HCT116 cells. The ampli-
ﬁ ed regions are indicated at the bottom of 
each panel. In the left panel, the arrowhead in-
dicates the speciﬁ c PCR fragment, and the as-
terisk indicates an unspeciﬁ c product. The right 
panel shows a nested PCR, where PCR pro-
ducts shown in the middle panel were used as 
templates. The two alternative splice forms ex-
pressed in MT1KO and DKO cells (right) and 
the positions of molecular weight markers are 
indicated. (C) Schematic drawing of the wt 
(top) and targeted DNMT1 alleles (middle) and 
alternatively spliced transcripts from the latter 
allele (bottom). Exons are shown as open rect-
angles (numbered on top) and are drawn to 
scale, whereas noncoding sequences are 
shown as lines and are not in scale. Sequences 
coding for major peptide domains are shown 
in different shades of gray, and their names are 
reported at the bottom. The positions of primers 
used for RT-PCR, translational start (ATG) co-
dons, and termination (STOP) codons are indi-
cated. (D) Western blot analysis of parental 
HCT116 cells and DNMT KO derivatives with 
antibodies to DNMT1 and lamin B1 (as a load-
ing control). The molecular mass of major 
bands is indicated. The 170-kD band detected 
with the anti-DNMT1 antibody in the parental 
cells lane has a higher molecular mass than the 
band detected in MT1KO and DKO lanes and 
likely represents a DNMT1 degradation pro-
duct. The percentages of normalized signal lev-
els from the DNMT1 variant in MT1KO and 
DKO cells with respect to wt DNMT1 levels in 
HCT116 cells (100%) are shown at the bottom 
of the corresponding lanes.
 on February 27, 2007 
w
w
w
.jcb.org
D
ow
nloaded from
 
JCB • VOLUME 176 • NUMBER 5 • 2007 568
(Fig. 2, C and D). These data strongly suggest that the 
DNMT1∆E3–6 enzyme expressed in MT1KO and DKO cells is 
fully catalytically active, localizes to the nucleus, and is capable 
of postreplicative methylation maintenance despite the loss of 
interaction with PCNA.
The level of DNMT1𝚫E3–6 in MT1KO cells 
is critical for cell survival and maintenance 
of global genomic methylation
We then sought to establish the contribution of DNMT1∆E3–6 to 
the maintenance of genomic methylation levels in MT1KO 
cells. To this aim, we knocked down DNMT1∆E3–6 by RNAi for 
a prolonged period of time and analyzed global genomic methy-
lation levels (Fig. 3). At each collection point, a relatively mod-
est but substantial decrease in DNMT1∆E3–6 protein levels was 
achieved (Fig. 3 A). Progressively fewer cells were found in 
cultures treated with DNMT1 siRNA with respect to cultures 
treated with control siRNA (Fig. 3 B). Microscopic inspection 
of cultures after 8 and 12 d of treatment with DNMT1 siRNA 
revealed large numbers of dead cells and cells with very long 
and thin cytoplasmic protrusions, whereas cells treated with 
control siRNA exhibited a normal morphology and death rate 
(Fig. 3 C). Interestingly, both of these phenotypes are reminis-
cent of the highly hypomethylated DKO cells. Global genomic 
Figure 2. GFP-DNMT1𝚫E3–6 is catalytically 
active in vitro and is capable of postreplicative 
DNA methylation in vivo. (A) In vitro DNMT as-
say of GFP-DNMT1 fusion variants transiently 
expressed in HEK293T cells and immunopuri-
ﬁ ed with an anti-GFP antibody. (B) Coimmuno-
precipitation of endogenous PCNA with either 
GFP-DNMT1wt or GFP-DNMT1∆E3–6 expressed 
in HEK293T cells. Input (I), ﬂ ow through (F), 
and bound (B) fractions are shown; 5% of in-
put and ﬂ ow through fractions with respect to 
bound fractions was loaded. The molecular 
masses of the two GFP fusions are indicated on 
the right. (C and D) Trapping assay for GFP-
DNMT1wt and GFP-DNMT1∆E3–6 transiently ex-
pressed in HeLa cells. (C) Images on the left 
show cells in early S phase according to the 
RFP-PCNA pattern and expressing the indi-
cated GFP-DNMT1 variant. The distribution of 
ﬂ uorescent fusions is shown before and at indi-
cated time points after the addition of 30 μM 
5-aza-dC. Regions targeted by photobleaching 
are indicated by boxes and are shown mag-
niﬁ ed at the bottom before and 0.3 (ﬁ rst 
postbleaching time point) and 20 s after 
bleaching. Bars, 5 μm. Plots on the right show 
FRAP curves of GFP fusions at targeted regions 
before and at indicated time points after the 
addition of 5-aza-dC from the corresponding 
cells shown on the left. (D) Trapping assays for 
GFP-DNMT1wt or GFP-DNMT1∆E3–6 were per-
formed as in C on three cells for each con-
struct, and the estimated immobilized fractions 
were plotted with respect to the time of incuba-
tion with 5-aza-dC.
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methylation was assayed by restriction with the endonuclease 
McrBC, which selectively digests methylated sequences, and 
by HPLC analysis (Fig. 3, D and E). Progressively lower geno-
mic methylation was detected from days 4 to 12 of treatment 
with DNMT1 siRNA, with cells treated for 8 and 12 d retaining 
only 10% of the methylated cytosines present in parental 
HCT116 cells, which is similar to the level found in DKO cells. 
Interestingly, the levels of DNMT3B remained unaffected until 
day 8 of RNAi treatment when global genomic methylation was 
already drastically decreased (Fig. 3, A, D, and E). A slight 
 reduction of DNMT3B levels was observed only after 12 d of 
RNAi treatment and is likely caused by secondary effects. Thus, 
a prolonged reduction of DNMT1∆E3–6 levels, although moderate, 
caused a drastic decrease of genomic methylation in the presence 
of normal levels of DNMT3B.
These results indicate that the residual level of the DNMT1 
mutant present in MT1KO cells provides most of the methyl-
transferase activity responsible for maintaining relatively high 
methylation levels in this cell line. Interestingly, DKO cells ex-
press a similarly reduced amount of DNMT1∆E3–6 (Fig. 1 D), 
which could explain their very low level of DNA methylation. 
Thus, the situation revealed here for the human MT1KO and 
DKO cell lines is reminiscent of transgenic mice bearing 
 hypomorphic and null dnmt1 alleles. Although homozygotes 
for the hypomorphic allele were phenotypically normal and 
showed nearly no molecular alterations, the combination of 
Figure 3. Prolonged knockdown of DNMT1𝚫𝚬3–6 in 
MT1KO cells leads to genomic demethylation and cell 
death. Equal numbers of MT1KO cells were plated 
and transfected with either DNMT1 or control siRNA 
the next day (day 0) and every second day for 12 d. 
On days 2, 4, 8, and 12, cells were harvested, ali-
quots were collected for protein extracts and DNA iso-
lation, and, except for day 12, equal numbers were 
replated. (A) Levels of DNMT1∆Ε3–6 and DNMT3B 
were analyzed by Western blotting of whole cell ex-
tracts collected at the indicated days of siRNA treat-
ment. Detection of β-actin was used to control for 
loading. (B) Cell numbers were plotted taking into 
 consideration the splitting factor at each passage. 
(C) Phase-contrast images of MT1KO cultures treated 
with either control (left) or DNMT1 (middle) siRNA for 
12 d and an image of DKO cells (right). Arrows point 
to dead cells, and arrowheads point to cells with thin 
and extended cytoplasmic protrusions that are present 
only in MT1KO cells treated with DNMT1 siRNA and 
in DKO cells. Bars, 50 μm. (D and E) Assays for the 
determination of global genomic methylation levels 
from the indicated cell lines and treatments. (D) Geno-
mic DNA was digested with the McrBC endonuclease, 
which selectively recognizes methylated sequences. 
The top panel shows electrophoretic separation of the 
digests. Progressive demethylation in cells treated with 
DNMT1 siRNA is indicated by the increasingly similar 
patterns between mock digestions (−) and samples in-
cubated with the enzyme (+). The bottom panel shows 
quantiﬁ cation of the McrBC-sensitive (methylated) 
DNA fraction from the samples shown in the top 
panel. (E) HPLC quantiﬁ cation of global 5-methyl-2′-
deoxycytidine (mdC) content. Bars and error bars rep-
resent mean values and SEM from ﬁ ve measurements, 
respectively, except for HCT116 parental cells and 
MT1KO cells treated with DNMT1 siRNA for 12 d (six 
and two measurements, respectively).
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a hypomorphic allele with a null allele resulted in severe 
hypomethy lation, growth defects, and cancer (Gaudet et al., 
2003). Analogously, the contrasting results previously obtained 
with DNMT1 knockdown experiments in human cell lines are 
likely caused by the varying effi ciency of RNAi that may or 
may not lower DNMT1 below the threshold level that is suffi -
cient for the maintenance of normal methylation levels. Also, 
the reduced proliferation rate and viability of severely hypo-
methylated cells may lead to an enrichment of cells with less ef-
fi cient knockdown of DNMT1, which may explain the variable 
results obtained in different RNAi studies. The drastically de-
creased viability of MT1KO cells that we observed upon the 
knockdown of DNMT1 is also consistent with the rapid cell 
death of mouse fi broblasts after the conditional KO of Dnmt1 
(Jackson-Grusby et al., 2001). While this manuscript was in 
preparation, a residual DNMT1 activity crucial for cell survival 
was independently identifi ed in MT1KO cells (Egger et al., 
2006). These results indicate that DNMT1 plays a similar and 
prominent role in the maintenance of DNA methylation in 
mouse and human cells and that the dependence on DNMT1 for 
the survival of differentiated cells is similar in these species and 
likely in all mammals.
We showed that the DNMT1∆E3–6 mutant expressed in 
MT1KO cells is enzymatically active and displays only a two-
fold reduced postreplicative methylation rate in vivo despite 
lacking the domain responsible for interaction with PCNA. We 
also showed by RNAi-mediated knockdown experiments that 
the expression level of this truncated DNMT1 is critical for the 
maintenance of genomic methylation. Collectively, these results 
demonstrate that the interaction of DNMT1 with the replication 
machinery is not strictly necessary for the maintenance of DNA 
methylation but improves its effi ciency. As most cell types ex-
press an excess of DNMT1, this improved effi ciency may not be 
critical for cell survival but may contribute to the faithful main-
tenance of epigenetic information and stable gene expression 
patterns in differentiated cells and developing organisms.
Materials and methods
Cell culture and transfection
HeLa, HEK293T, and HCT116 cells and their derivatives were maintained in 
DME supplemented with 10% FBS, 2 mM L-glutamine, and 50 μg/ml genta-
mycine. All HCT116 cell lines were supplied by B. Vogelstein and K. Schuebel 
(Johns Hopkins University, Baltimore, MD). Cells were transfected with Trans-
fectin (Bio-Rad Laboratories) according to the manufacturer’s instructions.
Northern blotting and RT-PCR analysis
5 μg poly (A)+ RNA from the indicated cell lines were subjected to North-
ern blotting and probed with a 1.1-kb BamHI fragment from DNMT1 cDNA 
according to standard procedures. For RT-PCR, total RNA was isolated form 
HCT116, MT1KO, and DKO cells with TRIzol reagent (Invitrogen), and 
reverse transcription was performed with the First Strand cDNA Synthesis kit 
(GE Healthcare) by priming with random hexamer oligonucleotides. PCR 
ampliﬁ cations were performed in a 50-μl ﬁ nal volume containing 1.5–2.0 
U SAWADY Taq DNA polymerase (PeqLab), 1× buffer (20 mM Tris, pH 
8.55, 16 mM [NH4]2SO4, 2 mM MgCl2, and 0.1% Tween 20), 0.2 μM of 
each primer, and 0.2 mM of each deoxynucleotide triphosphate. For pri-
mary PCR reactions, cDNA template from 0.75 μg of total RNA was used 
with either primers HMT1catF (5′-T G C A A C A T C C T G C T G A A G C T G G -3′; 
forward, exon 32) and HMT1catR (5′-G A C C C G A G C T C A A C C T G G T T A T G -3′; 
reverse, exon 35) or HMT1mF (5′-G T C T G C T G A A G C C T C C G A G A T G -3′; 
forward, exon 1) and HMT1e15R (5′-T T T G A G G T C A G G G T C G T C C A G G -3′; 
reverse, exon 15) as well as the following touchdown cycling proﬁ le: 
94°C for 2 min; 10 cycles at 94°C for 20 s; 68–60°C descending by 2°C 
every two cycles for 15 s; 72°C for 30 s plus a 3-s increment at each cycle; 
30 cycles at 94°C for 20 s; 58°C for 15 s; and 72°C for 1 min plus a 5-s 
increment at each cycle. For nested PCR reactions, 1 μl of primary reaction 
product was used as a template with primers HMT1e2F (5′-A A A G A T T T-
G G A A A G A G A C A G C T T A A C A G -3′; forward, exon 2) and HMT1e10R 
(5′-T C T C C A T C T T C G T C C T C G T C A G -3′; reverse, exon 10) and a cycling 
proﬁ le consisting of 25 cycles of 94°C for 20 s, 58°C for 15 s, and 72°C 
for 30 s plus a 5-s increment at each cycle.
Antibodies
Monoclonal antibodies were raised against puriﬁ ed recombinant DNMT1 
and 6×His-tagged PCNA. Approximately 50 μg of antigen was injected 
both i.p. and subcutaneously into Lou/C rats using CPG2006 (TIB MOL-
BIOL) as adjuvant. After an 8-wk interval, a boost was given i.p and subcu-
taneously 3 d before fusion. Fusion of the myeloma cell line P3X63-Ag8.653 
with the rat immune spleen cells was performed according to standard 
 procedures. DNMT3B was detected with a mouse monoclonal antibody that 
recognizes the conserved catalytic domain within the DNMT3 family (clone 
64B1446; Imgenex). The lamin B1 (H90), β-actin (clone AC-15), and GFP 
antibodies were obtained from Santa Cruz Biotechnology, Inc., Sigma-Aldrich, 
and Roche, respectively.
Plasmid construction
Expression constructs for mouse GFP-Dnmt1∆PBD, GFP-Dnmt1C1229W, human 
GFP-DNMT1wt, and RFP-PCNA were described previously (Easwaran 
et al., 2004; Schermelleh et al., 2005; Sporbert et al., 2005). The GFP-
DNMT1∆E3–6 expression construct was derived from the GFP-DNMT1wt con-
struct by overlap extension PCR (Ho et al., 1989).
Coimmunoprecipitation and DNMT assay
Extracts were prepared from transfected HEK293T cells in lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 2 mM PMSF, and 
0.5% NP-40), diluted with lysis buffer without NP-40, and incubated with 
an anti-GFP antibody for 30 min at 4°C with constant mixing. Immuno-
complexes were pulled down with protein A–Sepharose beads (GE Health-
care), and the beads were washed extensively with dilution buffer 
containing 300 mM NaCl. For coimmunoprecipitation, beads were resus-
pended in SDS-PAGE loading buffer. For in vitro methyltransferase assay, 
beads were further washed with and resuspended in assay buffer (100 mM 
KCl, 10 mM Tris, pH 7.6, 1 mM EDTA, and 1 mM DTT), and 30 μl methyl-
ation mix (0.1 μCi [3H]S-adenosyl-methionine, 1.67 pmol/μl hemimethyl-
ated double-stranded 35-mer oligonucleotide, and 160 ng/μl BSA in 
assay buffer) was added. After incubation at 37°C for 2.5 h, reactions 
were spotted onto DE81 cellulose paper ﬁ lters (Whatman), and radioactivity 
was measured by liquid scintillation.
Live cell trapping assay
The DNMT trapping assay was performed essentially as described previ-
ously (Schermelleh et al., 2005). In brief, transfected cells were incubated 
with 30 μM 5-aza-dC (Sigma-Aldrich) for the indicated periods of time 
before photobleaching experiments. FRAP analysis was performed with a 
confocal laser-scanning microscope (TCS SP2; Leica) equipped with a 
63× 1.4 NA plan-Apochromat oil immersion objective (Leica). GFP and 
RFP were excited with a 488-nm Ar laser and a 561-nm diode laser, 
 respectively. Image series were recorded with a frame size of 256 × 256 
pixels, a pixel size of 100 nm, and laser power set to 1–5% of transmission 
with a detection pinhole size of 1 Airy U. For FRAP analysis, regions of in-
terest were photobleached with an intense Ar laser beam (laser set to maxi-
mum power at 100% transmission of all laser lines) for 0.5 s. Image series 
were recorded before and after bleaching at 0.27-s intervals (typically 20 
prebleach and 50–100 postbleach frames). Mean ﬂ uorescence intensities 
of the bleached region were corrected for background and total loss of 
nuclear ﬂ uorescence over the time course and were normalized to the 
mean of the last 10 prebleach values.
RNAi
Equal numbers of MT1KO cells were plated and transfected the next day 
(day 0) and every second day with 40 nM of either DNMT1 ShortCut 
siRNA Mix (New England Biolabs, Inc.) or a control siRNA (AllStars Nega-
tive Control siRNA; QIAGEN) using HiPerFect transfection reagent (QIAGEN). 
On days 2, 4, and 8, cells were harvested, aliquots were collected 
for protein extracts and DNA isolation, and equal numbers were replated 
and simultaneously transfected. On days 6 and 10, cells were transfected 
without splitting. The medium was never changed in between transfections.
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Global genomic methylation analysis
Genomic DNA was isolated by the phenol-chloroform extraction method. 
For the McrBC nuclease assay, 0.5-μg aliquots were incubated with or 
without 10 U of the enzyme (New England Biolabs, Inc.) in buffer supplied 
by the manufacturer for 1 h at 37°C, and digests were separated by aga-
rose gel electrophoresis. ImageJ software (http://rsb.info.nih.gov/ij/) was 
used to quantify the McrBC-resistant fractions from digital images. The 
McrBC-sensitive fraction shown in Fig. 3 D was calculated as follows: 
 (resistant fraction − mock-resistant fraction)/mock-resistant fraction. For 
HPLC analysis, DNA samples were further treated with RNase A and T1, 
phenol extracted, dialyzed extensively against 10 mM Tris, pH 7.2, and 
0.1 mM EDTA, and hydrolyzed to nucleosides as described previously 
(Song et al., 2005) except that 5 U Antarctic phosphatase (New England 
Biolabs, Inc.) was used for dephosphorylation. HPLC was performed on 
the Alliance system (Waters) using a Nucleosil C-18 column at a ﬂ ow rate 
of 0.5 ml/min with a linear increase of buffer A (0.1 M HNEt3OAc) from 
0 to 20% in buffer B (0.1 M HNEt3OAc in 80% acetonitrile) in 30 min.
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2.5. Structure and function of the mouse Dnmt1 CXXC  
zinc finger domain. 
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Introduction and working hypothesis 
 
During early development and differentiation a cell type specific DNA methylation 
pattern is established by the ne novo methyltransferases Dnmt3a and Dnmt3b 
(Okano et al., 1999; Kaneda et al., 2004). This specific methylation pattern is then 
postreplicatively maintained over several cell division cycles by Dnmt1 that precisely 
copies the methylation mark from the parental to the daughter strand (Goll and 
Bestor, 2005; Vilkaitis et al., 2005). In accordance to this, Dnmt1 is associated with 
the DNA replication machinery throughout S phase (Leonhardt et al., 1992; Chuang 
et al., 1997; Easwaran et al., 2004; Schermelleh et al., 2007) and displays high 
binding preference for hemimethylated DNA substrates that are generated at the 
replication fork (Bestor and Ingram, 1983; Hermann et al., 2004b; Frauer and 
Leonhardt, 2009). How Dnmt1 mechanistically recognizes its hemimethylated DNA 
substrate and which domains are involved in this process is still unclear.  
Two hypotheses were raised, suggesting that the zinc finger (ZnF) domain as part of 
the large N-terminus may be involved in Dnmt1 maintenance activity (Figure 12) 
(Fatemi et al., 2001; Pradhan et al., 2008). The first hypothesis proposed that the 
ZnF domain could play an essential role in DNA binding and possibly discrimination 
of hemimethylated CpG sites, which would be the key property in faithful 
maintenance of DNA methylation. As shown previously, the CTD of Dnmt1 comprises 
all conserved motifs of a bacterial C5-methyltransferase, but requires the NTD for its 
catalytic activation (Leonhardt and Bestor, 1993; Margot et al., 2000; Fatemi et al., 
2001; Margot et al., 2003). Based on these data, the second hypothesis proposed 
that the ZnF domain as part of the regulatory N-terminus may be essential for 
allosteric activation of the catalytic domain and thus could control catalytic activity.  
In this study, we investigated the role of the Dnmt1 ZnF domain in substrate 
discrimination and allosteric enzyme activation. Furthermore, we addressed how this 
functional domain could affect the complex regulation of Dnmt1 in a living cell.  
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Results 
 
Dnmt1 contains a CXXC type zinc finger 
 
Multiple sequence alignments and data base domain annotations (PF02008) (Finn et 
al., 2008) show that the mouse Dnmt1 contains a cysteine-rich CXXC-type ZnF 
domain (aa 652-697) that is conserved in all species and displays high sequence 
homology with various CXXC fingers of other proteins (Figure 12).  
 
 
Figure 12: Schematic representation of the mouse Dnmt1 structure and alignment of CXXC zinc 
finger motifs.  
(A) Schematic representation of the functional subdomains in Dnmt1. PBD, PCNA binding domain; TS, 
targeting sequence; ZnF, zinc finger; BAH, bromo adjacent homology domain; (KG)7, lysine-glycine 
repeat. (B) Alignment of the Dnmt1 CXXC zinc finger motif from different species. Accession numbers: 
Mus musculus P13864; Homo sapiens P26358; Bos taurus O44952; Monodelphis domestica 
Q8MJ28; Gallus gallus Q92072; Xenopus laevis P79922; Danio rerio Q8QGB8; Paracentrotus lividus 
Q27746; Bombyx mori Q5W7N6; Apis mellifera GB 15130. (C) Alignment of mouse and human 
proteins containing a CXXC domain. The MBD1 protein contains three CXXC motifs; amino acid 
positions are indicated in parentheses. All sequences are from H. sapiens if not stated otherwise. 
Accession numbers: Dnmt1 (M. musculus): P13864; MLL: Q03164; MLL (M. musculus): P55200; 
MLL4: Q9UMN6; CGBP: Q9P0V4; CGBP (M. musculus): Q9CWW7; JHD1A: Q9Y2K7; JHD1B: 
Q8NHM5; MBD1:Q9UIS9. Conserved cysteine residues involved in zinc ion binding are gray shaded 
and the conserved KFGG motif is highlighted in red. (*) marks identical positions, (:) marks positions 
with conserved substitutions, (.) marks positions with semi-conserved substitution. 
 
Similar CXXC-type ZnF domains are present in the histone lysine 
N-methyltransferases mixed-lineage leukaemia (MLL and MLL4) (Allen et al., 2006; 
Ayton et al., 2004; Birke et al., 2002), in the CpG-binding protein (CGBP) (Voo et al., 
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2000; Lee et al., 2001; Butler et al., 2008), in JmjC domain-containing histone 
demethylases (JHD1A and B) (Tsukada et al., 2006; Frescas et al., 2007; Koyama-
Nasu et al., 2007) and in the methyl-CpG binding domain protein (MBD1) (Fujita et 
al., 2000; Jorgensen et al., 2004). It has been shown that these chromatin associated 
proteins bind selectively to CpG sites via their ZnF domain. Since all ZnFs display 
high sequence homology, it is likely that also the ZnF of Dnmt1 might be involved in 
substrate recognition and possibly also in the discrimination of hemimethylated CpG 
sites, which is the basis for the postreplicative maintenance of DNA methylation 
patterns.  
 
Homology model of the mouse Dnmt1 and MLL CXXC zinc finger 
 
Based on our ZnF sequence alignment and the human MLL NMR structure (PDB 
2J2S) (Allen et al., 2006), we created a homology model of the mouse Dnmt1 ZnF in 
collaboration with Johannes Söding (Figure 13). Similar to the MLL ZnF domain 
(green and blue) the mouse Dnmt1 ZnF (magenta) adopts an extended crescent-like 
structure, incorporating two zinc ions that are coordinated by four cysteine residues 
each. The tip of the MLL ZnF is composed of a 310-helix motif (P1177-F1179) that 
dictates the turn of this domain structure. The formation of a short two-stranded 
antiparallel β-sheet comprising residues R1151-R1154 and L1197-M1200 places the 
N- and C-terminal region of the ZnF domain in close proximity (marked in blue).  
 
Figure 13: Homology model of the mouse Dnmt1 ZnF (magenta) in superimposition with the 
ZnF domain of human MLL (green and blue). 
The model was generated in collaboration Johannes Söding. Human MLL NMR structure (PDB 2J2S) 
was used as template. Two zinc ions (spheres) are coordinated by four cysteine residues each. 
Antiparallel β-sheets (marked in blue) correspond to the remaining residues in the GFP-Dnmt1∆ZnF 
construct. The image was generated using the PyMol software (DeLano, 2002).  
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The isolated ZnF of Dnmt1 binds to nuclear structures in vivo 
 
Next, we tested localization and binding properties of the isolated mouse Dnmt1 ZnF 
in vivo. For this purpose we designed a GFP fusion construct including amino acids 
652-699 of mouse Dnmt1 (GFP-ZnF) and transiently expressed either GFP-ZnF or 
GFP alone in C2C12 myoblast cells (Figure 14).  
 
 
Figure 14: In vivo localization and binding kinetics of the isolated Dnmt1 ZnF domain.  
(A) Schematic representation of the fluorescent fusion proteins. (B) Live cell imaging of mouse C2C12 
myoblast cells coexpressing RFP-PCNA and either GFP-ZnF or GFP. Arrow heads mark nucleolar 
accumulation of the GFP-ZnF fusion protein. (C) Quantitative evaluation of half nucleus FRAP 
experiments. Binding kinetics of GFP-ZnF and GFP are shown as mean curves of 6-10 cell nuclei 
± SEM. Images display representative localization of the fusion proteins and rectangles indicate the 
bleached region of interest (ROI). t1/2: GFP~0.8 s; t1/2:GFP-ZnF~3.5 s. (D) FRAP experiment to control 
the influence of the nucleolar accumulation of GFP-ZnF on the overall protein kinetics. ROIs with 
identical size were selected for the nucleolus and nucleus (image inset). Recovery curve of the 
nuclear GFP-ZnF protein fraction showed significant slower kinetics than GFP-ZnF in the nucleolus. 
Bars: 5 µm 
 
GFP-ZnF was localized in the cell nucleus and showed a punctuated association with 
nuclear structures (Figure 14 B). In addition, GFP-ZnF was enriched in nucleoli, 
probably due to the high number of basic residues within the CXXC motif that 
unspecifically bind to nucleolar RNA (see alignment in Figure 12). For comparison, 
GFP showed a diffuse distribution in the nucleus and cytoplasm, but was not 
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localized in the nucleoli (Figure 14 B). As shown previously, also full-length Dnmt1 is 
excluded from the nucleoli (Easwaran et al., 2004; Schermelleh et al., 2007).  
To characterize the ZnF-mediated interaction, we performed quantitative 
fluorescence recovery after photobleaching (FRAP) analyses (Figure 14 C) 
(procedure as described in 1.2.2 and (Schermelleh et al., 2007)). We chose to bleach 
half of the nucleus to ensure that the bleached region contains a representative 
number of potential binding sites, including the nucleoli (Figure 14 C, inset). GFP 
alone was used as reference, since it displays high protein mobility that is not 
affected by any specific nuclear interaction and thus should reflect free diffusion 
(Phair et al., 2004b). GFP recovered with a halftime (t1/2) of ~ 0.8 seconds (s) and 
reached complete equilibration (t∞) in about ~ 10 s. In contrast, GFP-ZnF showed a 
four to five times slower recovery rate (t1/2 ~ 3.5 s; t∞ ~ 30 s) than GFP alone. In order 
to dissect the ZnF-mediated binding to nuclear structures from superimposing effects 
caused by the nucleolar interaction of the GFP-ZnF protein we performed 
simultaneous FRAP experiments in the nucleus and nucleolus (Figure 14 D). We 
found a significantly slower recovery rate in the nuclear GFP-ZnF fraction than 
displayed by the nucleolar fraction, arguing for a strong and independent binding of 
GFP-ZnF in the nucleus. Thus, the decreased protein kinetics measured by 
half-nucleus FRAP reflect indeed binding of the isolated Dnmt1 ZnF domain to 
nuclear structures like chromatin in vivo.  
 
Deletion of the ZnF motif does not impair localization, binding kinetics and 
activity of Dnmt1 in vivo 
 
To further analyze the role of the ZnF in context of the full-length Dnmt1 protein, we 
generated a ZnF-deletion mutant lacking the amino acids 655-696 (GFP-Dnmt1∆ZnF) 
(Figure 15). Based on the CXXC ZnF sequence alignment and the corresponding 
homology model (see Figure 13) we selected the deletion boundaries with the aim to 
precisely remove the ZnF without disrupting the overall protein folding. First, we 
investigated the cell cycle dependent localization of the ZnF-deletion mutant in 
comparison to wild-type (wt) Dnmt1 in living cells (Figure 15).  
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Figure 15: Schematic representation of the fluorescent fusion proteins and cell cycle 
dependent localization of wild-type Dnmt1 and ZnF-deletion mutant in vivo. 
Confocal mid sections of living mouse C2C12 myoblasts, expressing either GFP-Dnmt1wt (A) or 
GFP-Dnmt1∆ZnF (B). RFP-PCNA was coexpressed to distinguish S phase stages. Bars: 5 µm. Both 
fusion proteins accumulate at replication sites throughout S phase where they colocalize with 
RFP-PCNA. In G2 phase a fraction of GFP-Dnmt1 (wt and ΔZnF) remains associated with pericentric 
heterochromatin.  
 
Either GFP-Dnmt1wt or GFP-Dnmt1∆ZnF were transiently expressed in mouse C2C12 
myoblasts together with RFP-PCNA, which served as S phase marker as described 
before (Sporbert et al., 2005; Schermelleh et al., 2007). GFP-Dnmt1wt was localized 
within the nucleus and showed the typical cell cycle dependent localization patterns 
(Figure 15 A). Interaction with PCNA via the PBD directs Dnmt1 to replication foci 
during S phase (Chuang et al., 1997; Schermelleh et al., 2007; Spada et al., 2007). 
In late S phase and G2, the targeting sequence (TS) mediates accumulation of 
Dnmt1 at centromeric heterochromatin (Leonhardt et al., 1992; Easwaran et al., 
2004; Easwaran et al., 2005). In comparison to GFP-Dnmt1wt, GFP-Dnmt1∆ZnF 
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showed indistinguishable localization patterns throughout the cell cycle, indicating 
that the absence of the ZnF does not impair subnuclear localization in vivo (Figure 
15 B).  
Next, we investigated the cell cycle dependent kinetic properties of the ZnF-mediated 
interaction by measuring FRAP of GFP-Dnmt1wt or GFP-Dnmt1∆ZnF in early and late 
S phase cells (Figure 16).  
 
 
Figure 16: Quantitative evaluation of half nucleus FRAP experiments.  
Mouse C2C12 myoblasts were transiently transfected with either GFP-Dnmt1wt or GFP-Dnmt1∆ZnF. 
RFP-PCNA was coexpressed to distinguish S phase stages. Kinetics of GFP and GFP-ZnF are shown 
as reference. Binding kinetics are represented as mean curves of 6-10 cell nuclei ± SEM. 
GFP-Dnmt1wt and GFP-Dnmt1∆ZnF show similar protein mobility in early- and also in late S phase cells.  
 
FRAP kinetics of the ZnF-deletion mutant revealed no significant difference to wt 
Dnmt1, neither in early nor in late S phase. In early S phase both constructs 
recovered with a halftime (t1/2) of about 4-6 seconds that reflects the dynamic 
interaction of the PBD domain with the central replication ring PCNA (Schermelleh et 
al., 2007). Notably, both proteins displayed a reduced mobility in late S phase (t1/2 8-
10 s), pointing to an additional or stronger interaction of Dnmt1 at pericentric 
heterochromatin that is most likely mediated by the TS domain (unpublished data 
Daniela Meilinger and Katrin Schneider) and (Easwaran et al., 2004). The decreased 
mobility of the full-length constructs compared to the isolated GFP-ZnF protein can 
be explained by additional interactions occurring in the large regulatory N-terminus of 
Dnmt1. While the isolated ZnF domain clearly showed binding to nuclear structures 
in vivo, the ZnF domain seems to have no, or only minor, effect on protein 
localization and the overall protein kinetics in context of the full-length protein.  
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To finally test whether the ZnF-deletion construct is catalytically active in vivo, we 
performed a previously established trapping assay (Figure 17) (Schermelleh et al., 
2005). 
 
Figure 17: GFP-Dnmt1∆ZnF is catalytically active in vivo and displays similar postreplicative 
methylation activity than GFP-Dnmt1wt.  
Trapping assay for GFP-Dnmt1∆ZnF. (A, B) Confocal mid sections (upper panel) and corresponding 
FRAP series (lower panel) of C2C12 cells expressing GFP-Dnmt1∆ZnF either in early (A) or late (B) 
S phase, as indicated by the RFP-PCNA pattern (left). The distribution of the fusion protein is shown 
before and at the indicated time points after the addition of 30 µM 5-aza-dC. Regions targeted for 
photobleaching (boxes) are magnified in the lower panel and reflect the distribution of the fusion 
protein before (pre) and after photobleaching (0.15 s and 50 s). Bars, 5 µm. Quantitative FRAP 
analyses are shown on the right. (C) The immobilized enzyme fractions were plotted with respect to 
the incubation time with 5-aza-dC for early (red) and late (blue) S phase cells. GFP-Dnmt1wt is shown 
for comparison.  
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Mouse C2C12 myoblast cells coexpressing RFP-PCNA and either GFP-Dnmt1wt or 
GFP-Dnmt1∆ZnF fusion proteins were treated with the nucleoside analog 
5-aza-2′-deoxycytidine (5-aza-dC), which gets incorporated into the newly 
synthesized DNA during replication and serves as mechanism-based inhibitor. When 
Dnmt1 is engaged in the methyl group transfer reaction at the 5-aza-dC residue, an 
irreversible covalent complex is formed and Dnmt1 gets immobilized (trapped) at 
replication foci (RF), the site of action. This time-dependent immobilization of 
GFP-Dnmt1 (trapping rate) can be measured by FRAP analyses and reflects the 
enzymatic activity of the fusion protein.  
Upon the addition of 30 µM 5-aza-dC, a time-dependent accumulation of 
GFP-Dnmt1∆ZnF was observed at replication foci (Figure 17 A; B). Analog enrichment 
at RF could be visualized for the GFP-Dnmt1wt fusion protein (data not shown). Both 
Dnmt1 constructs (wt and ∆ZnF) were catalytically active and showed similar trapping 
rates during early- and late S phase, reaching ~100 % of trapped enzyme fraction 
after 40 minutes and 20 minutes, respectively (Figure 17 C). Together, the data 
demonstrate that the ZnF domain seems to be dispensable also for catalytic activity 
and postreplicative methylation maintenance in vivo. In summary, with the methods 
applied in this study, neither substrate preference (hypothesis one) nor allosteric 
activation (hypothesis two) was detectably affected by the deletion of the ZnF domain. 
Still, the data presented here cannot rule out that the ZnF domain features a relevant 
function in the full-length Dnmt1 protein, e.g. during development.  
 
Together with other data on the Dnmt1 ZnF, we are currently preparing a manuscript.  
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ABSTRACT 
DNA methylation and histone modifications play a central role in the epigenetic 
regulation of gene expression and cell differentiation. Recently, Np95 (also known as 
UHRF1 or ICBP90) has been found to interact with Dnmt1 and crystal structures 
showed binding to hemimethylated CpG sites, indicating a central role in the 
maintenance of DNA methylation. Using in vitro binding assays we observed only a 
weak preference of Np95 and its SRA (Set- and Ring-associated) domain for CpG sites 
independent of the methylation status. Moreover, the binding kinetics of Np95 in living 
cells was not affected by the complete loss of genomic methylation. Instead, we could 
show that Np95 preferentially binds trimethylated but not acetylated H3 N-terminal 
histone tails (H3K9) via a tandem Tudor domain. This domain contains three highly 
conserved aromatic amino acids that form an aromatic cage similar to the H3K9me3 
binding chromodomain of HP1ß. Mutations targeting the aromatic cage of the Np95 
tandem Tudor domain (Y188A and Y191A) abolished specific H3 histone tail binding. 
These results suggest that the multi-domain protein Np95 interacts with DNA, Dnmt1 
and repressive histone marks and thus connects the two major epigenetic silencing 
pathways. 
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INTRODUCTION 
DNA methylation and histone modifications are crucially involved in the regulation of 
gene expression, inheritance of chromatin states, genome stability and differentiation 
(Bird, 2002; Kouzarides, 2007; Reik, 2007). Although the biochemical networks 
controlling these epigenetic marks have been the subject of intensive investigation, their 
interconnection is still not well resolved in mammals. DNA methylation patterns are 
established by de novo DNA methyltransferases Dnmt3a and 3b, while Dnmt1 is largely 
responsible for maintaining this genomic methylation after DNA replication (Lei et al., 
1996; Okano et al., 1999). Dnmt1 possesses an intrinsic preference for hemimethylated 
DNA substrates and associates with proliferating cell nuclear antigen (PCNA) at 
replication sites in vivo (Bestor and Ingram, 1983; Leonhardt et al., 1992; Chuang et al., 
1997; Easwaran et al., 2004; Pradhan et al., 1997). The transient interaction of Dnmt1 
with PCNA enhances methylation efficiency but is not strictly required to maintain 
genomic methylation in human and mouse cells (Schermelleh et al., 2007; Spada et al., 
2007). 
Recently, Np95 has emerged as an essential cofactor for the maintenance of genomic 
methylation. Np95 co-purifies with Dnmt1, localizes at replication foci and genetic 
ablation of either Dnmt1 or Np95 leads to remarkably similar genomic hypomethylation 
and developmental arrest (Uemura et al., 2000; Miura et al., 2001; Bostick et al., 2007; 
Papait et al., 2007; Sharif et al., 2007; Achour et al., 2008;). Np95 and its Set- and Ring- 
associated (SRA) domain were shown to bind hemimethylated DNA with higher affinity 
than corresponding symmetrically methylated or unmethylated sequences both in vitro 
and in vivo ( Bostick et al., 2007; Sharif et al., 2007; Arita et al., 2008; Avvakumov et al., 
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2008; Qian et al., 2008). In addition, crystal structures of the SRA domain complexed 
with hemimethylated oligonucleotides revealed flipping of the 5-methylcytosine out of 
the DNA double helix, a configuration that would stabilize the SRA-DNA interaction 
(Arita et al., 2008; Avvakumov et al., 2008; Qian et al., 2008). Thus, recruitment of 
Dnmt1 to hemimethylated CpG sites by Np95 has been proposed as the mechanism 
underlying the crucial role in the maintenance of genomic methylation. In addition to its 
role in controlling DNA methylation, Np95 has been shown to take part in several other 
chromatin transactions. Np95 or its human homolog ICBP90/UHRF1 were reported to 
interact with the histone deacetylase HDAC1 and the histone methyltransferase G9a, 
suggesting a role of Np95 in gene silencing through histone modification (Unoki et al., 
2004; Kim et al., 2009). Np95 binds histone H3 and displays a Ring domain-mediated 
E3 ubiquitin ligase activity for core histones in vitro and possibly histone H3 in vivo 
(Citterio et al., 2004; Karagianni et al., 2008). The plant homeodomain (PHD) of Np95 
has been linked to decondensation of replicating pericentric heterochromatin (PH) but it 
is still unclear which domains recognize specific histone modifications (Papait et al., 
2007; Karagianni et al., 2008; Papait et al., 2008).  
In this study we systematically analyzed the binding properties of Np95 and its 
individual domains to DNA and histone tails in vitro and their binding kinetics in living 
cells. We find that the SRA domain mediates DNA binding, however, with no significant 
preference for either hemimethylated or fully methylated DNA. In addition, we show 
selective binding of the tandem Tudor domain to modified histone H3 N-terminal tails. 
Our data reveal a multi-functional modular structure of Np95 interconnecting DNA 
methylation and histone modification pathways. 
under revision at Nucleic Acids Research Rottach et al. 2009
 
-105- 
 
MATERIALS AND METHODS 
 
Expression constructs 
Expression construct for GFP-Dnmt1 and RFP-PCNA were described previously 
(Easwaran et al., 2004; Schermelleh et al., 2005; Sporbert et al., 2005). All Np95 
constructs were derived by PCR from corresponding myc- and His6-tagged Np95 
constructs (Citterio et al., 2004). To obtain GFP- and mCherry-fusion constructs the 
Dnmt1 cDNA in the pCAG-eGFP-Dnmt1-IRESblast construct (Schermelleh et al., 2007) 
or the pCAG-mCherry-Dnmt1-IRESblast was replaced by Np95 encoding PCR 
fragments. The GFP-Np95ΔTudor expression construct was derived from the 
GFP-Np95 construct by overlap extension PCR (Ho et al., 1989). The GFP-Tudor 
mutant (Y188A,Y191A) was derived from the GFP-Np95 construct by PCR-based 
mutagenesis (Ko and Ma, 2005). All constructs were verified by DNA sequencing. 
Throughout this study enhanced GFP (eGFP) or monomeric Cherry (mCherry) 
constructs were used and for simplicity referred to as GFP- or Cherry-fusions. 
 
Cell culture and transfection 
HEK293T cells and ESCs were cultured and transfected as described (Schermelleh et 
al., 2007), with the exception that FuGENE HD (Roche) was used for transfection of 
ESCs. The dnmt1-/- J1 ESCs used in this study are homozygous for the c allele (Lei et 
al., 1996). 
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In vitro DNA binding assay 
The in vitro DNA binding assay was performed as described previously (Frauer and 
Leonhardt, 2009) with the following modifications. Four different oligonucleotide 
substrates were labeled with distinct fluorophores and used in direct competition (see 
Figure S2 for details). For extract preparation 2 mM MgCl2 and 1 mg/ml DNaseI were 
included in the lysis buffer. Extracts from 1-3 transfected 10 cm plates were diluted to 
500-1000 µl with immunoprecipitation buffer and 1 µg of GFP-Trap (Rothbauer et al., 
2008) (ChromoTek, Germany) per final assay condition was added. After washing and 
equilibration beads were resuspended in 500 µl of binding buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 100 ng/µl BSA). Four oligonucleotide 
substrates were added to a final concentration of 125 nM each and incubated at room 
temperature (RT) for 60 min with constant mixing. Fluorescence intensity 
measurements were performed with a Tecan Infinite M1000 plate reader using the 
following excitation/emission wavelengths: 490±10 nm/511±10 nm for GFP, 
550±15 nm/580±15 nm for ATTO550, 600±15 nm/630±15 nm for ATTO590, 
650±10 nm/670±10 nm for ATTO647N and 700±10 nm/720±10 nm for ATTO700. 
Values were adjusted using standard curves obtained with ATTO-dye coupled 
oligonucleotides and purified GFP. Binding activity was expressed as the ratio between 
the fluorescent signals of bound DNA probe and GFP fusion protein bound to the 
beads, so that the signals from bound probes are normalized to the amount of GFP 
fusion. Furthermore, values were normalized to the amount of DNA probe bound to 
GFP-Np95.  
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Peptide Pull down assay 
Peptides were purchased as TAMRA conjugates (PSL, Germany) and are listed in 
Figure S5. The peptide pull-down assay was performed analogously to the DNA binding 
assay described above. After one-step purification of GFP fusion proteins with the 
GFP-Trap (ChromoTek, Germany), the beads were equilibrated in 1 ml 
immunoprecipitation buffer and resuspended in 500 µl binding buffer supplemented with 
100 ng/µl of BSA. Peptides were added to a final concentration of 0.74 µM and the 
binding reaction was performed at RT for 15 min to 60 min with constant mixing. The 
beads were washed twice with 1 ml of immunoprecipitation buffer and resuspended in 
100 µl of the same. Wavelengths for excitation and measurement of TAMRA were 
490±5 nm and 511±5 nm, respectively. Fluorescence intensity measurements were 
adjusted using standard curves from TAMRA coupled peptide and purified GFP. 
 
Live cell microscopy and Fluorescence Recovery after Photobleaching (FRAP) 
analysis 
Live cell imaging and FRAP analysis were performed as described previously 
(Schermelleh et al., 2007). For presentation, we used linear contrast enhancement on 
entire images. 
 
Statistical analysis 
Results were expressed as mean ± SEM. The difference between two mean values was 
analyzed by Student's t-test and was considered to be statistically significant in case of 
p < 0.05 and highly significant with p < 0.001. 
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RESULTS AND DISCUSSION 
 
Np95 chromatin binding is independent of DNA methylation 
Recent studies showed Np95 bound to hemimethylated DNA suggesting that the 
essential function of Np95 in the maintenance of DNA methylation consists of substrate 
recognition and recruitment of Dnmt1. To investigate the dynamics of these interactions 
in vivo we transiently transfected wild type (wt) J1 embryonic stem cells (ESCs) with 
expression constructs for Cherry-Np95 and GFP-Dnmt1 and monitored their subcellular 
distribution using live-cell microscopy (Fig. 1A and B). Np95 showed a nuclear 
distribution with a cell cycle dependent enrichment at replicating heterochromatin, 
similar to Dnmt1. Consistent with earlier observations (Leonhardt et al., 1992; Uemura 
et al., 2000; Miura et al., 2001; Papait et al., 2007; Spada et al., 2007) we detected a 
colocalization of Np95 and Dnmt1 at sites of DNA replication. We investigated the 
dynamics of Np95 binding at PH by quantitative fluorescence recovery after 
photobleaching (FRAP) analysis (Fig. 1B). As chromocenters are not homogeneously 
distributed in the nucleus, we chose to bleach half nuclei to ensure that the bleached 
region contains a representative number of potential binding sites. We observed a 
relatively fast and full recovery of relative GFP-Dnmt1 fluorescence intensity (Fig. 1B), 
reflecting a transient and dynamic interaction as described before (Schermelleh et al., 
2007). In contrast, Cherry-Np95 showed a considerably slower and only partial (~80%) 
recovery within the same observation period. These results indicated a relatively stable 
binding of Np95 to chromatin and revealed an immobile protein fraction of about 20%. 
These in vivo binding properties would be consistent with tight binding of Np95 to 
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hemimethylated CpG sites and flipping of the methylated cytosines out of the DNA 
double helix as shown in recent cocrystal structures of the SRA domain of Np95 (Arita 
et al., 2008; Avvakumov et al., 2008; Qian et al., 2008). 
To directly test the contribution of DNA methylation and the interaction with Dnmt1 to 
protein mobility, we compared the binding kinetics of GFP-Np95 in wt ESCs and ESCs 
lacking either Dnmt1 or all three major DNA methyltransferases Dnmt1, 3a and 3b 
(TKO). Surprisingly, Np95 binding to chromatin was not affected by either drastic 
reduction (dnmt1-/-) or even complete loss (TKO) of genomic methylation and showed in 
both cases a remarkably similar FRAP kinetics compared to wt J1 ESCs (Fig. 1C and 
S1). Analog results were obtained with a C-terminal GFP fusion (Np95-GFP; Fig. S1), 
arguing against conformational or sterical impairments of the N-terminal fusion protein 
that could affect the binding kinetics. These results showed that the binding kinetics of 
Np95 is completely independent of DNA methylation and the presence of all three major 
DNA methyltransferases in vivo. 
 
The SRA domain of Np95 is essential for DNA binding in vitro but not sufficient 
for heterochromatin association in vivo 
To investigate the contribution of distinct Np95 domains to nuclear binding kinetics we 
generated a systematic set of individual domains and deletion constructs fused to GFP 
(Fig. 2A). We first tested the DNA binding properties of these fusion proteins in vitro 
using our recently developed non-radioactive DNA binding assay (Frauer and 
Leonhardt, 2009). To directly compare the binding affinity regarding different 
methylation states, we generated DNA binding substrates with either no or one central 
under revision at Nucleic Acids Research Rottach et al. 2009
 
-110- 
 
un-, hemi- or fully methylated CpG site and labeled them with four distinct fluorophores. 
This assay allows fast comparison of different potential binding substrates in direct 
competition as well as the simultaneous quantification of GFP-labeled protein to 
calculate relative binding activity. The different GFP-Np95 fusion constructs were 
expressed in HEK293T cells, purified with the GFP-Trap (Rothbauer et al., 2008) and 
incubated with the fluorescently labeled DNA substrates. GFP fusion protein and bound 
DNA substrates were quantified with a fluorescence plate reader (Fig. 2B). Results were 
controlled and corrected for any bias due to incorporation of different fluorescent labels 
(Fig. S2). These assays showed a significant two- to three-fold preference of Np95 for 
DNA substrates containing a CpG site but did not detect any substantial preference for 
un-, hemi- or fully methylated substrates in vitro (Fig. S3). Similar DNA binding results 
were obtained with the C-terminal Np95-GFP fusion construct (Fig. S1). Deletion of the 
SRA domain completely abolished the DNA binding activity of Np95 whereas deletion of 
either the PHD or the Tudor domain had no effect. Consistently, the isolated PHD and 
Tudor domains did not bind to DNA, while the SRA domain alone showed similar 
binding strength and sequence preference as full length Np95. As a second line of 
evidence, also gel shift assays confirmed the methylation independent DNA binding of 
Np95 (Fig. S4). These results clearly demonstrate that the SRA domain of Np95 
preferentially binds to CpG sites but does not discriminate between un-, hemi- or fully 
methylated DNA substrates in vitro. 
Next, we investigated the role of distinct Np95 domains in nuclear interactions in vivo. 
To this aim, we expressed the same GFP-Np95 constructs in np95-/- ESCs and tested 
their binding kinetics with FRAP experiments (Fig. 2 C). Importantly, GFP-Np95 showed 
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similar FRAP kinetics in Np95 deficient, wt or Dnmt deficient ESCs (Fig. 1C and 2C). 
Among all domains tested, only the SRA domain showed similar kinetics as full length 
Np95, including the relatively slow recovery and an immobile fraction of about 20%, 
while the Tudor and PHD domain displayed the same high mobility as GFP. Also, FRAP 
curves of the corresponding deletion constructs indicated that the Tudor and the PHD 
domains have only a minor contribution to in vivo binding kinetics, while deletion of the 
SRA domain drastically increased the mobility of Np95. These data indicate that the 
SRA domain dominates the binding kinetics of Np95 in vivo. Curiously, the addition of 
the PHD to the SRA domain (GFP-PHD-SRA) resulted in intermediate kinetics and loss 
of the immobile fraction. This effect was, however, not observed in the context of the full 
length protein, suggesting that nuclear interactions of Np95 are controlled by a complex 
interplay among its domains. To directly study the role of the SRA domain in controlling 
the subcellular localization of Np95 we cotransfected np95-/- ESCs with expression 
constructs for Cherry-Np95 and either GFP-SRA or GFP-Np95∆SRA (Fig. 2D). This 
direct comparison showed that the isolated SRA domain does not colocalize with full 
length Np95 at PH. Together, these results indicate, that the SRA domain of Np95 is 
necessary and sufficient for DNA binding in vitro and also dominates the binding 
kinetics in vivo, but is per se not sufficient for proper subnuclear localization. The fact 
that the Np95∆SRA construct colocalized with Np95 suggests that other domains than 
the SRA control the subcellular targeting of Np95.  
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Np95 binds to histone H3 via a tandem Tudor domain 
Database searches showed that the sequence between the Ubl and PHD domain of 
Np95 is highly conserved in vertebrates and displays structural similarity to the family of 
Tudor domains ((Adams-Cioaba and Min, 2009); PDB 3db4; Fig. 3A und B ). The crystal 
structure revealed that the Tudor domain is composed of two subdomains (tandem 
Tudor) forming a hydrophobic pocket that accommodates a histone H3 N-terminal tail 
trimethylated at K9 (H3K9me3) (PDB 3db3; Fig. 3C). This hydrophobic binding pocket is 
created by three highly conserved amino acids (Phe152, Tyr188, Tyr191) forming an 
aromatic cage (Fig. 3A and C). Interestingly, a very similar hydrophobic cage structure 
has been described for the chromodomain of the heterochromatin protein 1ß (HP1ß) 
(Fig. S5) that is known to bind trimethylated lysine 9 of histone H3 and associates with 
PH (Jacobs and Khorasanizadeh, 2002). 
To further investigate the histone tail binding properties of Np95, we mutated the two 
amino acids of the aromatic cage (Y188A, Y191A) and tested the isolated tandem 
Tudor domain and corresponding mutant in comparison with Np95 using a peptide 
binding assay. GFP-Np95, GFP-Tudor and GFP-Tudor (Y188A, Y191A) were 
expressed in HEK293T cells, purified with the GFP-Trap and incubated with TAMRA 
labeled histone tail peptides. The fluorescence intensity of GFP fusion proteins and 
bound peptides was quantified and the relative binding activity calculated (Fig. 3D and 
S5). The tandem Tudor domain showed a highly significant preference for the 
trimethylated (H3K9me3) peptide, while this effect was less pronounced in the full 
length Np95. Interestingly, acetylation of K9 (H3K9ac), a modification largely 
underrepresented in silent chromatin, prevented binding of the tandem Tudor domain. 
under revision at Nucleic Acids Research Rottach et al. 2009
 
-113- 
 
Remarkably, point mutations targeting aromatic cage residues within the tandem Tudor 
domain completely abolished specific binding to N-terminal histone H3 peptides. 
Consistent with these binding data the tandem Tudor domain also showed a weak 
enrichment at PH, while the PHD domain, previously proposed as potential histone H3 
binding motif (Karagianni et al., 2008), did neither bind to H3K9 peptides in vitro nor to 
PH in vivo (Fig. S6). These results indicate that the tandem Tudor domain of Np95 
features a peptide binding pocket with structural and functional striking similarity to 
HP1ß and confers selective binding to histone modification states associated with silent 
chromatin.  
In summary, these results clearly indicate that binding of Np95 to DNA is independent of 
the CpG methylation state and level in vitro and in vivo, arguing against a simple 
function in the recognition of hemimethylated sites. We confirmed that DNA binding of 
Np95 is mediated by the SRA domain, but found only a preference for CpG 
dinucleotides regardless of the methylation status. In addition, we showed that Np95 
selectively binds to trimethylated but not acetylated lysine 9 of histone H3 via a tandem 
Tudor domain containing a binding pocket similar to the aromatic cage present in the 
chromodomain of HP1. These results indicate that the role of Np95 is far more complex 
than previously thought and especially the inter- and intramolecular interactions of its 
domains poses challenging questions. Subcellular localization, binding kinetics and 
function of Np95 is likely controlled by a complex interplay of its multiple domains. The 
interactions of Np95 with Dnmt1 and histone modifying enzymes together with its 
binding to DNA and repressive histone marks point to a central role in the integration of 
various epigenetic silencing mechanisms and the mediation of epigenetic crosstalk. 
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Figure 1.  
Np95 localization and binding is independent of methylation state and levels in vivo. 
(A) Schematic representation of Np95 and Dnmt1 fluorescent fusions. Ubl, ubiquitin-like 
domain; Tudor, tandem Tudor domain; PHD, plant homeodomain; SRA, Set- and Ring-
associated domain; Ring domain; PBD, PCNA binding domain; TS, targeting sequence; 
ZnF, zinc-finger; BAH, bromo adjacent homology domain; (KG)7, lysine-glycine repeat. 
(B) Dnmt1 and Np95 display different kinetics. Representative images from fluorescent 
recovery after photobleaching (FRAP) experiments on wt J1 embryonic stem cells 
(ESCs) transiently co-transfected with Cherry-Np95 and GFP-Dnmt1 constructs. Images 
show colocalization at chromocenters before (Pre) and at the indicated time points after 
(Pb) bleaching half of the nucleus. Bleached areas are outlined. Corresponding FRAP 
curves are shown on the right. Bars, 5 µm. (C) FRAP kinetics of GFP-Np95 in J1 ESCs 
with different genetic backgrounds (wt, dnmt1-/- and TKO). Kinetics of GFP-Dnmt1 is 
shown for comparison. Mobile and immobile fractions are indicated on the right. Values 
represent mean ± SEM. 
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Figure 2.  
In vitro DNA binding, in vivo nuclear localization and kinetics of Np95, deletion mutants 
and individual domains. (A) Schematic representation of the analyzed Np95 constructs. 
All constructs were N-terminal GFP fusions. (B) In vitro DNA binding properties of Np95 
constructs. Binding assays were performed using four fluorescently labeled double 
stranded oligonucleotide probes in direct competition. The oligonucleotides have the 
same sequence except for the absence or presence of one central un-, hemi- or 
symmetrically methylated CpG site (Fig. S2). Shown are fluorescence intensity ratios of 
bound probe / bound GFP fusion. Values represent means and standard deviations 
from three to six independent experiments. GFP was used as control. (C) Kinetics of 
Np95 constructs in living np95-/- ESCs determined by half nucleus FRAP analysis. GFP 
is shown as reference. Curves represent mean values from 6-15 nuclei. SEM (0.001-
0.005) is not shown for clarity of illustration. (D) Confocal mid sections of living np95-/- 
ESCs transiently expressing the indicated Np95 fusion constructs (left and mid panels). 
Merged images are displayed on the right. Bars, 5 µm. 
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Figure 3.  
Structure and H3 N-terminal tail binding of the tandem Tudor domain. (A) Schematic 
drawing of the multi-domain architecture of Np95 (top) and alignment of tandem Tudor 
domains from vertebrate Np95 homologues (bottom). Arrows show the end and start 
positions of the crystallized tandem Tudor domain shown in B. Residues forming the 
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aromatic cage shown in C are indicated by arrowheads. Absolutely conserved residues 
of the tandem Tudor domain are black shaded , while positions showing conservative 
substitutions are boxed with residues in bold face. Secondary-structure elements were 
generated with EsPript (Gouet et al., 1999) using the crystal structure of human UHRF1 
(PDB 3db3 and 3db4) and are shown above the amino acid sequence: α-helices (η), β-
strands, strict alpha turns (TT) and strict beta turns (TTT). Accession numbers: Homo 
sapiens Q96T88.1; Pan troglodytes XP_001139916.1; Bos Taurus AAI51672.1; Mus 
musculus Q8VDF2.2; Rattus norvergicus Q7TPK1.2; Dario rerio NP_998242.1; 
Xenopus laevis ABY28114.1, Gallus gallus XP_418269.2. (B) Side view of the tandem 
Tudor domain as a cartoon model (left) and as surface representation (right) in complex 
with a histone H3 N-terminal tail peptide trimethylated at lysine 9 (green stick model; 
only Arg8-Lys9-Ser10 of the H3 peptide are resolved). The image was generated with 
PyMOL (DeLano, 2002). (C) An aromatic cage is formed by Phe152, Tyr188 and 
Tyr191 and accommodates the trimethylysine 9 of H3 (H3K9me3). (D) Histone H3 
N-terminal tail binding specificity of GFP-Np95, GFP-Tudor and GFP-Tudor (Y188A 
Y191A) in vitro. Shown are fluorescence intensity ratios of bound probe / bound GFP 
fusion. GFP was used as negative control. Shown are means ± SEM from four to ten 
independent experiments and two-sample t-tests were performed that do or do not 
assume equal variances, respectively. Statistical significance compared to the binding 
ratio of H3K9me3 is indicated: * p<0.05, ** p<0.001. 
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SUPPLEMENTARY INFORMATION 
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Supplementary Figure 1.  
Nuclear localization, FRAP kinetics and DNA binding specificity for an Np95 construct 
C-terminally fused to GFP (Np95-GFP, respectively). (A) Schematic drawing of 
Np95-GFP. Abbreviations are as in Fig. 1. (B) Representative images from FRAP 
experiments for Np95-GFP transiently expressed in wt, dnmt1-/- and TKO J1 ESCs as 
indicated on the left. Images show confocal mid-sections of nuclei before (Pre) and at 
the indicated time points after bleaching (Pb) half of the nucleus. Bleached areas are 
outlined. Arrowheads mark pericentric heterochromatin. Bars, 5 µm. (C) FRAP kinetics 
of Np95-GFP in J1 ESCs with different genetic backgrounds as shown in B and Fig. 1C. 
Kinetics of GFP-Dnmt1 is shown for comparison. Mobile and immobile fractions are 
indicated on the right. Values represent mean ± SEM. Note that the kinetics are similar 
to those shown for GFP-Np95 in Fig. 1C and that there is no significant difference in 
cells with different genetic backgrounds. (D) Comparison of in vitro DNA binding 
properties of GFP-NP95 and Np95-GFP. Binding assays were performed as in Fig. 2C. 
Values represent means and standard deviations from four to six independent 
experiments. GFP was used as control. Note that the relative binding affinity of the two 
constructs for the different probes is essentially the same, although Np95-GFP shows a 
roughly 2-fold higher binding activity. 
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Supplementary Figure 2.  
(A) DNA oligonucleotides used for the preparation of double stranded probes for in vitro 
DNA binding assays. M: 5-methyl-cytosine. (B) Description of double stranded probes 
used for in vitro DNA binding assays. Name, status of the central CpG site, fluorescent 
label, as well as DNA oligonucleotides and nature of the dCTP used in the primer 
extension reaction are specified. (C) Composition of probe sets 1-4 and control set (see 
below). (D) By using a control set of four probes with identical sequence but different 
fluorescent labels we observed effects due to probe preparation and/or unspecific 
binding of ATTO dyes (not shown). The values obtained from the control set were used 
to normalize every probe / protein pair. To test this correction method, we performed a 
control experiment with GFP-Np95 and four probe sets with alternating ATTO dyes 
(probe sets 1-4 shown in C). The four probe sets gave similar results validating the 
correction method. 
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Supplementary Figure 3.  
Np95 DNA binding to fluorescently labeled substrates containing either no CG site or 
one central un-, hemi- or fully methylated CG site in direct competition. Six independent 
experiments were performed and preliminary tests for the quality of variances indicated 
that the variances of the four groups were not significantly different, except for no CG 
site containing and fully methylated substrate (p=0.02). Two-sample t-tests were 
performed that do or do not assume equal variances. The mean score for no CG 
substrate (mean=0.11, SD=0.01) was significantly smaller than the scores for 
unmethylated (mean=0.26, SD=0.02), hemimethylated (mean=0.34, SD=0.04) or fully 
methylated substrate (mean=0.29, SD=0.05) with p < 0.001. Values for fully methylated 
substrate were not statistically different from those for un- or hemimethylated substrate 
(p>0.05). The difference between binding ratios for un- and hemimethylated substrate is 
statistically significant (p<0.05), however with a factor of 1.3 only minor. 
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Supplementary Figure 4.  
Gel shift assay with GFP-Np95 using unmethylated (UMB647N) and hemimethylated 
DNA substrate (HMB550) in direct competition. 1 pmol of DNA was incubated with 
increasing amounts of GFP-Np95 (0, 1.5, 3.125, 6.25, 12.5, 25, 50 or 100 pmol) in 15 µl 
of reaction buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.05 % Tween-
20, 1 mM DTT). After addition of 5 µl 6x loading dye (30 % glycerol and bromophenol 
blue in TBE), samples were subjected to 6% non-denaturing PAGE (0.5x TBE, 70 Volt, 
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2 hours, 4°C). Gels were scanned with a Typhoon imager to detect ATTO647N (633 nm 
laser, 670PB30 filter) and ATTO550 (532 nm laser, 580BP30 filter). (A) Overlay of both 
channels (red: ATTO647N, green: ATTO550). (B) ATTO647N channel to detect 
unmethylated substrate. (C) ATTO550 channel to detect hemimethylated substrate. Full 
arrows represent free DNA substrate; dashed arrows indicate DNA bound by Np95. 
Fluorescently labeled primers that were not extended during substrate preparation are 
marked with a star. Note that there is no substantial difference of Np95 binding to un- or 
hemimethylated substrate as reproduced in independent experiments with substrates 
alternately labeled, in competition or incubated separately with Np95. 
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Supplementary Figure 5.  
(A) Amino acid sequences of TAMRA-labeled histone tail peptides used for the peptide 
binding assay. (B) Histone H3 and H4-tail binding specificity of GFP-Np95 in vitro. 
Ratios of bound TAMRA-labeled peptide over bound GFP fusion were determined and 
normalized to the ratio of H3K4/9un peptide over GFP-Np95. GFP was used as 
negative control. Shown are means ± SEM from six independent experiments. (C) 
Structural comparison of the H3K9me3-binding aromatic cages formed by the tandem 
Tudor domain of Np95 (left) and the chromodomain of HP1ß (right, PDB 1kne). In these 
structures, only Arg8-Lys9-Ser10 and Lys9-Ser10 from histone H3 are resolved 
peptides, respectively (green stick models). 
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Supplementary Figure 6.  
(A) Histone H3 N-terminal tail binding specificity of GFP-Tudor, GFP-PHD and GFP in 
vitro. Shown are fluorescence intensity ratios of bound probe / bound GFP fusion. GFP 
was used as negative control. Shown are means ± SEM from four to six independent 
experiments. Only the tandem Tudor domain shows preferential binding of H3K9 
trimethylated histone tails. (B) Schematic representation of the analyzed Np95 
constructs. All constructs were N-terminal GFP fusions (left panel). Confocal mid 
sections of living np95-/- ESCs transiently expressing the indicated Np95 fusion 
constructs and RFP-PCNA as S phase marker (left and mid panels). Merged images 
are displayed on the right. Bars, 5 µm. Only the GFP-Tudor fusion protein showed slight 
enrichment at pericentric heterochromatin.  
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Note added in proof:  
In the course of preparing a revised manuscript for submission in NAR, new in vitro 
non-radioactive DNA binding assays were performed with GFP-Np95 using longer 
DNA substrates containing multiple (one to three) CpG sites (Carina Frauer, 
preliminary data). With these longer DNA substrates containing three centered CpG 
sites, we could observe a strong binding preference of Np95 for hemimethylated 
DNA substrates. These recent data suggest, that Np95 likely discriminate between 
un-, hemi- or fully methylated DNA substrate sites in vitro but with high dependency 
on the amount of and / or position of the CpG sites. This raises interesting questions; 
e.g. why several CpG sites seem to be required for the Np95 binding preference for 
hemimethylated DNA substrates or how steric clashes with Dnmt1 at target CpG 
sites are bypassed. Subcellular localization, binding kinetics and function of Np95 
in vivo is apparently controlled by a complex interplay of its multiple domains.  
We will soon address these questions.  
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2.7. DNA methylation-mediated epigenetic control. 
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DNA Methylation-Mediated Epigenetic Control
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ABSTRACT
During differentiation and development cells undergo dramatic morphological, and functional changes without any change in the DNA
sequence. The underlying changes of gene expression patterns are established and maintained by epigenetic processes. Early mechanistic
insights came from the observation that gene activity and repression states correlate with the DNAmethylation level of their promoter region.
DNAmethylation is a postreplicative modiﬁcation that occurs exclusively at the C5 position of cytosine residues (5mC) and predominantly in
the context of CpG dinucleotides in vertebrate cells. Here, three major DNA methyltransferases (Dnmt1, 3a, and 3b) establish speciﬁc
DNA methylation patterns during differentiation and maintain them over many cell division cycles. CpG methylation is recognized by at
least three protein families that in turn recruit histone modifying and chromatin remodeling enzymes and thus translate DNA methylation
into repressive chromatin structures. By now a multitude of histone modiﬁcations have been linked in various ways with DNA methylation.
We will discuss some of the basic connections and the emerging complexity of these regulatory networks. J. Cell. Biochem. 108: 43–51,
2009.  2009 Wiley-Liss, Inc.
KEY WORDS: DNA METHYLATION; Dnmt1; Dnmt3a; Dnmt3b; METHYL-CpG BINDING PROTEIN; Uhrf1; HISTONE MODIFICATION; EPIGENETICS
D uring embryonic development a single cell, the zygote, givesrise to a multitude of drastically different cell types all
carrying essentially the same genetic information. Biochemical
processes determining transcriptionally active and silent states
make it possible for the same genome to execute the many alternate
expression programs that specify all the functional and structural
diversity among the cell types produced during the lifespan of
an organism. Canonical transcription factor networks respond
to developmental signals and environmental cues and crucially
contribute to initiate speciﬁc transcriptional programs. However,
due to the complexity of genomic functions in eukaryotes,
transcription factors are not sufﬁcient for full establishment and
long-term stability of transcriptional states. A number of additional
factors and processes contribute to the setup of speciﬁc chromatin
structures that in turn determine the transcriptional activity. These
processes include DNA methylation, histone posttranslational
modiﬁcation, incorporation of speciﬁc histone variants, and
chromatin remodeling. At least for DNA methylation and some
histone modiﬁcations, the respective marks and associated
chromatin states are inherited through successive cell generations
constituting a memory system for gene expression programs. In
special cases, speciﬁc epigenetic states are even inherited through
the germ line from one generation of an organism to the next. As
these processes affect chromatin structure leaving the underlying
genomic sequence unaltered they are deemed ‘‘epigenetic’’ and their
comprehensive makeup across the genome is generally referred to as
the epigenome [Bird, 2007]. Although epigenetic marks function to
stabilize transcriptional states, they and their associated chromatin
states can be altered under speciﬁc conditions. Thus, epigenetic
systems allow proliferating cells to preserve their identity while
retaining the necessary plasticity to adapt to environmental
conditions or respond to developmental signals and differentiate.
DNA methylation is the longest known and perhaps most
extensively characterized epigenetic mark. We will ﬁrst outline the
basic features of DNA methylation and then present an overview of
its intricate crosstalk with other epigenetic pathways. These complex
systems show clear parallels, but also distinguishing properties in
plants and animals. Here we focus on knowledge gathered from
vertebrates.
THE BASICS OF DNA METHYLATION
IN VERTEBRATES
DNA methylation is a postreplicative modiﬁcation that occurs
exclusively at the C5 position of cytosine residues (5mC) and
predominantly in the context of CpG dinucleotides in vertebrates.
The covalent addition of a methyl group to cytosine is catalyzed by
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DNA (cytosine-C5) methyltransferases. Vertebrate DNA methyl-
transferases (Dnmts; Fig. 1) contain a highly conserved catalytic
domain which includes 10 sequence motives also found in
prokaryotic DNA (cytosine-C5) methyltransferases [Goll and Bestor,
2005]. Therefore, it is thought that all these enzymes use the same
catalytic mechanism involving substrate recognition, ﬂipping of the
target cytosine out of the DNA double helix, formation of a covalent
complex with C6 position of the cytosine, transfer of the methyl
group from S-adenosylmethionine to the activated C5 position and
release of the enzyme by elimination. Apart for Dnmt2 all Dnmts
comprise in addition to a C-terminal catalytic domain (CTD) also a
regulatory N-terminal region (NTR) with several distinct domains.
Bioinformatic analysis suggests that Dnmt1 evolved by the fusion
of at least three ancestral genes, one contributing to the CTD and two
to the NTR [Margot et al., 2000]. Dnmt1 is ubiquitous and by far the
most abundant Dnmt in proliferating somatic cells, interacts with
the DNA replication clamp proliferating cell nuclear antigen (PCNA)
throughout S phase, displays substrate preference for hemimethy-
lated DNA and its genetic deletion results in drastic loss of DNA
methylation [Leonhardt et al., 1992; Li et al., 1992; Chuang et al.,
1997; Easwaran et al., 2004]. These properties constitute the basis for
a major role of Dnmt1 in maintaining genomic methylation patterns
through successive DNA replication cycles. The interaction of
Dnmt1 with the DNA replication machinery points to a mechanism
coupling replication of genetic and epigenetic information.
Although this interaction likely contributes to the accurate
propagation of DNA methylation patterns, it was shown to be not
strictly required for maintaining global genomic methylation
[Schermelleh et al., 2007; Spada et al., 2007]. Recently, the SET-
and Ring-associated (SRA) domain protein Uhrf1 has emerged as an
essential cofactor for the maintenance of DNA methylation. It has
been shown that Uhrf1 binds hemimethylated DNA, interacts and
colocalizes with Dnmt1 at replication foci and that its genetic
ablation leads to remarkably similar genomic hypomethylation and
developmental arrest to those observed in Dnmt1 null mice [Uemura
et al., 2000; Bostick et al., 2007; Papait et al., 2007; Sharif et al.,
2007]. In addition, crystallographic studies revealed that the SRA
domain ﬂips the 5mC out of the DNA double helix, a mechanism ﬁrst
identiﬁed with DNA methyltransferases [Arita et al., 2008;
Avvakumov et al., 2008; Hashimoto et al., 2008]. Thus, it has been
proposed that Uhrf1 mediates the maintenance of genomic
methylation by recruiting Dnmt1 to hemimethylated CpG sites
generated during DNA replication. Despite of two potential
mechanisms for faithful propagation of methylation patterns
(Dnmt1-PCNA and Dnmt1-Uhrf1 interactions) the overall accuracy
has been estimated only around 96% (1 error for every 25 5mCs),
which is consistent with the observed maintenance of overall
patterns and site by site variability even in clonal populations [Silva
et al., 1993; Laird et al., 2004].
Dnmt2 comprises only a catalytic domain, shows very weak
DNA methyltransferase activity and is involved in methylation of
cytoplasmic tRNAAsp [Hermann et al., 2004; Goll et al., 2006].
However, Dnmt2 may be responsible for rare cytosine methylation
at sequence contexts other than CpG [Kunert et al., 2003; Mund
et al., 2004]. To date a clear phenotype after ablation or reduction of
Dnmt2 levels has been shown only in zebraﬁsh [Okano et al., 1998;
Rai et al., 2007].
Dnmt3a and 3b are largely responsible for de novo establishment
of genomic methylation patterns during development [Okano et al.,
1999; Kaneda et al., 2004]. Dnmt3L lacks crucial catalytic motifs and
is enzymatically inactive. However, Dnmt3L interacts with Dnmt3a
and 3b, stimulates their catalytic activity and is essential for the
establishment of maternal imprints and methylation of retro-
transposable elements in the male germ line [Gowher et al., 2000;
Fig. 1. Schematic representation of the mammalian DNA methyltransferase family. All Dnmts have a similar catalytic domain that features highly conserved motifs (I–X) also
found in prokaryotic DNA (cytosine-5) methyltransferases. The Dnmts differ, however, in their regulatory region. Dnmt1 contains the PCNA binding domain (PBD), the
pericentric heterochromatin targeting sequence (TS), a CXXC-type zinc ﬁnger motif (ZnF), and two bromo adjacent homology domains (BAH). The start codon of the long (ATGL)
and short (ATGS) isoforms, as well as the seven lysine–glycine repeat linker (KG7) are indicated. The regulatory domains of Dnmt3a and 3b comprise a PWWP domain named after
a conserved Pro-Trp-Trp-Pro motif and a plant homeodomain (PHD).
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Bourc’his et al., 2001; Hata et al., 2002; Margot et al., 2003;
Bourc’his and Bestor, 2004].
A categorical distinction between maintenance Dnmt1 and de
novo Dnmt3 enzymes, however, does not precisely reﬂect their
respective functions. On one hand, Dnmt3 enzymes seem to be
required for proper maintenance of DNA methylation in both
somatic and embryonic stem cells (ESCs) [Liang et al., 2002; Chen
et al., 2003; Dodge et al., 2005]. On the other hand, some de novo
methylation was reported in ESCs lacking both Dnmt3a and 3b,
although it is not clear whether this is due to the activity of Dnmt1 or
Dnmt2 [Lorincz et al., 2002]. Also, direct interaction of Dnmt1 with
transcription factors and its recruitment to their target sequences
suggests an involvement of Dnmt1 in de novo methylation of these
sequences [Robertson et al., 2000; Di Croce et al., 2002; Esteve et al.,
2005]. Importantly, while the evidence for interaction and
cooperation of Dnmt1 with Dnmt3 enzymes is available, the precise
mechanisms, mode of targeting, and protein complex composition
are unknown [Fatemi et al., 2001; Kim et al., 2002; Datta et al.,
2003].
Approximately 60–70% of CpG sites are methylated in
mammalian genomes. This includes all types of sequences:
single copy genes and intergenic sequences as well as all kinds
of repetitive elements, the latter displaying higher methylation
density. Conspicuous exceptions are relatively short regions
characterized by high CpG density (CpG islands) and mainly
located at promoters and ﬁrst exons of housekeeping genes.
Nearly ubiquitous genomic methylation has been proposed as a
mechanism to reduce spurious transcriptional activity (transcrip-
tional noise) [Bird, 2002]. Promoters and enhancers with relatively
low CpG density are often differentially methylated in different
tissues and there is now very substantial evidence for dynamic
changes of methylation patterns at these sites during cell
differentiation, especially at promoters of lineage-speciﬁc and
pluripotency genes [Fouse et al., 2008; Meissner et al., 2008; Mohn
et al., 2008]. However, it is still debated whether the absence of
DNA methylation only from selected regulatory regions is a mere
consequence of transcription factor occupancy or a mechanism to
favor selective binding of transcription factors to target sequences
[for detailed review, see Suzuki and Bird 2008]. Nevertheless, it is
generally accepted that DNA methylation marks these sequences
for heritable transcriptional silencing. This forms the basis for
the crucial role of DNA methylation in embryonic development,
cell differentiation, neoplastic transformation, imprinting, and
X chromosome inactivation [Bird, 2002]. However, as the net
transcriptional state is the resultant of several interconnected
epigenetic processes, cytosine methylation does not always
translate in transcriptional repression [Fouse et al., 2008]. Dense
methylation at repetitive elements is also thought to play a
crucial role in genome stability at the level of whole organisms, as
exempliﬁed by the high tumor incidence in hypomethylated mice
due to mobilization of retrotransposons and human syndromes
resulting from hypomethylation of satellite repeats [Xu et al.,
1999; Gaudet et al., 2003]. Surprisingly though, no major genomic
alteration is apparent in cultured cells with drastically reduced or
nearly no methylation [Tsumura et al., 2006; Lande-Diner et al.,
2007].
Genomic methylation patterns are known to be actively erased
both at speciﬁc developmental stages (e.g., demethylation of sperm
chromatin upon fertilization) and during artiﬁcial reprogramming
procedures such as somatic cell nuclear transfer and fusion of
somatic and highly pluripotent stem cells. In vertebrates active
demethylation mechanisms have long been elusive and contro-
versial, but there is now increasing evidence for the enzymatic
deamination of 5mC to thymidine followed by base or nucleotide
excision repair (BER/NER) of G/T mismatches [Barreto et al., 2007;
Metivier et al., 2008; Rai et al., 2008; Schmitz et al., 2009; Ma et al.,
2009b]. Both Dnmt3 enzymes and cytosine deaminases of the
APOBEC family have been involved in 5mC deamination, while BER
is likely mediated by thymidine deglycosylases TDG and MBD4. In
order to avoid deleterious accumulation of C to T transitions, these
two processes seem to be tightly coupled by members of the Gadd45
protein family. Nonetheless, several important aspects remain to be
deﬁned, including whether this is the only pathway for active DNA
demethylation operating in vertebrates, how many alternative and/
or additional factors are involved and how the demethylation
machinery is targeted to speciﬁc sequences.
MECHANISMS OF DNA METHYLATION-MEDIATED
TRANSCRIPTIONAL REPRESSION AND THEIR
INTERCONNECTION WITH OTHER
EPIGENETIC PATHWAYS
DNA methylation-mediated transcriptional repression is thought to
occur through at least two types of mechanism. The methylation
mark can directly prevent the binding of transcription factors when
present at their target sites, as it is the case for CTCF binding at
the H19/Igf2 imprinting control region [reviewed in Bird, 2002].
Alternatively, methylated CpG sites (mCpGs) are speciﬁcally
recognized by mCpG binding proteins (MBPs) that recruit repressive
chromatin modiﬁers and remodeling complexes. At least three types
of domains and corresponding MBP families have been shown to
bindmCpGs: the methyl-CpG binding domain (MBD), the UHRF, and
the Kaiso protein familes (Fig. 2).
Four out of ﬁve members of the mammalian MBD family
speciﬁcally bind mCpGs, the exception being MBD3 due to sequence
divergence in its MBD [Hendrich and Tweedie, 2003]. Apart from the
above-mentioned MBD4, all other MBDs form complexes with
histone deacetylase (HDAC) and nucleosome remodeling activities
(such as MeCP1 and NuRD) associated with transcriptional silencing
[reviewed in Hendrich and Tweedie, 2003]. MBD1 also interacts
with histone H3 lysine 9 methyltransferase (H3K9MT) SetDB1 to
enforce silencing (Fig. 3A) [Sarraf and Stancheva, 2004]. Interest-
ingly, both MBD1 and MeCP2 have been found to bind DNA and
induce chromatin compaction independently of DNA methylation
[Georgel et al., 2003; Jorgensen et al., 2004; Nikitina et al., 2007].
Surprisingly, a large-scale survey indicated that the majority of
MeCP2 target genes in neurons are transcriptionally active [Yasui
et al., 2007]. The relatively mild phenotypes of mice lacking
individual MBD members have been taken to suggest a high extent
of functional redundancy. However, this is in contrast with the lack
of sequence and structural similarity among MBD family members
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outside the MBD. Taken together, these studies suggest that the
function of MBD proteins is highly context dependent and that they
are not global effectors of DNA methylation.
As mentioned above, it has been proposed that Uhrf1 contributes
to the maintenance of DNA methylation patterns by recruiting
Dnmt1 to asymmetrically mCpGs through its SRA domain (Fig. 3B).
Uhrf1 and its homolog Uhrf2 are the only SRA domain containing
proteins that have been shown to be expressed in mammalian cells.
However, plants express several SRA containing proteins, including
two with H3K9MT activity [Johnson et al., 2007]. Intriguingly, Uhrf1
was reported to interact with the H3K9MT G9a and HDAC1 and was
involved in the silencing of tumor suppressor genes [Unoki et al.,
2004; Kim et al., 2009]. Several observations suggest additional
roles of Uhrf1/2 in linking CpG methylation with histone
modiﬁcation. Uhrf1 and 2 contain a plant homeodomain (PHD)
that has been involved in binding to histone H3 and hetero-
chromatin decondensation and PHD domains in other proteins can
discriminate the methylation state of H3K4 [Citterio et al., 2004;
Papait et al., 2008]. Available crystallographic data show a snug ﬁt
of a trimethylated H3K9 peptide in a hydrophobic cage within the
tandem Tudor domain of Uhrf1 (PBD 3DB3). The Ring domain of
Uhrf1 has been shown to mediate ubiquitination of histone H3 in
vitro [Citterio et al., 2004]. However, the exact mechanisms and
speciﬁcity of Uhrf proteins in connecting DNA methylation to
repressive chromatin states are still to be resolved.
Kaiso and Kaiso-like proteins ZBTB4 and ZBTB38 share a three
zinc ﬁnger motif and a broad complex, tramtrack, and bric a`
brac (BTB)/POZ domain at the C-terminus and are differentially
expressed in mouse tissues [Yoon et al., 2003; Filion et al., 2006]. In
vitro and in vivo studies showed that Kaiso binds methylated DNA
through the zinc ﬁnger motif, but in contrast to the MBD and
UHRF families, it requires two consecutive mCpGs for efﬁcient
binding. Biochemical analyses revealed a direct interaction of Kaiso
with the repressive NCoR complex, which also contains HDAC and
remodeling activities, again linkingmethylated DNA sequences with
a deacetylated and highly structured chromatin states (Fig. 3C). In
parallel with another MBD proteins, Kaiso was reported to bind a
consensus sequence devoid of CpG sites, suggesting also in this case
complex, context-dependent functions.
It is important to realize that in addition to DNA methylation
being translated into repressive chromatin structures, DNA
methylation and chromatin modiﬁcation and remodeling pathways
Fig. 2. The three classes of mCpG binding proteins (MBPs). The ability to recognize methylated CpG sites is mediated by different modules, the methyl-CpG binding domain
(MBD), the SET- and Ring-associated (SRA) domain, or zinc ﬁnger (ZnF) motifs. MBD proteins are shaded in yellow. In addition to the MBD, MBD1, MBD2, and MeCP2 contain a
trans-repressor domain (TRD). The MBD1a isoform is shown. Amino acid repeats (GR and E) are depicted in orange. Uhrf1 and the very similar Uhrf2 (shaded in blue) recognize
methylated DNA via the SRA domain and contain, in addition, an Ubiquitin-like (Ubl) motif, a Tudor domain, a plant-and homeodomain (PHD), and a Ring ﬁnger. The third class
of MBPs (Kaiso, Kaiso-like, and ZBTB38) is characterized by several zinc ﬁnger motifs. Binding to methylated DNA is mediated by a C2H2 zinc ﬁnger motif (yellow). The broad
complex, tramtrack, and bric a` brac (BTB/POZ) domain is depicted in gray.
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reciprocally affect each other in multiple ways. An example is the
demethylation of H3K4 by LSD1. This creates a binding site for the
PHD of Dnmt3L, which in turn recruits the Dnmt3a, linking
the H3K4 methylation state to DNA methylation (Fig. 3D) [Jia et al.,
2007]. However, LSD1 also controls maintenance of DNA methyla-
tion by demethylating Dnmt1, as Dnmt1 methylation drastically
decreases its stability [Wang et al., 2009]. Dnmt1 and/or Dnmt3
enzymes have been shown to interact directly with SNF2H, an
ATPase subunit common to several chromatin remodeling com-
plexes, the H3K9MTs Suv39h1, SetDB1 and G9a, components of the
Polycomb repressive complex 2, heterochrmatin protein 1 (HP1),
and HDACs [Fuks et al., 2000, 2001, 2003; Robertson et al., 2000;
Geiman et al., 2004; Li et al., 2006; Vire et al., 2006; Epsztejn-Litman
et al., 2008; reviewed in Cedar and Bergman, 2009]. While G9a and
the PRC2 complex have been proposed to recruit Dnmts at their
target genes, no functional hierarchy has been established in other
cases. Nevertheless, the interaction network formed by Dnmts,
MBPs, H3K9MTs, HP1, and HDACs (and including HP1 binding to
H3K9MTs, methylated H3K9 and MeCP2) suggests the existence
of positive feedback loop mechanisms stabilizing and possibly
spreading silent chromatin states (Fig. 3E) [Lachner et al., 2001;
Nielsen et al., 2002; Agarwal et al., 2007]. In addition, direct
interaction between Dnmt1 and G9a at replication foci was proposed
as a mechanism coupling maintenance of DNA and H3K9 methyl-
ation (Fig. 3B) [Esteve et al., 2006].
Finally, the remodeling factors of the SNF2H ATPase family Lsh
and ATRX have been involved in the control of DNA methylation.
ATRX mutations affect DNA methylation at rDNA loci and other
repeats and ATRX interacts with HP1, MeCP2, and the PRC2
component Ezh2 [Gibbons et al., 2000; Nan et al., 2007]. Genetic
targeting of Lsh resulted in global genomic hypomethylation and
Lsh was shown to be required for de novo DNA methylation [Dennis
et al., 2001; Zhu et al., 2006]. However, involvement of Lsh in
chromatin remodeling has been questioned and Lsh was shown to
mediate silencing of Hox loci by associating with both Dnmt3b and
PRC1 [Xi et al., 2007; Myant and Stancheva, 2008].
Fig. 3. Molecular links between DNA methylation, histone modiﬁcation and chromatin structure. A: MBD1 binds methylated DNA via the MBD domain and recruits the lysine
methyltransferase SetDB1 to enforce silencing. B: Replication-coupled maintenance of DNA methylation and histone modiﬁcation. PCNA serves as a loading platform for
Dnmt1 and Uhrf1. Uhrf1 recognizes hemimethylated CpG sites via the SRA domain, interacts with Dnmt1 and thus allows maintenance of genomic methylation. Interacting
chromatin modifying enzymes such as HDAC1, HDAC2 (deacetylation), G9a (dimethylation of H3K9), or Suv39h1 (trimethylation of H3K9) enforce gene silencing by removing
permissive acetyl-groups or introducing repressive lysine methylation on histones. C: Kaiso binds pairs of methylated CpG sites via the zinc ﬁnger motif. Interaction with the
NCoR repressive complex and HDAC3 (deacetylation) promotes repression of transcription. D: De novo methylation requires the DNA methylatransferases Dnmt3a and 3b.
Dnmt3L serves as a regulatory factor and via its plant homeodomain (PHD) mediates the interaction with unmethylated histone H3 lysine 4 (H3K4) generated by LSD1.
E: Binding of HP1 mediates long-term silencing of chromatin regions. A positive feedback loop is created by HP1 recruiting Suv39H1 that trimethylates H3K9 generating
additional binding sites for HP1.
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DNA METHYLATION AND HIGHER ORDER
CHROMATIN STRUCTURE
The formation of highly condensed pericentromeric hetero-
chromatin domains (chromocenters) in mouse ESCs is clearly not
affected by severe genomic hypomethylation and even near absence
of DNA methylation [Tsumura et al., 2006; Gilbert et al., 2007].
However, there is still some discrepancy concerning the effect of
hypomethylation on global levels of histone modiﬁcations. Severe
genomic hypomethylation in ESCs was also reported to increase the
clustering of chromocenters, whereas a modest increase in 5mC
content at these domains, together with higher MBD proteins levels,
resulted in increased clustering during differentiation of myoblasts
to myotubes [Brero et al., 2005; Gilbert et al., 2007]. In addition,
severe genomic hypomethylation was shown to restrict the
mobility of linker histones H1 and H5 in ESCs [Gilbert et al.,
2007]. Conversely, simultaneous genetic deletion of three histone
H1 gene variants was reported to reduce methylation and alter the
expression of some imprinted and X chromosome-linked genes,
while leaving global DNAmethylation patterns unaltered [Fan et al.,
2005]. Thus, although DNA methylation has been shown to have
some impact on higher order chromatin structure there is no clear
consensus on the underlying mechanisms and direction of these
effects.
CONCLUDING REMARKS
A major unresolved issue about the DNA methylation system (as
well as other epigenetic pathways) concerns target speciﬁcity. Only
few interactions between Dnmts and sequence-speciﬁc factors have
been described and it cannot be excluded that most have gone
undetected due to their sheer numbers and transient nature. Another
possibility is that structural chromatin features, i.e., other epigenetic
marks, generate a spectrum of afﬁnity sites for Dnmt complexes. An
example is demethylation of H3K4 by LSD1, which creates an
afﬁnity site for the PHD of Dnmt3L and thus may recruit the
Dnmt3a-Dnmt3L complex. However, this only shifts the question of
speciﬁcity to other epigenetic pathways. An exciting alternative is
provided by small noncoding RNAs. While RNA-directed DNA
methylation is well established in plants, a similar mechanism has
only been recently described in mammalian cells for Piwi protein
family-associated RNAs (piRNAs) involved in de novo methylation
and silencing of transposable elements during differentiation of
the male germ line [Kuramochi-Miyagawa et al., 2008]. However,
the precise mechanism by which piRNAs direct de novo DNA
methylation is not currently known. Also, changes in promoter
methylation have been associated with small RNA-mediated
transcriptional gene silencing in mammalian cells, but it is not
clear whether these RNAs are actually guiding de novo methylation
to the target sequence or methylation is a consequence of the
silencing process [reviewed in Guil and Esteller, 2009].
Currently, complete epigenomes of a variety of different cell types
are being established that include detailed information on genome
wide DNA methylation, histone modiﬁcations, and nucleosome
positioning as well as binding of regulatory factors and noncoding
RNAs. In parallel, a rapidly growing number of factors, post-
translational modiﬁcations and interactions are being identiﬁed that
establish, maintain, and modify these epigenomes. The ultimate
challenge for the next decades is to understand how these regulatory
epigenetic networks change during development and disease and
explain in quantitative terms their effect on gene expression
patterns. Given the number of factors involved and the complexity
of their interactions, it is clear that any comprehensive under-
standing of these epigenetic networks will require sophisticated and
powerful bioinformatics tools.
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3. Discussion 
 
3.1. Monitoring Dnmt1 and interacting proteins in their natural 
environment 
 
The main objective of this study was the analysis of the cell cycle dependent 
localization, activity and dynamics of Dnmt1 and its interaction partners PCNA and 
Np95 in living cells. For this purpose, tools and techniques to monitor Dnmt1, PCNA 
and Np95 in their natural, cellular environment were developed. More specifically, 
specific monoclonal antibodies (MAbs) were generated as tools to study Dnmt1, 
PCNA and red fluorescent fusion proteins in a different set of cell biological and 
biochemical applications including western blot, immunofluorescence- and 
immunoprecipitation assays. In addition, advanced live cell microscopy and 
photobleaching techniques were established in somatic and embryonic stem (ES) 
cells. Benefits and limitations of both methods are discussed in the following.  
 
Production of monoclonal antibodies using the hybridoma technology 
 
In the course of this study, we successfully generated three rat MAbs to detect PCNA, 
DNMT1 and red fluorescent proteins in several cell biological and biochemical 
applications (Figure 18). The results were presented in three articles that are 
accepted for publication (Spada et al., 2007; Rottach et al., 2008a; Rottach et al., 
2008b). Two of the MAbs (16D10 and 5F8) are now commercially available.  
 
Figure 18: Overview of MAbs established and characterized in this study.  
The figure shows a summary of antigens used to generate rat MAbs against human PCNA (16D10), 
human DNMT1 (2E8) and multiple red fluorescent proteins (5F8). A schematic representation of the 
interaction between the fluorescent fusion protein mCherry-DNMT1 and PCNA is depicted. PCNA 
binding domain (PBD). PCNA; PDB: 1VYM. mCherry; PDB: 2H5Q. The figure was generated using 
the PyMol software (DeLano, 2002).  
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Focusing on protein dynamics and interactions in living cells, we greatly benefited 
from improved red fluorescent proteins (FPs) that allowed simultaneous monitoring of 
green (GFP) and red (mRFP, mCherry, mPlum or mOrange) fusion-proteins (Shaner 
et al., 2004; Shaner et al., 2005; Giepmans et al., 2006). However, the lack of 
corresponding antibodies detecting the red FPs in biochemical approaches 
prevented further characterization of the red fusion-proteins like mCherry-DNMT1 
in vitro. In result 2.1 we bridged the methodological gap by generating a MAb against 
multiple red fluorescent proteins. This rat MAb 5F8 (isotype IgG2a) enables the 
application of one and the same red fluorescent fusion tag in bio-imaging as well as 
in biochemical assays. This versatile antibody allows the characterization of red 
fusion proteins and their interactions simultaneous in vivo and in vitro. As an example, 
the MAb 5F8 was already used in immunoprecipitation assays to analyze the dimeric 
complex formation of Dnmt1 and to map the dimerization interface within several 
mCherry-tagged fusion constructs (Fellinger et al., 2009).  
 
In result 2.2 we described the generation of an anti-PCNA antibody 16D10 and found 
its isotype to be rat IgG2b. We mapped a linear minimal core epitope to a beta-sheet 
structure, which forms part of the head-to-tail interface of the trimeric PCNA ring. 
Notably, the 16D10 antibody detects the PCNA antigen only in immunofluorescence 
stainings if the sample was fixed by a two-step fixation method. This technique was 
recently established in the lab and includes formaldehyde and subsequent methanol 
treatment. This fixation method allows the structural preservation of the protein 
network via formaldehyde cross-linking and guarantees the accessibility of the 
epitope by methanol fixation. These data illustrate, that efficient and specific epitope 
binding is highly dependent on either antigen or antibody conformation. Often 
antibodies don´t bind their epitope when the protein is in a denatured state (see e.g. 
(Lipman et al., 2005; Rothbauer et al., 2008)). We successfully used this antibody to 
detect PCNA in western blot and co-immunoprecipitation assays (see results chapter 
2.3 and 2.4; (Schermelleh et al., 2007; Spada et al., 2007)).  
 
Finally, we generated and described a rat MAb against human DNMT1 (see results 
2.4). Using the 2E8 anti-DNMT1 antibody, we were able to detect a truncated 
DNMT1 mutant protein in human HCT116 colorectal carcinoma cells that were 
supposed to be dnmt1 knock out (Rhee et al., 2000; Spada et al., 2007).  
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However, the generation of MAbs via the hybridoma technology has a few 
drawbacks: First, the hybridoma technology is not a high throughput method. The 
generation and characterization of MAbs is cost and time intensive, laborious and 
needs a lot of knowledge and practice. Second, successful generation of MAbs still 
relies on the immune system reaction and capacity of immunized animals. 
Furthermore, immunization is artificial and not every antigen is equally immunogenic. 
An immune response is often not initiated if the antigen is either too small (<1000Da), 
too simple structured e.g. homopolymers (ala, ala, ala) or not degradable (Maurer, 
1970) (E.Kremmer) (Janeway et al., 2005). Moreover, immunizations might fail to 
produce any specific MAb when the immunized antigen is identical or highly similar to 
self antigens of the host organism. During thymocyte maturation, T cells whose 
receptors bind strongly to self antigens (autoreactive T cells) receive signals to their 
death and thus are removed from the repertoire (negative selection in the thymus) 
(Miller, 2002; Sprent and Kishimoto, 2002; Janeway et al., 2005). This natural 
mechanism to avoid autoimmune reaction is essential for the organism, but 
counterproductive in generating antibodies. In such cases, it is recommended to use 
an adjuvant (like complete Freund´s adjuvant) or an antigen carrier (like 
microparticles or liposomes) for immunization (Preis and Langer, 1979; Aucouturier 
et al., 2001).  
Despite these shortcomings, the supply of a specific MAb is practically unlimited with 
low costs and little batch to batch variations. All in all, we could demonstrate that the 
specific MAbs 16D10, 2E8 and 5F8 are useful tools in cell biological and biochemical 
research.  
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FRAP analysis and parameters influencing protein dynamics 
 
Photobleaching techniques, such as fluorescence recovery after photobleaching 
(FRAP), fluorescence loss in photobleaching (FLIP) or fluorescence resonance 
energy transfer (FRET), are powerful methods to explore protein localization, 
interactions and dynamics in vivo (Periasamy, 2001; Lippincott-Schwartz et al., 2003; 
van Royen et al., 2009b). The multiple steps from cell transfection till data evaluation 
as well as parameters that could influence these steps are depicted in Figure 19.  
 
Figure 19: Simplified workflow of a FRAP experiment and influencing parameters. 
Multiple steps of a FRAP experiment from cell transfection to image acquisition and data evaluation 
are error-prone and influenced by several parameters. Only if one takes these factors into 
consideration the conclusion about protein kinetics reflects the real protein function in a living cell. 
(The model was modified after Katrin Schneider, unpublished data).  
 
First, transient transfection of mammalian cells with expression vectors encoding 
fluorescent fusion proteins might result in unphysiological overexpression of the 
proteins and dependent on the used transfection reagent might cause toxic side 
effects. Especially overexpression should be controlled in FRAP experiments since 
the saturation of cellular binding sites drastically affects the FRAP kinetics. In this 
and other studies, we could observe an influence of RFP-PCNA overexpression on 
Dnmt1 protein localization and binding kinetics (unpublished data Katrin Schneider, 
Fabio Spada and (Dobay et al., in preparation)). Moreover, overexpression of Np95 
has led to drastic chromatin rearrangements and was shown to be elevated in 
several tumors including ALL / MLL (Papait et al., 2008) (unpublished data Stefan 
Bohlander).  
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Second, the significant size of the fused fluorescent protein tag might interfere with 
protein function, localization or interactions. Controls, including antibody stainings 
against the endogenous protein are therefore crucial to assure that the fusion protein 
is distributed and regulated like its endogenous counterpart. Furthermore, potential 
influences on cellular properties and interference with cellular processes such as cell 
cycle have to be considered (Sporbert et al., 2005).  
Third, bleaching and imaging of the fluorescent fusion proteins by intensive laser 
radiation might induce DNA damage and could affect cell viability (Dobrucki et al., 
2007). Furthermore, imaging and chromophore maturation might trigger the building 
of reactive oxygen species (H2O2) (Cook et al 1991). FRAP data are also influenced 
by the ROI size, bleaching parameters like laser intensities and cell cycle stages of 
the imaged cells. Next, the evaluation of the FRAP data might be biased due to 
cellular movement during imaging or the application of different sets of imaging ROIs 
and evaluation ROIs (Katrin Schneider and (Dobay et al., in preparation)). Especially, 
FRAP experiments in ES cells are critical due to their high cellular mobility.  
 
In summary, a FRAP experiment should be performed under controlled conditions 
and requires the proper evaluation of the FRAP data. Only then, the kinetics of a 
protein can provide information about its function and regulation in living cells.  
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3.2. Dnmt1 dynamics and cell cycle dependent regulation in living cells  
 
Dnmt1 localization and activity is tightly regulated by a multitude of subdomains 
within the large regulatory N-terminal domain (NTD) and was shown to be highly cell 
cycle dependent (Figure 20) (Bestor and Ingram, 1983; Leonhardt and Bestor, 1993; 
Fatemi et al., 2001; Margot et al., 2003) (reviewed in (Spada et al., 2006)).  
 
Figure 20: Schematic representation of the coordinated targeting of Dnmt1 by several 
regulatory subdomains and their interaction partners during the cell cycle.  
Proliferating cell nuclear antigen (PCNA); pericentric heterochromatin (PH); PCNA binding domain 
(PBD); nuclear localization signal (NLS); the pericentric heterochromatin targeting sequence (TS), a 
CXXC type zinc finger motif (ZnF), and two bromo adjacent homology domains (BAH). The function of 
the polybromo homology domain (PBHD) containing two bromo adjacent homology (BAH) domains 
are still unclear (Nicolas and Goodwin, 1996) (Liu et al., 1998). The start codon of the long (ATGL) and 
short (ATGS) isoforms, as well as the seven lysine-glycine repeat linker (KG7) and methyltransferase 
motifs I-X are indicated. Cell cycle stages are indicated below.  
 
The PCNA binding domain (PBD) interacts with PCNA and localizes Dnmt1 to the 
replication machinery throughout S phase (Chuang et al., 1997; Easwaran et al., 
2004). This interaction was proposed as an efficient mechanism, coupling replication 
of genetic and epigenetic information. In this study, we investigated the dynamics of 
Dnmt1 and its interaction with the replication machinery in living cells. Furthermore, 
we addressed the question whether the PBD mediated interaction is strictly required 
for methylation activity or efficiency of Dnmt1 in vivo (see results chapter 2.3; 2.4 and 
discussion 3.2.1).  
The targeting sequence (TS) recruits Dnmt1 to pericentric heterochromatin (PH) from 
late S phase to G2, in a process that is independent of replication, the presence of 
H3K9 trimethylation, the interacting histone methyltransferase SUV39H1 and HP1 
(Leonhardt et al., 1992; Easwaran et al., 2004) (unpublished data Karin Fellinger, 
Weihua Quin, Katrin Schneider). As indicated by several studies, the TS domain of 
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Dnmt1 harbors in addition to pericentric heterochromatin (PH) targeting a multitude of 
functions including dimerization of Dnmt1 and the interaction with Np95 (Leonhardt et 
al., 1992; Easwaran et al., 2004; Meilinger et al., 2009). Interestingly, the interaction 
of Dnmt1 with Np95 was proposed as a key step in the maintenance of genomic DNA 
methylation (Bostick et al., 2007; Sharif et al., 2007). However, the molecular 
mechanisms of this interaction, controlling the activity of Dnmt1 and the maintenance 
of epigenetic information after DNA replication was still largely unknown. To elucidate 
the mechanistic basis of the Np95 function, deletion mutants and isolated Np95 
domains were generated to solve the individual domain properties using different 
in vitro and in vivo approaches (see results chapter 2.6 and discussion 3.3).  
Among the domains within the N-terminal region of Dnmt1 the zinc finger (ZnF) was 
suggested to play an essential role in Dnmt1 enzyme activation and DNA substrate 
recognition (Bestor, 1992; Fatemi et al., 2001; Pradhan et al., 2008). However, the 
exact role of this regulatory subdomain is still controversial. In this study, we explored 
the cell cycle dependent regulation of Dnmt1 and mutants thereof to elucidate the 
mechanistic basis of the Dnmt1 maintenance function in vivo. By comparing the 
subcellular localization and binding kinetics of GFP-tagged wt Dnmt1 and specific 
mutants, the function of the ZnF domain, its interactions and its contribution to the 
maintenance of epigenetic information after DNA replication was analyzed (see 
results chapter 2.5 and discussion 3.2.2).  
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3.2.1. Functional and structural consequences of the PCNA interaction 
 
The association of Dnmt1 with PCNA throughout S phase was proposed as an 
efficient mechanism for coupling replication of genetic and epigenetic information 
(Leonhardt et al., 1992; Chuang et al., 1997). Although the PBD-PCNA interaction 
has been analyzed in vitro (Araujo et al., 2001; Iida et al., 2002) and in vivo 
(Easwaran et al., 2004; Easwaran et al., 2005), the functional relevance of this 
interaction and its contribution to the maintenance of epigenetic information after 
DNA replication, however, remained unclear. We have addressed this question by 
comparing the kinetics and activity of GFP-tagged wt Dnmt1 and PCNA binding 
deficient mutants in live cell photodynamic assays and Dnmt1 deficient embryonic 
stem (ES) cells ((Schermelleh et al., 2007; Spada et al., 2007) see results 2.3 and 
2.4). Our data showed that the association of Dnmt1 with the replication machinery is 
highly transient and, surprisingly, not strictly required for restoring global CpG 
methylation in vivo. However, the PBD-PCNA interaction enhances the efficiency of 
postreplicative methylation by twofold. This raises the question, how Dnmt1 
maintenance function benefits from the PBD mediated interaction with the replication 
machinery? Three explanations for this enhancement are possible:  
First, the PBD-PCNA interaction likely elevates local Dnmt1 protein concentrations at 
the replication fork and thereby increases the postreplicative methylation rate in vivo. 
As shown previously and in this study, Dnmt1 concentrations are critical for the 
preservation of normal DNA methylation levels, since Dnmt1 expression below a 
certain threshold level caused global hypomethylation, tumor formation and affected 
cell viability (Gaudet et al., 2003; Gaudet et al., 2004; Spada et al., 2007). To ensure 
proper maintenance of DNA methylation, most cell types express an excess of 
Dnmt1 protein than necessary and the PBD-PCNA interaction can be considered as 
an additional safety mechanism in vivo. That the PBD is dispensable for maintaining 
global methylation level over time, can be explained in two ways: On the one side, 
simple protein diffusion or the intrinsic preference of Dnmt1 for hemimethylated 
substrate sites might be sufficient for this process (Bestor and Ingram, 1983; 
Hermann et al., 2004b; Frauer and Leonhardt, 2009). On the other side, 
additional / alternative targeting mechanisms (e.g. via the TS domain) might be 
important (Easwaran et al., 2004). Thus strict coupling of replicating the genetic and 
epigenetic information is not required in vivo.  
DISCUSSION 
 
- 158 - 
Second, the PBD-PCNA interaction could act as adaptor between DNA and Dnmt1, 
and thus may facilitate the transfer of Dnmt1 to hemimethylated substrate sites.  
Third, binding of the PBD to PCNA might induce structural rearrangements in the 
overall Dnmt1 conformation, leading to allosteric activation of the enzyme or 
increased substrate preference. Such a mechanism was already described for Fen1 
and DNA ligase 1 (Lig1) (Chapados et al., 2004; Sakurai et al., 2005; Pascal et al., 
2006). Indeed, first in vitro data indicated that Dnmt1 affinity for hemimethylated DNA 
substrate was enhanced when PCNA was coupled to DNA compared to free DNA 
(Iida et al., 2002). Thus, the PBD could increase the processivity of Dnmt1 also 
in vivo. Notably, it is still unclear whether the formed complex between PBD and 
PCNA displays an induced fit conformation or represents a stably folded interaction 
interface. However, looking at the co-crystal structure of p21-PBD and PCNA (Gulbis 
et al., 1996) revealing a snug fit along the whole peptide-protein interface, the 
induced fit model is more likely (Figure 21).  
 
Figure 21: Variability plot of the PBD sequence motif (A) and structural features of the 
PBD-PCNA interaction (B).  
The variability plot was generated via the protein variability server (PVS). The diversity was calculated 
by the shannon entropy (H) algorithm (Shannon, 1948), using the displayed multi-sequence alignment 
as input. H≥2 are considered as variable. H<2 are considered as conserved. Highly conserved 
positions are H<1. The PIP-Box motif (yellow box) defines the minimal core of the PBD and glutamine 
(Q) is invariable. Q144 anchors the PBD peptide on the PCNA surface. (PDB: 1AXC) 
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As shown in this study, the PBD domain was necessary and sufficient to target 
Dnmt1 to replication sites in vivo. Moreover, the PBD was shown to recruit Dnmt1 to 
sites of DNA repair, arguing for an additional role of the PBD-PCNA interaction in the 
restoration of DNA methylation after DNA damage (Mortusewicz et al., 2005). Even 
the PIP-Box motif alone, representing the minimal core element of the PBD with only 
eight amino acids (Figure 21), was sufficient to bind to PCNA in vivo (data not 
shown). On the other hand, one single point mutation within the highly conserved 
PIP-Box of the PBD (Q162E) prevented targeting of the GFP-Dnmt1 construct to 
replication foci (Schermelleh et al., 2007). These data support the idea that the 
glutamine (Q) anchors the whole PBD peptide on the surface of the PCNA monomer 
(Figure 21).  
 
To gain more structural and functional insights in the interaction of Dnmt1 with the 
replication machinery, one should try to crystallize the NTD of Dnmt1 including the 
PBD in complex with PCNA. Furthermore, the design of a short and affine PBD 
peptide, or superbinder, might help in the treatment of highly proliferative tumors, by 
blocking the PCNA interaction site or stalling the replication machinery. Indeed, 
several publications indicated the potential interest in replication inhibitors (Chen et 
al., 1995; Kontopidis et al., 2005). As they previously showed in biochemical assays, 
DNA replication can indeed be stalled by adding competitive PIP-Box containing p21 
peptides. However, disruption of PBD-mediated interactions with PCNA (e.g. by 
knocking specific PBD point mutations into the Fen1 alleles) has severe effects on 
replication and was shown to induce pulmonary hypoplasia and newborn lethality in 
mice (Zheng et al., 2007).  
The sheer number of potential PBD-containing PCNA binding partners suggests that 
binding to PCNA must be highly regulated and is likely competitive and mutual 
exclusive (Bruning and Shamoo, 2004; Ivanov et al., 2006). Thus, the question arises, 
how the PCNA ring coordinates the multitude of PBD-containing interaction partners 
and thereby controls several biochemical pathways. Our data suggest, that Dnmt1 
rapidly binds to and dissociates from the PCNA ring, arguing against a constant 
traveling along with the replication machinery. In line with this theory, trapping of 
GFP-Dnmt1 does not prevent the progression of the replication machinery. This 
highly transient nature of the PBD-PCNA interaction would enable a constant and 
rapid exchange of PBD-containing interaction partners that bind PCNA through the 
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identical binding site on the PCNA monomer. Indeed, a multitude of PBD containing 
proteins like Fen1 or Lig1 rapidly exchange at the replication fork (Sporbert et al., 
2005), arguing for a common dynamic feature of the PBD interactions. This dynamic 
exchange at the replication sites would enable the necessary plasticity to coordinate 
a multitude of processes linked with the replication machinery.  
However, this model is not sufficient to explain the orchestration of the sheer number 
of PBD containing proteins. Alternative regulatory mechanisms in controlling 
sequential enzyme binding and enzyme activity are imaginable, like different binding 
affinities (Levin et al., 2000; Warbrick, 2000; Maga and Hubscher, 2003), 
conformational changes upon PCNA binding (Chapados et al., 2004; Sakurai et al., 
2005; Pascal et al., 2006) and post-translational modifications, occurring either on 
PCNA itself or on the interaction partners (Moldovan et al., 2007; Hishiki et al., 2009). 
Additionally, spatio-temporal differences including cell cycle dependent protein levels 
or subcellular localization might also control these interactions. For instance, PCNA 
protein level peak during S phase, whereas the protein level of p21 (a high affinity 
PCNA binding protein) remain low (Warbrick et al., 1995; Chuang et al., 1997). This 
clears the way for other cell cycle dependent PCNA interactions, like Polδ-PCNA or 
Dnmt1-PCNA without being challenged by p21.  
 
Interestingly, the ancestral PBD motif appears only in metazoa Dnmt1s whereas it is 
not obviously present in invertebrates or plants (Warbrick, 1998; Dalrymple et al., 
2001). Furthermore, the TS domain seems to be duplicated in plants (Colot and 
Rossignol, 1999; Easwaran et al., 2004), arguing for a methylation mechanism that is 
uncoupled from DNA replication. Indeed, plants show different methylation patterns 
whereas methylation occurs mainly at repetitive heterochromatic elements 
(Rabinowicz et al., 1999). Interestingly, these genomic regions are replicated 
relatively late during S phase where the TS domain of Dnmt1 targets the protein to 
pericentric heterochromatin. Hence, besides the PBD domain, also other regulatory 
domains within the large N-terminus of Dnmt1 are involved in targeting of Dnmt1 to 
potential substrates sites and are crucial for the faithful propagation of DNA 
methylation.  
In summary, the PBD might serve as additional safety mechanism that was acquired 
in the course of evolution and contributes to the faithful propagation of DNA 
methylation marks over the entire lifetime of a complex organism.   
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3.2.2. Role of the CXXC zinc finger in Dnmt1 mobility and activity 
 
In this study, we investigated the role of the ZnF domain in the complex regulation of 
Dnmt1 in a living cell. We addressed this question with two different strategies: First, 
we characterized the function of the isolated ZnF domain (aa 652-697). Second, we 
precisely deleted the ZnF motif (Δ655-696) in the context of the full-length protein 
(Dnmt1∆ZnF), trying not to disrupt the folding of the remaining Dnmt1 domains. We 
compared these mutants with wild-type (wt) Dnmt1 in several in vitro and in vivo 
approaches (see results chapter 2.5).  
Earlier work has suggested that the ZnF domain of Dnmt1 is involved in DNA binding 
(Fatemi et al., 2001; Pradhan et al., 2008). Our data demonstrated that the isolated 
ZnF domain features a high binding preference for unmethylated DNA in vitro 
(unpublished data from Carina Frauer). A similar binding preference has been 
reported also for other ZnF containing proteins (see CXXC ZnF alignment in Figure 
12). Unlike previous reports, we assessed the binding properties of the isolated ZnF 
domain to its natural chromatin substrate also in living cells. Using live cell 
microscopy and quantitative FRAP analyses we showed that the isolated ZnF 
domain localizes in the nucleus and interacts with nuclear structures, most likely DNA, 
in vivo.  
That the ZnF domain might be involved in the interaction with the CTD and in 
allosteric activation of the catalytic domain of Dnmt1 was suggested in (Fatemi et al., 
2001). Recently, (Pradhan et al., 2008) published that even point mutations in 
zinc-ion coordinating cysteine residues or the complete ZnF deletion abolished DNA 
binding in vitro and reduced catalytic activity of Dnmt1 in a radioactive 
methyltransferase assay. To study the role of the ZnF we determined the sequence 
specificity and catalytic activity of the Dnmt1∆ZnF mutant. Unlike these two previous 
publications ((Fatemi et al., 2001; Pradhan et al., 2008)), our data showed that the 
ZnF-deletion did neither impair N-C terminal interaction (unpublished data from Karin 
Fellinger) nor catalytic activity in vitro (unpublished data from Carina Frauer). This 
discrepancy might result from the use of different ZnF constructs or experimental 
setups. In (Fatemi et al., 2001) the authors produced isolated Dnmt1 domains 
recombinantely in E. coli that may influence folding or posttranslational modifications 
of the protein. Furthermore, they tested N-C-terminal interaction via affinity 
purification that is highly artificial. The differences between the results described by 
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Pradhan et al. and our data might originate from differences in the size of the deletion 
and the endpoints that might disrupt protein folding and structural integrity. (Pradhan 
et al. used human DNMT1 protein with a larger deletion (Δ647-690)). Moreover, most 
of their experiments were done in vitro, that cannot reproduce the complexity of a 
living cell.  
In this study, we systematically analyzed cell cycle dependent nuclear localization 
and protein kinetics of the ZnF-deletion versus wt also in vivo. Furthermore, we 
measured the catalytic activity of the deletion construct using the previously 
published trapping assay (Schermelleh et al., 2005). Surprisingly, in these in vivo 
assays, the ZnF seems to be dispensable for protein localization, protein mobility as 
well as protein activity in context of the full-length Dnmt1. The question arises, how 
one could finally assess the role of the ZnF domain in the Dnmt1 protein?  
A recent publication dealing with human DNMT1 tested the effect of the ZnF-deletion 
on methylation maintenance function in vivo (Pradhan et al., 2008). They produced a 
permanent HEK293T-A7 cell line containing a Rheoswitch promoter driven human 
dnmt1∆ZnF (Δ647-690) gene and induced expression of the truncated protein for 10 
days. The authors suggested that the DNMT1∆ZnF protein has a dominant negative 
effect on the catalytic activity of the endogenous DNMT1 protein that resulted in a 
significance decrease of activity on hemimethylated substrate and in 25 % lower 
methylation at rDNA repeats compared to control cells. Apart from the ectopic 
expression of the deletion construct over the endogenous DNMT levels, the authors 
analyzed the methylation level only from one specific DNA sequence type (rDNA 
repeats) via bisulfide sequencing. It would be necessary to include at least the 
analyses of major and minor satellite sequences, retroviral elements like the IAPs 
and single copy genes like the skeleton α-actin promoter. Moreover, as described in 
(Fellinger et al., 2009) Dnmt1 can form stable dimers. Thus, heterodimer formation 
between the DNMT1ΔZnF and endogenous DNMT1 cannot be excluded and may 
influence or mask the mutant effect. Optimally, catalytic activity and substrate 
preference of Dnmt1 mutants should be studied in vivo by rescuing Dnmt1 knock-out 
(dnmt1-/-) ES cells that are severely hypomethylated in all genomic compartments (Li 
et al., 1992; Lei et al., 1996). Here, we took advantage of this excellent model system 
and tested whether Dnmt1∆ZnF can rescue methylation levels and patterns in 
dnmt1-/- ES cells (unpublished data Daniela Meilinger). For this purpose, either 
GFP-Dnmt1∆ZnF or GFP-Dnmt1wt fusion proteins were transiently expressed in 
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dnmt1-/- ES cells for 48 hours and the methylation status of various representative 
sequence types was quantitatively analyzed using pyrosequencing (Varionostic, 
GmbH, Ulm). Interestingly, we found no significant difference in methylation levels 
and methylation patterns after rescue with Dnmt1∆ZnF and wt construct (unpublished 
data Daniela Meilinger). In summary, with the methods applied in this study, we 
showed that the ZnF domain of Dnmt1 seems to be dispensable for substrate 
preference, catalytic activity and faithful maintenance of DNA methylation in vivo.  
Although we give several lines of evidence that the isolated ZnF domain features 
DNA binding activity, the functional role of the ZnF in context of the full-length protein 
is not prominent. Three reasons are imaginable. First, the effect of the ZnF function 
could be minor in context of the full-length protein and simply not detectable by our 
assays. For example, a stronger interaction that is mediated by another domain in 
Dnmt1 (e.g. the PBD or TS) may dominate the overall protein binding kinetics and 
thus makes it impossible to resolve the minor binding affinity of the ZnF for DNA 
substrates by FRAP analysis. Second, the ZnF domain could be masked by other 
regulatory domains in the three dimensional structure of the full-length protein. Third, 
the ZnF does not play any role in the mouse Dnmt1 protein, what would imply that 
the observed strong DNA binding activity of GFP-ZnF protein was redundant.  
Nevertheless, that the CXXC ZnF motif is still highly conserved in different species 
without featuring a relevant function in vivo is unlikely.  
 
Hence, we will expand our experimental repertoire and test another hypothesis. 
During early embryonic development, the shorter, oocyte-specific isoform of Dnmt1 is 
actively retained in the cytoplasm from the zygote to blastocyst stage, with the 
exception of the 8-cell stage in which Dnmt1 transiently enters the nucleus (Carlson 
et al., 1992; Cardoso and Leonhardt, 1999; Grohmann et al., 2005). Dnmt1 retention 
might be essential to erase genomic DNA methylation patterns in the preimplantation 
stages and thus may allow epigenetic reprogramming. This retention process 
involved several domains in the large NTD including the ZnF domain. Whether the 
ZnF of Dnmt1 is indeed essential for this early developmental regulation will need 
further investigation.  
Prospective experiments should include FRAP analyses of ZnF mutants in ES cells 
with normally methylated (wt J1), reduced methylated (dnmt1-/-) and unmethylated 
genomes (TKO) to test binding preference, mobility and activity of the ZnF mutant 
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dependent on the methylation level in vivo. Furthermore, we cannot exclude, that the 
ZnF of Dnmt1 features also a binding preference for RNA instead of DNA. With 
increasing evidence, it is suggested that regulatory small RNAs may influence Dnmt 
activity and expression ((Svedruzic and Reich, 2005; Svedruzic, 2008) reviewed in 
(Guil and Esteller, 2009)). Also, the nucleolar localization of the GFP-ZnF protein 
could be an indication for RNA binding preference. Besides binding to nucleic acids 
the ZnF might be involved in several intermolecular protein-protein interactions. 
Dnmt1 has been shown to interact with several chromatin-associated proteins 
through this N-terminal region, including pRb, HDAC1/2 (Fuks et al., 2000; Robertson 
et al., 2000; Pradhan and Kim, 2002), transcription factor E2F1 (Robertson et al., 
2000) or remodeling complexes like Tip5/Snf2h (Santoro et al., 2002). Interestingly, 
Dnmt3a and Dnmt3b also contain a zinc ion coordinating PHD finger that is 
necessary for selective anchoring the Dnmt3 proteins to methylated nucleosomes 
(Jeong et al., 2009). This PHD domain was also shown to interact with HDACs (Fuks 
et al., 2001; Geiman et al., 2004). To further investigate the role of the Dnmt1 ZnF 
domain in protein-protein interactions, one could perform pull-down experiments in 
dnmt1-/- ES cells either rescued with the ZnF-deletion or wt Dnmt1 and subsequently 
compare mass spectrometrical data to identify possible interaction partner of the ZnF 
domain. Additionally, one should analyze whether the ZnF domain is engaged in 
other intramolecular interactions. Protein interactions or substrate recognition might 
not involve just one subdomain, but might involve the interplay of several 
subdomains. One example of multivalent engagement in substrate recognition (e.g. 
histone modifications) is the NURF protein. There, cooperative binding of PHD finger 
and Bromo domain enhances substrate specificity and binding strength (Li et al., 
2006a; Ruthenburg et al., 2007). Thus we could hypothesize that the Dnmt1 ZnF 
might function cooperatively with e.g. the BAH domains (Nicolas and Goodwin, 1996; 
Liu et al., 1998).  
Very recently, a new epigenetic regulatory mechanism emerged that might explain 
the process of active demethylation. The 2-oxoglutarate- and iron(II)-dependent 
dioxygenase superfamily (2OGFeDO), including Tet/JBP family members recognize 
and modify the methylated cytosine residue (5mC) to 5-hydroxymethylcytosine 
(5hmC) and thus may promote active demethylation (Tahiliani et al., 2009). Indeed, 
catalytic mutation in the Tet2 protein correlates with hypermethylation in multiple 
myeloproliferative neoplasms (Tefferi et al., 2009a; Tefferi et al., 2009c) and myeloid 
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malignancies (Tefferi et al., 2009b). Surprisingly, some of the 2OGFeDO enzymes 
(Tet1 and Tet3) contain also the highly conserved CXXC ZnF motif or are suggested 
to form a complex with a CXXC domain that is encoded in cis (Tet2) (Iyer et al., 
2009). There, the authors propose that this Tet CXXC ZnF domain might be involved 
in the recognition of 5mC substrate sites in DNA. However, all previously tested 
CXXC ZnF containing proteins show strong binding preference to unmethylated CpG 
substrate sites and not to 5mC nor to 5hmC. The question arises, whether Dnmt1 
binds to 5hmC via the ZnF domain or whether binding to the modified base is 
blocked in vivo. However, whether and how this new DNA base serves as new 
epigenetic regulatory mechanism also for Dnmt1 has to be elucidated.  
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3.2.3. Coordinated binding kinetics of Dnmt1 regulatory subdomains 
 
In this thesis, we investigated the cell cycle dependent localization, mobility and 
activity of Dnmt1 and interacting factors in vivo, by employing live cell imaging and 
photobleaching techniques in combination with mechanism based methyltransferase 
inhibitors. Furthermore, we analyzed the role of the Dnmt1 functional subdomains in 
the complex regulation of Dnmt1 in living cells.  
Two domains of Dnmt1, the PCNA-binding domain (PBD) and the targeting 
sequence (TS) domain have been shown to be responsible for targeting to replication 
sites and to pericentric heterochromatin (Chuang et al., 1997; Leonhardt et al., 1992; 
Easwaran et al., 2004). However, their temporal coordination and regulation was still 
unclear. By comparing the subcellular localization and binding kinetics (FRAP) of 
GFP-tagged wt Dnmt1 and specific mutants, the function of the PBD and ZnF domain, 
their interactions and their contribution to the maintenance of epigenetic information 
after DNA replication was analyzed. Together with previous FRAP results obtained 
with the TS domain (unpublished data Karin Fellinger, Florian Rieß, 
Daniela Meilinger and Katrin Schneider) we can present a model resolving the 
detailed cell cycle dependent binding kinetics of GFP-Dnmt1 and its regulatory 
subdomains in living cells (Figure 22).  
 
Figure 22: Schematic representation of the domain structure of Dnmt1 (A) and the coordinated 
binding kinetics of Dnmt1 and its individual regulatory subdomains during the cell cycle (B).  
The PBD-mediated interaction with PCNA targets Dnmt1 to the replication machinery during S phase. 
Binding kinetics peak during late S phase where the TS domain targets Dnmt1 to pericentric 
heterochromatin. The TS domain mediates also interaction with Np95. The ZnF domain has only minor 
or no effect on the Dnmt1 binding affinity. Color code in (B) represents functional domain in (A). (The 
design of the model was inspired by discussions with Katrin Schneider and Lothar Schermelleh). 
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Our data show that the PBD mediated interaction of Dnmt1 with PCNA is highly 
transient, occurs throughout S phase and contributes to the decreased mobility of 
Dnmt1 compared to G1 phase. This interaction enhances the efficiency of 
postreplicative methylation by the factor two, but is not required for maintaining global 
CpG methylation in vivo. As depicted in Figure 22, the TS domain mediates a very 
strong interaction of Dnmt1 with PH. By comparing the mobility of wt Dnmt1 and PBD 
mutant Dnmt1Q162E, we observe the onset of the TS mediated interaction in the 
transition to late S phase, while the PBD mediated binding still persists (Easwaran et 
al., 2004; Schermelleh et al., 2007; Spada et al., 2007) (unpublished 
Katrin Schneider and (Dobay et al., in preparation)). Consistently, a 
GFP-Dnmt1Q162E/ΔTS double mutant shows no targeting to replication foci as well as 
pericentric heterochromatin and displays fast recovery rates throughout S phase and 
G2. These mutant kinetics point to a complete depletion of all S phase specific 
interactions (unpublished data Florian Rieß; Karin Fellinger and Katrin Schneider). 
Interestingly, the protein levels of Np95, the interaction partner of the TS domain, 
peak during late S phase (Muto et al., 1995; Miura et al., 2001). Thus the question 
arises, whether the potential switch between the transient PBD-PCNA binding and 
the strong TS association to PH might be mediated by the interaction with Np95 
(Meilinger et al., 2009) (unpublished data Karin Fellinger; Weihua Quin).  
Based on localization and kinetics analyses, the Dnmt1 ZnF seems to be 
dispensable for the overall protein mobility and activity. However, the total sum of 
binding affinities reflecting Dnmt1 interactions exceeds the binding affinities of the 
isolated subdomains (PBD; TS; ZnF). This argues for additional interactions within 
the large Dnmt1 molecule or indicates a mutual enhancement of multiple regulatory 
subdomains. Interestingly, it has been shown that the interaction between the 
regulatory N-terminal domain and the catalytic domain induces not only allosteric 
activation but affects also Dnmt1 mobility. FRAP of the isolated Dnmt1 NTD displays 
slow and incomplete recovery rates, indicating that the NTD needs the interaction 
with the catalytic domain for full mobility (unpublished data Daniela Meilinger and 
Katrin Schneider). Moreover, FRAP analyses in wt and different knockout ES cells 
revealed that the methylation levels might affect the TS mediated association of 
Dnmt1 in late S phase (data not shown).  
Clearly, more experiments are required, to gain further insights in the Dnmt1 
dynamics, the underlying coordinated binding events and the interacting proteins.  
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3.3. Role and regulation of the multi-domain protein Np95 in living cells 
 
Earlier work has shown that Np95 binds to hemimethylated DNA, interacts and 
colocalizes with Dnmt1 at replication foci and that its genetic depletion leads to 
remarkably similar genomic hypomethylation and developmental arrest to those 
observed in Dnmt1 null mice (Uemura et al., 2000; Bostick et al., 2007; Papait et al., 
2007; Sharif et al., 2007; Achour et al., 2008). Thus, it has been proposed that Np95 
contributes to genome-wide maintenance of DNA methylation patterns by recruiting 
Dnmt1 to hemimethylated CpG sites through its SRA domain (Arita et al., 2008; 
Avvakumov et al., 2008; Hashimoto et al., 2008). Furthermore, our group recently 
demonstrated that Np95 interacts with all three DNA methyltransferases Dnmt1, 
Dnmt3a and Dnmt3b, strongly arguing for a key-regulatory role of Np95 in DNA 
methylation (Meilinger et al., 2009).  
Since recognition of hemimethylated CpG sites via Np95 and subsequent targeting of 
Dnmt1 to these DNA substrates is considered as a crucial step in the faithful 
propagation of DNA methylation, we first investigated the influence of different 
methylation levels on Np95 localization and dynamics in living wt and knockout ES 
cells. Surprisingly though, Np95 localization and binding kinetics were not affected by 
either reduced (dnmt1-/-) or completely absent (TKO; dnmt1-/-3a-/-3b-/-) DNA 
methylation compared to wt (J1) ES cells in vivo. The relatively slow and incomplete 
recovery curve of Np95 revealed a very strong interaction with, and partial 
immobilization at chromatin that is dominated by the SRA domain. However, 
subnuclear localization of the GFP-Np95 protein was not consistent with antibody 
stainings of the endogenous Np95 protein, as published in (Sharif et al., 2007). This 
difference might result from the use of different cell lines, GFP-fusion proteins and 
Np95 expression levels. To test the activity of the GFP-Np95 fusion proteins, we 
performed a rescue assay in np95 -/- ES cells. First results indicate that the position 
of the GFP (N- or C- terminal fusion) is critical for Np95 activity.  
Next, we analyzed the Np95 binding preference also in vitro. Non-radioactive DNA 
binding-, gel shift- and supershift assays (Frauer and Leonhardt, 2009) with DNA 
substrates containing one central CpG site showed only a significant preference of 
Np95 for DNA substrates containing a CpG versus non CpG substrates, suggesting 
that Np95 does not discriminate between un-, hemi- or fully methylated DNA 
substrate also in vitro. However, previously published in vitro DNA binding data 
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showed a strong preference for hemimethylated DNA substrates (Bostick et al., 
2007; Arita et al., 2008; Avvakumov et al., 2008; Hashimoto et al., 2008). This 
discrepancy might originate from the use of different types and lengths of DNA 
substrates. Besides the fact, that (Bostick et al., 2007) included unphysiological many 
CpG sites in their oligos, also sequence mismatches could be detected that might 
interfere with the folding of the substrates and thus might induce binding artifacts. To 
probe the cause of this different binding preference, we very recently performed 
in vitro non-radioactive DNA binding assays with larger DNA substrates containing 
multiple CpG sites. Using these DNA substrates that center three CpG sites, we 
could detect a strong binding preference of Np95 to hemimethylated DNA substrates 
(Carina Frauer, preliminary data). Hence, Np95 seems to have a binding preference 
to hemimethylated DNA substrates in vitro, but with high dependency on the amount 
of CpG sites. These recent findings raise interesting questions:  
For instance, why several CpG sites are required for the Np95 binding preference for 
hemimethylated DNA substrates? Possibly, the distance or orientation of the CpG 
sites within the DNA helix could affect Np95 binding specificity. Moreover, 
co-crystallization of the isolated SRA domain of Np95 point to sterical interference at 
one and the same target CpG site and would likely prevent synchronized binding of 
Np95 and Dnmt1 (Arita et al., 2008; Avvakumov et al., 2008; Hashimoto et al., 2008). 
Questionable is, how sterical clashes with Dnmt1 at target CpG sites are bypassed? 
Np95 and Dnmt1 could bind one CpG site successively. Alternatively, Np95 might 
function as stable anchor point in the DNA, thereby recruiting Dnmt1 to these sites 
that subsequently slides along the DNA and spreads the methylation to close CpG 
sites. Finally, the question arises, whether and how these in vitro observations reflect 
the state in vivo? For instance, the preference for hemimethylated CpG sites seems 
to have no measurable effect on the overall Np95 binding kinetics in vivo, as there 
was no detectable difference in wt, dnmt1-/- and TKO ES cells. Furthermore, the SRA 
domain of Np95 per se was not sufficient for proper subnuclear localization. Hence, 
alternative mechanisms that are mediated by Np95 could be essential for the faithful 
propagation of DNA methylation in vivo.  
In this study, we could show that the multi-domain protein Np95 and the very similar 
Np97 harbor at least five subdomains comprising different functions (Figure 23). 
Besides the question what roles the various domains of Np95 play in maintaining 
DNA methylation, it is still unclear, whether Np95 and Np97 are redundant. Although 
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both proteins feature high sequence similarity, Np97 does not substitute Np95 
function in vivo, as indicated by the drastic phenotype of np95 -/- mice. Possible 
explanations for this dramatic effect could be non-overlapping expression profile, an 
obligate heterodimerization or simply different functions of both proteins. First results 
on mRNA expression profiles from different cell lines showed that both mRNAs, Np95 
and Np97, are expressed at least in ES cells (unpublished data Christine Schmidt). 
To further analyze potential differences in protein levels, we now want to generate 
specific monoclonal antibodies against Np95 and Np97 to answer these questions.  
 
 
Figure 23: Schematic outline of the Np95 and Np97 domain structure, functions and 
interactions.  
Both proteins contain several highly conserved functional domains including an Ubiquitin-like domain 
(Ubl), a tandem Tudor domain, a plant and homeodomain (PHD), a Set and Ring associated (SRA) 
domain and a Ring domain. Np97 differs from Np95 by a 32 amino acid stretch (156-188) in the 
tandem Tudor domain. Other potential motifs are depicted: AlkB homologue 2 PCNA-interacting motif 
(APIM); PCNA-interacting-peptide-(PIP)-Box. Lines represent interaction interface with Dnmt1 and 
Dnmt3a/3b. The Ubl domain likely mediates dimerization (Bezsonova et al., 2009). Dashed lines 
indicate type of interaction and width indicates interaction strength. Arrows mark intramolecular 
interactions or cooperative binding, ubiquitination (Ub) and amino acids are indicated.  
 
Direct interaction of Np95 with PCNA, the core component of the replication 
machinery, was shown previously by co-immunoprecipitation and co-localization 
analyses (Miura et al., 2001; Sharif et al., 2007; Bostick et al., 2007). However, the 
Np95 domains, essential for this interaction were not mapped. Very recently, a so far 
unknown APIM PCNA interaction motif [KR]-[FYW]-[LIVA]-[LIVA]-[KR] was 
discovered and identified also in Np95 and Np97 (Gilljam et al., 2009). The APIM 
motif is located in the SRA domain (Figure 23). In addition, we could identify a 
potential PIP-Box motif in Np95 and Np97 at the very C-terminus.  
Previous results suggested that Np95 and possibly Np97 link DNA methylation not 
only with DNA replication but also with repressive histone modifications. Np95 and 
Np97 contain a plant and homeodomain (PHD) that was shown to be involved in 
binding to histone H3 (Citterio et al., 2004; Karagianni et al., 2008; Papait et al., 
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2008). Furthermore, overexpression of Np95 induced large scale, higher order 
chromatin rearrangements in heterochromatic regions (Papait et al., 2008).  
This effect was dependent on the PHD finger and occurred independently of DNA 
methylation levels, as the experiment was done in TKO ES cells. The PHD mediated 
binding to histone H3 tails couldn´t be confirmed using our assays.  
Instead, we could find a so far undescribed module in Np95 called the tandem Tudor 
domain that selectively binds to trimethylated but not to acetylated lysine 9 of histone 
H3 (H3K9). Interestingly, structural data revealed that the tandem Tudor domain 
(PBD 3DB4) contains a binding pocket similar to the aromatic cage present in the 
chromodomain of HP1β (PDB 1KNE), showing a snug fit of a trimethylated H3K9 
peptide; a histone modification that is associated with silent chromatin states. Notably, 
sequence analysis revealed that Np97 differs from Np95 only in the tandem Tudor 
domain by an additional stretch of 32 amino acids (Figure 23). Whether this stretch 
alters the substrate preference for histone tails or brings along additional functions 
has to be tested.  
Another question to be answered is, whether the tandem Tudor domain acts 
independently or in a cooperative fashion. Multivalent engagement of one or multiple 
histone modifications at the same time was proposed previously for the NURF protein 
(Li et al., 2006a). There, an α-helical structure connects the PHD finger and the 
bromodomain and defines the relative orientations of their binding pockets. This 
cooperation was suggested to enhance binding specificity and binding strength to 
chromatin targets (Ruthenburg et al., 2007) (reviewed in (Taverna et al., 2007)). In 
Np95 and Np97 the tandem Tudor - and PHD domain are located in close proximity 
and are connected via a proline-rich linker that could form a specific three 
dimensional conformation. Synergistic binding of histone tails in cis or trans and 
interactions with other chromatin associated factors might increase the specificity for 
certain chromatin states in vivo. Clearly, more experiments are required to test 
whether this hypothesis is true for Np95 or Np97 and should include the analysis of 
combinatorial assemblies of the Np95 or Np97 modules in vivo. Pointing to such a 
mechanism the deletion of the single tandem Tudor or PHD domains within Np95 
didn´t show a severe effect in Np95 localization in vivo. Moreover, first results from 
the peptide binding assay hint to a cooperative binding of the tandem Tudor domain 
and PHD domain in Np97 (unpublished data Patricia Wolf and Garwin Pichler) 
(Figure 23).  
DISCUSSION 
 
- 173 - 
The multivalent binding properties of Np95 or Np97 would enable a synchronized 
binding to several epigenetic marks like DNA methylation and posttranslational 
histone modifications, thereby connecting multiple epigenetic pathways. However, 
the exact mechanisms and specificity of Np95 and Np97 proteins in connecting DNA 
methylation with repressive chromatin states are still to be resolved.  
Notably, Np95 is connected to chromatin also by the Ring domain (Figure 23) that 
possesses E3 ubiquitin ligase activity and mediates ubiquitination of histone H3 and 
possibly H2b in vitro (Citterio et al., 2004; Karagianni et al., 2008). Whether Np95 
and Np97 mediate ubiquitination also in vivo and whether they are able to auto-
ubiquitinate has to be investigated in further experiments. In addition, one could 
speculate, that Np95 and Np97 play a crucial role in linking proteasomal degradation 
with post-translational modified chromatin. Indeed, it has been shown in yeast, that 
ubiquitination of H2b recruits proteasome subunits to chromatin (Ezhkova and 
Tansey, 2004). That Np97 might be involved in intranuclear degradation processes 
was also suggested recently (Iwata et al., 2009). Thus Np95 or Np97 mediated 
ubiquitination may induce nucleosomal displacement or depletion, and thereby may 
support opening up the chromatin at specific sites in chromatin, e.g. at sites of DNA 
replication. This mechanism could contribute to a better accessibility of potential 
target sites within the DNA, especially for the Dnmts. Whether Dnmt1 activity is 
blocked by densely packed chromatin (Robertson et al., 2004) or whether the 
maintenance function is not affected by nucleosomal DNA (Okuwaki and Verreault, 
2004; Gowher et al., 2005) is still controversial. In fact, (Papait et al., 2008) showed a 
chromatin decondensation after Np95 overexpression. Here, the authors mapped the 
PHD finger as crucial domain in this process. However, one could speculate that the 
drastic hypomethylation in np95 -/- ES cells is either a consequence of the missing 
interaction and targeting of Dnmts by Np95, or in contrast a result of the reduced 
accessibility at highly condensed chromatin regions. To test this hypothesis, one 
could rescue np95 -/- ES cells with specific Np95 mutants (ΔRing, ΔPHD) and assay 
the effect on methylation levels, histone tail binding and chromatin organization.  
 
Even though the crystal structure of the Ubl domain is solved, the function of the Ubl 
domain is still elusive. The Ubl domain reveals around 35 % similarity to ubiquitin, 
which is known to play a crucial role in cell cycle progression, protein-protein 
interactions, aggregation and association with proteasomal subunits (Heir et al., 
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2006). Very recently, the Ubl domain of the Ring1B protein was crystallized and 
shown to build homodimers and to interact with the Polycomb protein Cbx 
(Czypionka et al., 2007; Wang et al., 2008; Bezsonova et al., 2009). Hence, the Ubl 
domain of Ring1B was suggested to mediate binding between nucleosomes and 
members of the PRC1 complex. By structural homology search, (Bezsonova et al., 
2009) found a highly similar Ubl structure in Np95, arguing that this structural domain 
may serve as a common adapter motif. Indeed, our group verified an interaction 
between the Ubl domain of Np95 and the DNA methyltransferases Dnmt1, Dnmt3a 
and Dnmt3b (Meilinger et al., 2009). Moreover, the dimerization potential of the Ubl 
domain supports the idea of complex formation either within Np95 molecules or Np95 
or Np97 heterodimers (Figure 23). Together, the potential to dimerize, the 
association with chromatin and the interaction with repressive protein complexes 
(PRC1/PRC2) point to an adaptor role of Np95. Hence, Np95 could function as 
architectural chromatin protein, similar to HP1 or MeCP2 (Nielsen et al., 2001; 
Nielsen et al., 2002; Brero et al., 2005; Agarwal et al., 2007).  
 
Moreover, the multi-domain protein Np95 was reported to interact not only with itself, 
but also with a multitude of protein members involved in DNA methylation, DNA 
repair and histone modification (Figure 24). Still, the temporal coordination and 
functional hierarchy of these multiple factors remains to be established.  
 
 
Figure 24: Np95 and Np97 as mediator between DNA methylation and histone modification.  
Np95 mediated replication coupled crosstalk between DNA methylation and histone modifications. 
Reported interactions are marked in black or white. Suggested interactions are displayed in gray. 
PCNA: (Miura et al., 2001; Bostick et al., 2007; Sharif et al., 2007); Dnmt1, Dnmt3a, Dnmt3b: (Bostick 
et al., 2007; Sharif et al., 2007; Achour et al., 2008; Meilinger et al., 2009); G9a: (Kim et al., 2009a); 
MeCP2: (Papait et al., 2008); HDAC1: (Unoki et al., 2004); Tip60: (Achour et al., 2009); Rb1: 
(Jeanblanc et al., 2005); PRC1: (Bezsonova et al., 2009); Eme1, PARP1, SSRP1/FACT: (Sharif et al., 
2007).  
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These interactions of Np95 and Np97 represent only a small selection of this rather 
complex epigenetic protein network. Nevertheless, the interplay of Np95/Np97 with 
Dnmts and histone modifying enzymes, together with their binding to DNA and 
repressive histone marks, point to a central role in the integration of various 
epigenetic silencing mechanisms and the mediation of epigenetic crosstalk. 
Furthermore, the interaction network formed by Np95 suggests a direct or indirect 
modulation of the chromatin structure and possibly spreading of silent chromatin 
states. It is also important to realize, that DNA methylation, chromatin modification 
and remodeling pathways mutually affect each other in multiple ways (Cedar and 
Bergman, 2009). In summary, these results indicate that the role of Np95 is far more 
complex than previously thought and especially the inter- and intramolecular 
interactions of its domains poses challenging questions. Subcellular localization, 
binding kinetics and function of Np95 is likely controlled by a complex interplay of its 
multiple domains.  
 
In conclusion, we investigated two potential mechanisms (Dnmt1-PCNA and Dnmt1-
Np95 interactions) that emerged to play a crucial role in the faithful propagation of 
methylation patterns. After carefully analyzing in vivo data, we propose that the PBD 
of Dnmt1 represents an additional safety mechanism by elevating local protein 
concentrations at the replication fork. The dynamic Dnmt1-PCNA interaction may 
assure the flexibility to rapidly find potential hemimethylated target sites at the 
replication machinery. Furthermore, we suggest that Np95 targets Dnmt1 to 
pericentric heterochromatin in a methylation and PCNA independent manner. The 
stable interaction of Np95 with chromatin may serve as anchor point for the transient 
binding of Dnmt1 and thereby may enable the faithful propagation of DNA 
methylation marks in living cells.  
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4.2. Abbreviations 
2OGFeDO: 2-oxoglutarate and iron(II) dependent dioxygenase superfamily 
5-aza-dC: 5-aza-2´-deoxycytidine   
5hmC: 5 hydroxymethylcytosine   
5mC: 5-methyl-cytosine   
ADCC: antibody-dependent cellular cytotoxicity  
AID: activation induced cytidine deaminase  
APIM: AlkB homologue 2 PCNA-interacting motif  
BAH: bromo adjacent homology domain  
BER: base excision repair  
BTB/POZ: broad complex, tramtrack and bric à brac/Poxvirus and zinc finger  
CDRs: complementarity determining regions  
CGBP: CpG-binding protein   
CpG: cytosine-phosphatidyl-guanine  
CTD: catalytic domain  
DKO: Dnmt3a and Dnmt3b knockout embryonic stem cells   
DNA: deoxyribonucleic acid  
Dnmt: DNA methyltransferase  
DsRed: Discosoma Red   
eGFP: enhanced green fluorescent protein   
ELISA: enzyme linked immunosorbent assay   
ES: embryonic stem   
Fab: fragment antigen binding   
Fc: constant effector-determining region   
Fen1: flap-endonuclease 1   
FLIP: fluorescence loss in photobleaching   
FP: fluorescent protein  
FRAP: fluorescence recovery after photobleaching   
FRET: fluorescence resonance energy transfer   
GFP: green fluorescent protein   
H2O2: hydrogen peroxide   
H3K9MT: H3 lysine 9 methyltransferase   
HAT: hypoxanthine-aminopterine-thymidine   
HDAC: histone deacetylase  
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HGPRT: hypoxanthine-guanine-phosphoribosyltransferase  
HP1: heterochromatin protein 1   
IDCL: interdomain connecting loop   
IF: immunofluorescence   
IFP: infrared-fluorescent protein  
Ig: Immunoglobulin  
JHD1: JmjC domain-containing histone demethylase 1 
KG7: lysine-glycine repeat  
Lig1: DNA ligase 1   
MAb: monoclonal antibody   
MBD: methyl-CpG binding domain protein   
mCpG: methylated CpG  
MF: mobile fraction   
MLL: mixed-lineage leukaemia   
NER: nucleotide excision repair  
Np95: nuclear protein with 95 kilodalton   
NTD: N-terminal domain  
PAbs: polyclonal antibodies   
PBD: PCNA binding domain  
PCNA: proliferating cell nuclear antigen   
PDB: protein data bank   
PEG: polyethylene glycol   
PH: pericentric heterochromatin   
PHD: plant homeodomain   
PIP-box: (PCNA-interacting-peptide)-box   
piRNA: Piwi protein family associated RNA   
PRC: polycomb repressive complex   
RF: replication foci   
RFP: red fluorescent protein  
Ring: really interesting new gene   
RNA: ribonucleic acid  
ROI: region of interest   
S phase: synthesis phase   
scFv: heterodimers of VH and VL  
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SEM: standard error of the mean   
SRA: SET and Ring associated  
t1/2: half time of recovery   
TDG: thymidine deglycosylase   
TKO: dnmt1,3a,3b knockout embryonic stem cells   
TRD: trans-repressor domain   
TS: targeting sequence   
Ubl: ubiquitin-like   
VH: variable heavy chain  
VL: variable light chain   
WB: western blot   
wt: wild type   
ZnF: zinc finger   
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4.3. Contributions 
 
Declaration of contributions to “Generation and Characterization of a Rat Monoclonal 
Antibody Specific for Multiple Red Fluorescent Proteins” 
I conceived the study and laid out the project aims together with Heinrich Leonhardt 
and Cristina M. Cardoso. Danny Nowak purified the red fluorescent proteins. 
Elisabeth Kremmer generated the hybridoma cell lines and provided us with the 
hybridoma supernatants. I designed and performed the prescreening of the 
hybridoma supernatants as well as all further experiments. I analyzed the data, 
prepared the figures and wrote the manuscript with the help and advice of M. Cristina 
Cardoso and Heinrich Leonhardt.  
 
Declaration of contributions to “Generation and Characterization of a Rat Monoclonal 
Antibody Specific for PCNA” 
This project was conceived by Ulrich Rothbauer, Cristina M. Cardoso and Heinrich 
Leonhardt. Danny Nowak did the PCNA protein purification. Elisabeth Kremmer 
generated the hybridoma cell lines and provided us with the hybridoma supernatants.  
I performed the prescreening of the hybridoma supernatants and characterized the 
antibodies by western blot analysis (Figure 2 A, B) as well as by immunofluorescence 
stainings (Figure 4). Danny Nowak performed the western blot in Figure 2 D. Ulrich 
Rothbauer performed the immunoprecipitation (Figure 3). Prisca Boisguérin mapped 
the epitope. I analyzed the data, prepared the figures and wrote the manuscript with 
the help of M. Cristina Cardoso, Heinrich Leonhardt and Ulrich Rothbauer.  
 
Declaration of contributions to “Dynamics of Dnmt1 interaction with the replication 
machinery and its role in postreplicative maintenance of DNA methylation” 
This study was conceived by Heinrich Leonhardt and Lothar Schermelleh. I initiated 
the project and cloned all the PCNA binding deficient PBD point mutants and 
performed the biochemical experiment (CoIP) as well as the localization analysis, the 
FRAP experiments and the trapping assay. I contributed and prepared Figure 1, 2, 4, 
5 A-C, Supplementary Figures 2, 3, wrote the corresponding figure legends and 
materials and methods sections. I helped Lothar Schermelleh and Heinrich 
Leonhardt to write the manuscript. 
 
ANNEX 
 
- 200 - 
Declaration of contributions to “DNMT1 but not its interaction with the replication 
machinery is required for maintenance of DNA methylation in human cells” 
This study was initiated and conceived by Fabio Spada and Heinrich Leonhardt. The 
published antibody anti-Dnmt1 2E8 was developed by Elisabeth Kremmer. I 
prescreened and analyzed the MAb further in western blot and immunofluorescence 
assay. I designed and generated the human DNMT1 ΔΕ3−6 expression construct. In 
addition, my contributions to this publication were: coimmunoprecipitation analyses of 
the wild-type and deletion DNMT1 construct, live cell imaging, binding kinetics and 
trapping assay (Figure 2 B, C and D). I analyzed the data, prepared the Figure 2 and 
helped Fabio Spada and Heinrich Leonhardt to write the manuscript.  
 
Declaration of contributions to “The multi-domain protein Np95 connects DNA 
methylation and histone modifications” 
This study was conceived by Fabio Spada, Heinrich Leonhardt and me. I laid out the 
project aims and cloned most of the mutant Np95 fusion constructs. I established in 
vivo imaging and photobleaching techniques in embryonic stem (ES) cells. I 
produced and evaluated FRAP data of Np95 in ES cells carrying different genetic 
backgrounds. Carina Frauer verified the data using an in vitro DNA binding and gel 
shift assay. Garwin Pichler performed the peptide pulldown assay and cloned the 
tandem Tudor point mutant. I prepared all the figures with the help of Garwin Pichler 
and Carina Frauer, discussed the data with Fabio Spada and I.M Bonapace, and 
wrote the manuscript with the help of Heinrich Leonhardt.  
 
Declaration of contributions to “Structure and function of the Dnmt1 CXXC zinc finger” 
This study was initiated by Fabio Spada, Stefan Hasenöder and Heinrich Leonhardt. 
Carina Frauer and I picked up the project, laid out the project aims and conceived the 
study together with Heinrich Leonhardt and Fabio Spada. I designed and performed 
all localization analyses as well as in vivo binding kinetics by FRAP analysis, in vivo 
activity measurements by the trapping assay and imaged the injected embryos in 
every cell stage. I contributed and prepared Figure 1, 2, 4, 5, Supplementary Figure 1, 
wrote the corresponding figure legends and materials and methods sections. I am 
currently working on the manuscript together with Carina Frauer and Heinrich 
Leonhardt. 
 
ANNEX 
 
- 201 - 
Declaration of contributions to “DNA methylation-mediated epigenetic control” 
This review was conceived by Heinrich Leonhardt and me. I prepared all the figures 
and wrote the manuscript with the help of Fabio Spada and Heinrich Leonhardt. Parts 
of the review are included in the introduction of this thesis.  
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Declaration according to the  
“Promotionsordnung der LMU München für die Fakultät Biologie” 
 
 
Betreuung:  Hiermit erkläre ich, dass die vorgelegte Arbeit an der LMU von Herrn 
Prof. Dr. Leonhardt betreut wurde.  
 
 
 
Anfertigung:   Hiermit versichere ich ehrenwörtlich, dass die Dissertation selbstständig 
und ohne unerlaubte Hilfsmittel angefertigt wurde. Über Beiträge, die im 
Rahmen der kumulativen Dissertation in Form von Manuskripten in der 
Dissertation enthalten sind, wurde im Kapitel 4.3 Rechenschaft abgelegt 
und die eigenen Leistungen wurden aufgelistet.  
 
 
 
Prüfung:  Hiermit erkläre ich, dass die Dissertation weder als Ganzes noch in 
Teilen an einem anderen Ort einer Prüfungskommission vorgelegt 
wurde. Weiterhin habe ich weder an einem anderen Ort eine Promotion 
angestrebt oder angemeldet oder versucht eine Doktorprüfung 
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